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Abstract 
 
 
Rho  GTPases  are  molecular  switches  controlling  many  aspects  of  cell  behaviour, 
including cell cycle progression, cell division, migration and morphology.  The activity 
of Rho proteins is regulated by conformational changes induced by binding of guanine 
nucleotides, with GTP-bound Rho being active and GDP-bound Rho inactive.  Families 
of regulatory proteins have evolved to catalyse cycling between these states.  Guanine 
nucleotide  exchange  factors  (GEFs)  catalyse  nucleotide  exchange,  allowing  GDP  to 
dissociate  and  GTP  to  bind  to  Rho,  thus  activating  it.    GTPase  activating  proteins 
(GAPs) enhance the intrinsic GTPase activity of Rho, leading to GTP hydrolysis and 
inactivation of Rho.  Active GTP-bound Rho can interact with and regulate a number of 
effector proteins, through which cellular responses are elicited. 
 
Epithelial  cells  are  a  specialized  cell  type  that  form  selectively  permeable  barriers 
between different compartments of a multicellular organism, and thus play an important 
role  in  tissue  organization  and  homeostasis.    The  formation  of  cell-cell  junctions, 
including tight junctions and adherens junctions, is critical for this function.   
 
Experiments carried out in model organisms and in cell culture have shown that Rho 
GTPases  are  important  regulators  of  epithelial morphogenesis.    I  sought to  identify 
components of the signalling pathways through which Rho GTPases regulate junction 
formation.  RNAi screens were carried out with siRNA libraries targeting Rho GEFs, 
GAPs and effectors, using tight junction formation in the human bronchial epithelial 
cell line 16HBE as readout.  This approach led to the identification of three Rho effector 
proteins required for junction formation, namely PRK2, PAK4 and PAR6B. 
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CHAPTER 1 – Introduction 
 
1.1 Overview 
 
Rho  GTPases  are  signalling  proteins  that  belong  to  the  Ras  superfamily  of  small 
GTPases.    They  can  exist  in  two  structurally  distinct  conformations,  a  GTP-bound 
active conformation and a GDP-bound inactive conformation.  Cycling between these 
two states is controlled by two families of regulatory proteins.  Guanine nucleotide 
exchange factors (GEFs) catalyse nucleotide exchange, during which GDP dissociates 
and  GTP  associates  with  the  GTPase,  resulting  in  its    conformational  activation.  
GTPase activating proteins (GAPs) enhance the intrinsic GTPase activity of GTPases, 
resulting in hydrolysis of GTP and conformational inactivation of the GTPase.  Rho 
GTPases thus act as molecular switches, cycling between active and inactive states in a 
regulated manner.  Active Rho GTPases can interact with a number of effector proteins.  
Binding  of  Rho  GTPases  to  their  effector  proteins  regulates  the  activity  of  these 
proteins.    Rho  GEFs  and  GAPs  are  regulated  by  a  wide  range of  extracellular  and 
intracellular  signals,  and  the  interactions  between  components  of  Rho  GTPase 
signalling pathways are highly specific, allowing Rho GTPase signalling pathways to 
couple a wide range of upstream signals to diverse downstream responses in a tightly 
controlled manner. 
 
A  large  number  of  Rho  effector  proteins  have  been  identified,  including  kinases, 
phosphatases, lipases, adaptors and scaffolds.  Rho GTPases can therefore regulate a 
number  of  basic  processes  in  the  cell,  such  as  the  organization  of  the  actin  and 
microtubule cytoskeletons, membrane trafficking events and gene expression.  Through 
the regulation of these basic processes, Rho GTPases control many complex cellular 
behaviours,  including  cell  cycle  progression,  cell  division,  migration,  adhesion, 
differentiation and morphogenesis (Figure 1.1). 
 
Epithelial cells are a specialized cell type that act as selective barriers between different 
compartments  of  multicellular  organisms.    Epithelial  cells  are  characterized  by  the   12 
presence of intercellular junctions, which play essential roles in cell-cell adhesion and 
epithelial barrier function.  Epithelial junctions are dynamic structures, whose assembly, 
maintenance and disassembly is tightly controlled during the morphogenesis of tissues 
and organs, and which become misregulated in diseases such as cancer.  A number of 
signalling pathways have been found to regulate epithelial junctions, including  Rho 
GTPase-dependent signalling pathways.   13 
1.2 Molecular regulation of Rho GTPases 
 
1.2.1 The Rho family of small GTPases 
 
Rho GTPases belong to the Ras superfamily of small GTPases, which comprises over 
150  members  in  mammals  (Wennerberg  et  al.,  2005).    These  proteins  contain  a 
conserved  G  domain  of  approximately  150  amino  acids,  which  is  responsible  for 
guanine  nucleotide  binding.    The  Ras  superfamily  is  typically  divided  in  to  5 
subfamilies based on sequence similarities.  Members of the Rho family contain a small 
12  amino  acid  insert  region  in  the  G  domain,  which  forms  an  additional  α-helical 
structure.  22 proteins were assigned to the Rho family.  However, Miro-1 and Miro-2 
have  since  been  reassigned  to  their  own  atypical  family,  leaving  20  Rho  family 
members.  Of these, RhoA, Rac1 and Cdc42 are by far the best characterized. 
 
Rho  GTPases  are  signalling  proteins  that  regulate  a  number  of  important  cellular 
processes.    They  act  as  molecular  switches,  and  exist  in  two  structurally  distinct 
conformations.  The active conformation is bound to GTP, and is able to interact with a 
number of effector proteins to regulate their activity.  The inactive conformation is 
bound to GDP, and is not able to interact with effector proteins.  Rho GTPases are 
activated at cell membranes by nucleotide exchange, during which GDP dissociates and 
is replaced by GTP.  Nucleotide exchange requires catalysis by a group of proteins 
called  guanine  nucleotide  exchange  factors  (GEFs).    Most  Rho  GTPases  possess 
intrinsic  GTPase  activity  and  hydrolyse  GTP,  leaving  the  GTPase  GDP-bound  and 
inactive.    The  GTPase  activity  of  Rho  GTPases  is  poor,  and  can  be  enhanced  by 
GTPase activating proteins (GAPs).  GEFs and GAPs thus regulate the activity of Rho 
GTPases  by  controlling  their  guanine  nucleotide  binding  status,  which  in  turn 
determines  the  conformation  of  the  GTPase  and  its  ability  to  interact  with  effector 
proteins (Figure 1.2).  A third group of Rho GTPase regulatory proteins are the Rho 
GDIs  (guanine  nucleotide  dissociation  inhibitors),  which  are  thought  to  sequester 
inactive  GDP-bound  GTPases  in  the  cytosol  and  prevent  their  activation  by  GEFs.  
However, compared to GEFs and GAPs, Rho GDIs have not been well studied and little 
is known about their function.  Rho GEFs and GAPs are themselves regulated by a wide   14 
range of extracellular and intracellular signals, and this enables signals to be transduced 
through Rho GTPases to Rho effector proteins and ultimately to the cellular machinery. 
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1.2.2 Guanine nucleotide exchange factors for Rho GTPases (Rho GEFs) 
 
Guanine  nucleotide  exchange  factors  (GEFs)  activate  small  GTPases  by  promoting 
nucleotide exchange.  Rho GEFs are regulated by extracellular and intracellular signals, 
and this is essential for Rho-dependent cellular processes to be properly controlled.  
Rho GEFs show specificity in terms of which GTPase(s) they activate, which allows 
tight control of signal transduction pathways, linking upstream signals to the activation 
of specific Rho GTPases.  Approximately 80 Rho GEFs exist in humans, falling in to 
two structurally unrelated families, the Dbl family and the DOCK family. 
 
Dbl family GEFs - The first Rho GEF to be identified was Dbl, isolated from diffuse 
B-cell lymphoma by its ability to transform fibroblasts.   Dbl has a region homologous 
to Cdc24, a GEF for Cdc42 in Saccharomyces cerevisiae involved in cell polarity, and 
directly activates Cdc42 by promoting nucleotide exchange (Hart et al., 1991).  This 
conserved Dbl-homology (DH) domain has subsequently been found in a large number 
of  proteins  (approximately  70  in  humans),  which  constitute  the  Dbl  family  of  Rho 
GEFs.  Like Dbl, many of these Rho GEFs act as oncogenes in transformation assays in 
fibroblasts, which has been a useful way of identifying them (Rossman et al., 2005).  
They  invariably  contain  a  PH  (pleckstrin  homology)  domain  adjacent  to  the  DH 
domain, which is essential for GEF activity in vivo (see below). 
 
The DH domain, approximately 200 amino acids, is the minimal domain required for 
nucleotide exchange activity in vitro.  DH domains of different Rho GEFs typically 
show low sequence homology, but structural studies of a number of them, including 
Dbl, Dbs, Tiam1, Vav1 and Sos1, have revealed conserved structures.  The DH domain 
is  composed  of  a  number  of  α-helices  and  310-helices  that  form  a  helical  bundle.  
Crystal structures of DH domains bound to GTPases have been used to elucidate the 
mechanism of nucleotide exchange.  Extensive contacts exist between the DH domain 
and the GTPase, including residues that are very varied amongst different GEF:GTPase 
complexes, and so are important for determining specificity.  Binding of the GEF DH 
domain causes structural rearrangements in the switch I and switch II regions of the 
GTPase,  resulting  in  disorganization  of  the  nucleotide-binding  site  such  that  the   16 
nucleotide and the associated magnesium cofactor dissociate.  This leaves the GTPase 
with its nucleotide-binding site exposed, and GTP binds as it is more abundant in the 
cell than GDP.  Binding of GTP causes dissociation of the GEF, leaving the GTPase in 
its active conformation capable of interacting with effector proteins (Rossman et al., 
2005).  This mechanism of nucleotide exchange is different than that catalysed by the 
unrelated DOCK family of Rho GEFs (discussed below), which insert residues in to the 
nucleotide-binding site of the GTPase to directly disrupt magnesium ion binding (Yang 
et al., 2009).  There are some similarities in the mechanism of nucleotide exchange 
exchange catalysed by DH family GEFs and GEFs for other Ras superfamily GTPases.  
Binding of the GEF Sos to Ras, for example, induces  similar structural changes in 
switch  II  of  the  GTPase,  resulting  in  exclusion  of  nucleotide  and  magnesium  ion.  
However, in contrast to DH family GEFs, Ras GEFs also insert residues directly in to 
the nucleotide-binding site of the GTPase, and these residues are directly involved in 
displacement of the nucleotide and magnesium ion (Boriack-Sjodin et al., 1998). 
 
PH (pleckstrin homology) domains are invariably found adjacent to DH domains in Dbl 
family GEFs.  Deletion analysis of a number of Rho GEFs has revealed an essential role 
for PH domains for GEF activity in the cell.  However no clear general role for PH 
domains in regulating GEF activity has been discerned, and it seems the PH domain 
plays different roles in different GEFs.  The PH domain of Dbs makes direct contact 
with Cdc42 and residues in the PH domain contribute to nucleotide exchange (Rossman 
et al., 2003).  However, in crystal structures of other Rho GEFs the PH domains are 
positioned  differently  relative  to  the  DH  domain,  and  are  not  directly  involved  in 
GTPase binding, so direct regulation of GEF activity is not a general mechanism for PH 
domain  function.    PH  domains  have  been  found  to  regulate  GEF  activity  through 
binding to phosphoinositides, but different mechanisms have been proposed.  In some 
cases,  such  as  P-Rex1  (PtdIns(3,4,5)P3-  and  Gβγ-  activated  Rac  GEF),  addition  of 
soluble  PtdInsP3  in  vitro  stimulates  the  GEF  activity,  presumably  by  an  allosteric 
mechanism (Welch et al., 2002).  However other GEFs are either not activated or are 
inhibited by soluble phosphoinositides (Rossman et al., 2005). 
   17 
Rho GEFs are normally activated at membranes, and the PH domain has been proposed 
to play a role in membrane targeting through its phospholipid interactions.  Lfc, for 
example, transforms fibroblasts and this depends on the presence of a functional PH 
domain.    Addition  of  a  general  isoprenylation  signal  to  target  Lfc  to  the  plasma 
membrane was able to compensate for loss of the PH domain, suggesting the role of the 
PH domain is simply to target the GEF to the membrane (Whitehead et al., 1995).  
However  several  GEFs  are  known  to  target  to  the  membrane  in  the  absence  of 
functional  PH  domains  (Rossman  et  al.,  2003),  showing  additional  mechanism  for 
membrane targeting must exist. 
 
Another possible mechanism that has been proposed for the regulation of GEF activity 
by phosphoinositides is not membrane recruitment per se, but orientation of membrane-
bound GEFs correctly to facilitate activation of their cognate GTPases.  Consistent with 
this idea, specific point mutations have been made in the PH domain of Dbs which 
block phospholipid binding without affecting GEF activity in vitro (Rossman et al., 
2003).  This mutant is inactive in cellular transformation assays, despite being localized 
properly at the plasma membrane, suggesting phosphoinositide binding is required to 
activate the GEF downstream of membrane localization. 
 
PH domains can interact with proteins in addition to lipids, and in some cases this is 
important  for  regulating  GEF  activity.    Trio,  for  example,  interacts  with  the  actin-
binding  protein  filamin  via  its  DH-associated  PH  domain,  and  this  interaction  is 
necessary  for  localization  of  Trio  to  actin  filaments  to  promote  membrane  ruffles 
(Bellanger et al., 2000).  Whatever the mechanism of regulation, the fact that Dbl family 
proteins invariably contain a PH domain adjacent to their DH domain suggests it plays 
an important role in GEF function. 
 
DOCK family GEFs - The second family of Rho GEFs are the DOCK180-related 
family, also called CZH proteins (CDM and zizimin homologous, where CDM stands 
for ced-5-DOCK180-Myoblast city) (Meller et al., 2005).  DOCK180, the founding 
member of this family in mammals, was originally identified as a binding partner for 
Crk,  an  adaptor  protein  involved  in  receptor  tyrosine  kinase  signalling,  and  was   18 
subsequently shown to directly catalyse nucleotide exchange on Rac (Brugnera et al., 
2002).  11 mammalian DOCK proteins have been identified.  These proteins lack the 
characteristic DH-PH module found in classical Dbl family GEFs.  Instead they have 
two conserved DOCK homology regions (DHR).  The DHR2 domain is responsible for 
nucleotide exchange activity, and is sufficient to catalyse nucleotide exchange in vitro 
(Brugnera et al., 2002).  In contrast to DH family GEFs, the structure and catalytic 
mechanism  of  DOCK  family  GEFs  have  not  been  studied  extensively.    However  a 
catalytic  mechanism  for  DOCK  family  GEFs  has  been  proposed  based  on  a  recent 
crystal structure of DOCK9 in complex  with Cdc42 (Yang et al., 2009).  Residues 
within  the  DHR2  domain  insert  in  to  the  nucleotide-binding  pocket  of  Cdc42  and 
interfere  with  magnesium-binding.    In  particular,  a  highly  conserved  valine  residue 
blocks the magnesium-binding site.  Magnesium ion is an essential cofactor for binding 
of  nucleotides  to  GTPases,  as  it  neutralizes  the  negative  charge  on  the  nucleotide.  
Nucleotide-binding is further perturbed by conformational changes in switch I of the 
GTPase, which result in disorganization of the nucleotide-binding site.  In contrast to 
DH family GEFs (discussed above), binding of DOCK9 to Cdc42 does not affect the 
structure of switch II. 
 
The DHR1 domain of DOCK family GEFs binds phosphoinositides.  This domain is not 
necessary for GTPase activation in vitro, but is necessary for membrane targeting of 
DOCK180  and  GTPase  activation  in  vivo  (Cote  et  al.,  2005).    The  DHR1  domain 
therefore seems to play an analogous role to the PH domain in Dbl family GEFs, at least 
some of which require their PH domain for membrane targeting (see above). 
 
1.2.3 GTPase activating proteins for Rho GTPases (Rho GAPs) 
 
GTPase activating proteins (GAPs) bind to GTP-bound forms of GTPases and enhance 
their GTPase activity.  This results in inactivation of GTPase signalling pathways.  The 
first Rho GAP to be identified was Bcr (breakpoint cluster region) (Diekmann et al., 
1991),  and  since  then  a  large  family  of  related  Rho  GAPs  has  been  identified 
(approximately 70 in humans) (Tcherkezian and Lamarche-Vane, 2007).  Rho GAPs 
contain a conserved 150 amino acid Rho GAP domain that is sufficient to promote GTP   19 
hydrolysis on Rho GTPases.  Structural studies have shown Rho GAP domains are 
related to other Ras family GAPs, despite low sequence homology (Moon and Zheng, 
2003).  The Rho GAP domain comprises 9 α-helices and contains a highly conserved 
arginine  residue  in  a  loop  region.    Mutational  analysis  has  shown  this  residue  is 
essential for GAP activity, and structural studies have shown this residue forms part of 
the catalytic active site, the co-called ‘arginine-finger’, promoting GTP hydrolysis by 
directly  contacting  and  stabilizing  the  transition  state  intermediate  of  the  GTP 
hydrolysis reaction (Moon and Zheng, 2003).  The GAP domain makes contacts with 
the  conserved  switch  I  and  switch  II  regions  of  the  GTPase,  regions  that  become 
restructured  upon  GTP-binding.    Like  Rho  GEFs,  Rho  GAPs  show  specificity  for 
GTPase substrates, and contacts between the GAP  and non-conserved regions of the 
GTPase contribute to this. 
 
1.2.4 Regulation of Rho GEF and Rho GAP signalling 
 
The activity of Rho GTPases needs to be tightly regulated in the cell, both temporally 
and spatially.  Initially it was thought that Rho GEFs are the major sites of regulation 
for  Rho  GTPase  signalling  pathways,  but  it  is  now  clear  that  Rho  GAPs  play  an 
important role too.  In addition to conserved catalytic domains (DH, DHR2 and GAP), 
Rho GEFs and GAPs contain a huge variety of other functional domains, which are 
important for regulating GEF and GAP activity in the cell and for coordinating Rho 
GTPase signalling pathways (Rossman et al., 2005; Tcherkezian and Lamarche-Vane, 
2007).  This variety in domain organization means GEFs and GAPs are regulated in a 
variety of ways.  These can broadly be grouped in to two types of regulation: direct 
regulation of catalytic activity, and regulation of signalling output by controlling Rho 
GEF  and  GAP  localization  and  interaction  with  other  components  of  signalling 
pathways. 
 
 
GEF  and  GAP  catalytic  activity  can  be  directly  regulated  by  post-translational 
modifications and protein-protein interactions.  In some cases activation involves relief 
of  autoinhibition.  A  number  of  Rho  GEFs  can  be  activated  experimentally  by   20 
truncations, normally of the N-terminus, which suggests these GEFs are autoinhibited.  
The clearest example of relief of autoinhibiton as a regulatory mechanism is provided 
by Vav1.  Vav1 is phosphorylated downstream of activated receptors by Src family 
kinases (SFKs), and this phosphorylation is necessary for activation.  Structural studies 
show that the N-terminus of Vav1 contains an autoinhibitory domain that binds to the 
DH  domain  (Aghazadeh  et  al.,  2000).    Phosphorylation  of  tyrosine  174  in  the 
autoinhibitory domain causes it to become unstructured, which disrupts the interaction 
with the DH domain and activates the GEF.  α-chimaerin, a GAP for Rac, also seems be 
regulated by an autoinhibitory mechanism.  Deletion of the N-terminus activates the 
GAP activity of α-chimaerin in vitro.  This region contains a C1 domain, which binds 
lipids and phorbol esters.  α-chimaerin is activated by binding of phosphatidylserine 
and phorbol esters, which might act by relieving N-terminal autoinhibition (Ahmed et 
al., 1993).  
 
A number of other GEFs and GAPs are regulated by phosphorylation.  For example, 
CdGAP  activity  is  inhibited  in  vitro  by  phosphorylation  downstream  of  ERK 
(Tcherkezian et al., 2005), while RICS is inhibited by CaMKII (calcium/calmodulin-
dependent kinase II) (Okabe et al., 2003).  The GEF activity of Ras-GRF1 towards Rac 
is enhanced by Src phosphorylation (Kiyono et al., 2000).  In these cases the structural 
details of how GEF and GAP activity are regulated by phosphorylation are not known.   
 
RGS  (Regulator  of  G-protein  signalling)  domain-containing  GEFs  are  activated  by 
protein-protein interactions.  These GEFs bind to heterotrimeric Gα subunits via their 
RGS domains and act as GAPs to turn off G protein signalling.  Binding of Gα13 to 
p115-RhoGEF enhances the GEF activity of p115-RhoGEF in vitro (Hart et al., 1998).  
This is not thought to involve relief of autoinhibition, because deletion of the RGS 
domain does not lead to constitutive activation of the GEF, which would be the case if 
the RGS domain had an autoinhibitory function (Wells et al., 2001).  Instead Gα13 
might be playing a direct role in stimulating nucleotide exchange, as it binds to the DH-
PH module in addition to the RGS domain (Wells et al., 2002).  The Rho GAP ARAP3 
is activated in vitro by GTP-bound Rap.  Rap is a member of the Ras family of small 
GTPases and binds to a Ras-binding domain located adjacent to the GAP domain of   21 
ARAP3, however it is not clear how Rap binding stimulates GAP activity (Krugmann et 
al., 2004). 
 
In the above examples the catalytic activity of the GEF and GAP domain is directly 
regulated.  Another commonly used mechanism for regulating GEF and GAP activity in 
the cell is controlling the localization of GEF and GAP proteins and their interactions 
with other signalling molecules.  GTPases normally function at membranes, and as 
describe above PH domains and DHR1 domains of GEFs can in some cases regulate the 
activity of GEFs in the cell by recruiting them to membranes.  While Rho GAPs in 
general do not contain conserved lipid-binding domains, some do have lipid-binding 
domains,  such  as  the  C1  domain  in  chimaerins,  which  binds  to  diacylglycerol  and 
targets chimaerins to cellular membranes (Caloca et al., 2001). 
 
Domains outside the conserved GEF and GAP catalytic domains can mediate a wide 
range  of  molecular  interactions  to  control  localization  of  Rho  GEF  and  Rho  GAP 
proteins.  For example the Rho GEFs Ect2 and Net1 both contain nuclear localization 
signals that target them to the nucleus, where they are not able to access their substrate 
RhoA (Schmidt and Hall, 2002).  Ect2 regulates cytokinesis, and its nuclear localization 
signal keeps it inactive during interphase.  During mitosis, the nuclear envelope breaks 
down and Ect2 is released, and localizes to the cortex where the cleavage furrow forms.  
Activation  of  RhoA  by  Ect2  is  necessary  for  cleavage  furrow  ingression  and  cell 
division (Kim et al., 2005; Yuce et al., 2005).  The Rac GEF Tiam1 is required for tight 
junction formation in keratinocytes, during which Rac activation at nascent cell-cell 
contacts is thought to activate aPKC.  Tiam1 localizes to cell-cell contacts through its 
interaction with the scaffold protein Par3, which interacts with the N-terminal region of 
Tiam1, and this interaction restricts Rac activation to cell-cell contacts (Mertens et al., 
2005).  Failure to restrict Tiam1 activity to these sites, as occurs when Par3 is knocked 
down, results in inappropriate activation of Rac and tight junctions do not form properly 
(Chen  and  Macara,  2005).  The  Cdc42  GAP  Rich1  is  required  for  tight  junction 
maintenance in epithelial cells, as Rich1 knockdown results in loss of epithelial barrier 
function (Wells et al., 2006).  The function of Rich1 is dependent on its GAP activity, 
as expression of a GAP-defective mutant of Rich1 acts in a dominant-negative fashion   22 
and also results in loss of barrier function.  Overexpression of constitutively active 
Cdc42 also disrupts epithelial junctions (Kroschewski et al., 1999; Rojas et al., 2001), 
and Rich1 is thought to function by limiting the levels of GTP-Cdc42 at tight junctions.  
Rich1 is localized to tight junctions by an interaction with the scaffold protein Amot, 
involving  a  coiled-coil  heterodimerization  between  Amot  and  the  BAR  domain  of 
Rich1. 
 
The multidomain nature of Rho GEFs and Rho GAPs allows them to bind to multiple 
proteins  simultaneously.    Formation  of  large  protein  complexes  can  control  which 
signalling pathways are regulated downstream of Rho GEFs and GAPs, and therefore 
regulate cellular activity.  There are an increasing number of examples of Rho GEFs 
and GAPs in complexes with Rho effectors, either through interactions with scaffold 
proteins or by acting as scaffolds themselves (see section 1.2.7 below). 
 
1.2.5 Rho GTPase effector proteins 
 
Rho GTPases regulate signalling pathways by binding to and regulating the cellular 
activities  of  effector  proteins.    A  Rho  effector  protein  is  defined  as  a  protein  that 
interacts preferentially with the GTP-bound form of a Rho GTPase.  A large number of 
Rho  effectors  have  been  identified  (at  least  90  in  humans),  including  kinases, 
phosphatases, lipases, adaptors and scaffolds.  Specificity exists between effectors and 
GTPases, such that particular GTPases interact with only a subset of effector proteins.  
Effector proteins thus need to distinguish between GTP- and GDP-bound forms of the 
GTPase, and between different Rho family members.  
 
Structural studies of GTPases bound to GDP and GTP have shown that conformational 
changes upon GTP-binding are limited to two short (about 15 amino acid) stretches on 
the  surface  of  the  protein,  called  switch  regions  (Ihara  et  al.,  1998).    Given  the 
specificity of effectors for GTP-bound forms of the GTPase, these regions must be 
involved  in  effector  binding,  and  structural  studies  have  shown  this  to  be  the  case 
(Bishop and Hall, 2000; Zhao and Manser, 2005).  While switch II is almost identical 
between different Rho family members, switch I shows some significant amino acid   23 
substitutions between Rho family members, and therefore contributes to the specificity 
seen between different GTPase:effector pairs.  Indeed mutations in switch I, also called 
the effector loop, can interfere with specific effector interactions while leaving others 
unchanged (Sahai et al., 1998). 
 
GTPase-binding domains (GBDs) have been defined for some Rho effector proteins 
through mutational analysis.  Conserved GBDs are present in some Rho effectors, and 
structural studies have shown how selective GTPase binding occurs (Bishop and Hall, 
2000; Zhao and Manser, 2005).  Several Cdc42 and Rac effectors contain a conserved 
CRIB  motif  (Cdc42  and  Rac  interactive  binding),  including  PAK  (p21-activated 
kinase),  ACK  (activated  Cdc42-associated  kinase)  and  WASP  (Wiskott-Aldrich 
syndrome protein).  The CRIB motif is a short stretch of 15 amino acids found within a 
larger GBD, which is typically about 50 amino acids in length.  Structural studies of the 
GBDs of WASP, ACK and PAK bound to active Cdc42 have revealed a similar mode 
of interaction (Abdul-Manan et al., 1999; Morreale et al., 2000; Mott et al., 1999).  
Conserved residues in the CRIB motif form an intermolecular β-sheet with residues in 
the Switch I region of the GTPase.  Residues within the GBD but outside the CRIB 
motif make extensive contacts with the switch regions and also non-switch regions of 
the GTPase.  These contacts between the GBD and non-switch regions of the GTPase 
involve non-conserved residues, which explains the selectivity of GTPases for effector 
proteins,  even  amongst  those  containing  CRIB  domains.    WASP  and  ACK,  for 
example, bind specifically to Cdc42 but not to Rac, and make hydrophobic contacts 
with leucine 174 of Cdc42, which is not conserved in Rac.  PAK1 binds to both Cdc42 
and  Rac,  and  does  not  make  hydrophobic  contacts  with  leucine  174  of  Cdc42,  but 
instead contacts other residues that are conserved between Cdc42 and Rac (Zhao and 
Manser, 2005). 
 
The RhoA effector PRK (PKC-related kinase, also called PKN, protein kinase novel) 
shows a completely different mode of GTPase interaction.  The N-terminus of PRK 
contains three antiparallel coiled-coil repeats, named HR1a-c, which mediate GTPase-
binding.  The crystal structure of the HR1a domain from PRK1 in complex with RhoA 
shows  it  forms  an  antiparallel  coiled-coil  dimer,  making  contacts  with  both  switch   24 
regions of RhoA as well as non-switch regions, using a hydrophobic patch and also a 
number of charged residues (Maesaki et al., 1999).  Importantly, the switch I residues 
making direct contacts with the PRK antiparallel coiled-coil are different from those 
making direct contact to CRIB motifs, and the contacting residues outside of the switch 
regions  are  not  conserved  between  RhoA  and  Cdc42,  explaining  the  observed 
specificity of binding.  Conserved HR1 domains have also been found in other Rho 
effector proteins, including rhotekin and rhophilin (Bishop and Hall, 2000; Zhao and 
Manser, 2005). 
 
Rho kinase (ROK), also called ROCK (Rho coiled-coil kinase), is another Rho effector 
that has been studied structurally.  ROCK binds to and is activated by RhoA, B and C 
but not Rac1 or Cdc42 (Zhao and Manser, 2005).  ROCK, and the related Rho effector 
citron kinase, contain a coiled-coil region that mediates dimerization and contains a 
Rho-binding domain.  Structural studies have shown this coiled-coil Rho-binding region 
forms contacts with RhoA using a similar hydrophobic patch to that observed with PRK 
(Dvorsky et al., 2004), although it should be noted that there is no sequence similarity 
between the coiled-coil regions of PRK and ROCK.  Again ROCK makes a number of 
contacts with residues in RhoA that are not conserved in other GTPases such as Rac and 
Cdc42, which can account for the binding specificity. 
 
These structural studies highlight some general principles of how active Rho GTPases 
interact with their effector proteins.  The switch regions of the GTPase, which become 
restructured  when  the  GTPase  is  activated, make  contacts  with  the  GTPase-binding 
domain of the effector, allowing selectivity for the GTP-bound form of the GTPase, 
while interactions between non-conserved residues in the GTPase and the effector allow 
for selectivity between different GTPases and effectors.  These general principles are 
likely to apply to other GTPase:effector interactions.  However it should be noted that 
many effectors do not contain Rho-binding domains that can be recognized by sequence 
analysis, and identification of Rho effector proteins in general requires a biochemical 
approach.  This is in contrast to Rho GEFs and GAPs, which can be identified on the 
basis of conserved GEF (DH and DHR2) and GAP domains.  
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1.2.6 Regulation of Rho effector proteins  
 
For  an  effector  protein  to relay  signals  from  an  active  Rho  GTPase  to  the  cellular 
machinery its activity must be regulated by binding to the GTPase.  Effector proteins 
are a diverse group of proteins with diverse functions and modes of regulation, but 
some  general  principles  can  be  discerned.    Many  effector  proteins  are  enzymes, 
including kinases, phosphatases and lipases, and their catalytic activity can be directly 
regulated by binding to the GTPase.   Other effector proteins, such  as adaptors  and 
scaffolds, are regulated in the cell by changes in their localization or protein-protein 
interactions.  
 
PAK (p21-activated kinase) was the first kinase to be identified as an effector protein 
for Rho GTPases.  PAKs are highly conserved in evolution.  Genetic analysis in yeast 
has shown PAK plays important roles in regulating the actin cytoskeleton and MAPK 
signalling, and these functions are conserved in mammals (Hofmann et al., 2004).  A 
total  of  6  mammalian  PAK  proteins  have  been  identified.    These  fall  in  to  two 
subfamilies based on sequence homology and mode of regulation: class I PAKs (PAK1-
3) and class II PAKs (PAK4-6) (Arias-Romero and Chernoff, 2008).  PAK2 and PAK4 
are ubiquitously expressed, while the other PAKs show more tissue specific expression 
profiles.    All  PAK  proteins  contain  a  C-terminal  kinase  domain  and  an  N-terminal 
GTPase-binding domain (GBD).  Outside of these domains class I and class II PAKs 
show no sequence homology.  
 
Class I PAKs bind to GTP-bound Rac1 and Cdc42.  PAK1 also binds the related Rho 
GTPases Rac2, Rac3, TC10 and Wrch-1 (Zhao and Manser, 2005).  The N-terminal 
GBD  of  PAK  contains  a  conserved  CRIB  motif,  described  above.  Binding  of  the 
GTPase enhances the kinase activity of class I PAKs.  Mutational analysis suggested 
that the C-terminal GBD acts in an autoinhibitory fashion and defined an autoinhibitory 
region  that  overlapped  with  the  GBD  (Zhao  et al.,  1998).    This  was  confirmed  by 
structural studies of the autoinhibitory region bound to the kinase domain of PAK1 (Lei 
et  al.,  2000).    This  regulatory  region,  also  called  the  inhibitory  switch  (IS),  makes 
extensive contacts with the kinase domain, and blocks the kinase catalytic site.  Binding   26 
of active GTPase is predicted to alter the conformation of the IS region, resulting in 
dissociation  from  the  kinase  domain  and  relief  of  inhibition.    Activated  PAK 
autophosphorylates  on  a  conserved  threonine  residue  in  the  kinase  domain  (in  the 
activation  loop)  to  further  activate  the  kinase  domain,  and  also  autophosphorylates 
residues in the autoinhibitory domain, which blocks binding to the kinase domain (Gatti 
et al., 1999). 
 
The  catalytic  activity  of  some  other  kinases,  including  ROCK  and  PRK,  is  also 
enhanced  by  GTPase-binding,  and  relief  of  autoinhibition  seems  to  be  a  common 
mechanism of activation. Rho-kinase (ROCK) was the first kinase to be identified as an 
effector for RhoA.  Two ubiquitously expressed mammalian ROCKs (ROCK1 and 2) 
are activated by RhoA, B and C but not by Rac1 or Cdc42 (Leung et al., 1996).  ROCK 
activates myosin II by inhibiting myosin light chain (MLC) phosphatase and directly 
phosphorylating myosin light chain (MLC) (see section 1.3.1, below), and regulates 
cellular processes requiring actomyosin contraction, such as cytokinesis, migration and 
morphogenesis.  ROCK proteins contain an N-terminal kinase domain, a central coiled-
coil homodimerization domain, and C-terminal PH domain.  The Rho-binding domain 
has been mapped to the C-terminal end of the coiled-coil region.  Deletion of the C-
terminus of ROCK1, including the Rho-binding domain, increases the activity of the N-
terminal kinase domain, while expression of the C-terminal fragment inhibits activation 
of ROCK (Amano et al., 1999), suggesting an autoinhibitory mechanism.  Binding of 
Rho to the Rho-binding domain is presumed to relieve this autoinhibition, but structural 
details are not known. 
 
Relief of autoinhibition is used to  activate other non-kinase effectors, including the 
WASP (Wiskott-Aldrich syndrome) proteins.  WASP, and the related N-WASP, are 
adaptor proteins linking Rho GTPases to the Arp2/3 actin nucleation complex (Millard 
et al., 2004).  WASP proteins bind to the Arp2/3 complex, which results in activation of 
Arp2/3-dependent actin polymerization.  WASP and N-WASP are effector proteins for 
Cdc42, and contain a CRIB motif in their N-terminus (Aspenstrom et al., 1996; Symons 
et al., 1996).  In vitro, activation of the Arp2/3 complex by N-WASP is dependent on 
GTP-bound Cdc42 and PtdInsP2, which bind cooperatively to N-WASP and relieve an   27 
autoinhibitory interaction between its N-terminal regulatory domain and its C-terminal 
WCA region (which activates the Arp2/3 complex, see section 1.3.1 below) (Prehoda et 
al., 2000; Rohatgi et al., 1999).  In the autoinhibited state, the CRIB domain makes 
contacts with the C (central) domain of the WCA region, resulting in a closed inactive 
conformation.  GTP-bound  Cdc42  binds  to  the  CRIB  domain  of  N-WASP,  while 
PtdInsP2 binds to the adjacent basic region, resulting in conformational activation of the 
Arp2/3 complex.  This autoinhibition model is supported by the observation that the C-
terminal WCA region of N-WASP, lacking the N-terminal regulatory domain, is a much 
stronger activator of the Arp2/3 complex than full length N-WASP, and indeed does so 
in a Cdc42-independent manner.  Biochemical purification and characterization of the 
haematopoietic-specific  WASP  revealed  a  similar  cooperative  regulation  by  GTP-
Cdc42 and PtdInsP2, and the crystal structure of WASP confirmed that the CRIB motif 
binds to the C-terminal WCA domain.  (Higgs and Pollard, 2000). 
 
Another  mechanism  used  to  regulate  the  activity  of  Rho  effector  proteins  is 
dimerization.  MLKs (mixed-lineage kinases) are serine/threonine kinases activated by 
Cdc42  and  Rac  (Zhao  and  Manser,  2005).    They  are  MAP  kinase  kinase  kinases 
(MAPKKKs) and act upstream of MAPK cascades.  Like PAK they contain a conserved 
CRIB motif in their GTPase-binding domain, which is required for binding to Cdc42 
and Rac, but in contrast to PAK and the other kinases discussed above, activation is not 
thought to involve relief of autoinhibition.  These kinases dimerize through their leucine 
zipper domains, and GTPase-binding activates the kinase by promoting dimerization, 
but the structural details are not known (Leung and Lassam, 1998). 
 
A  number  of  Rho  effectors  are  not  activated  by  GTPase-binding,  but  instead  are 
regulated  by  changes  in  localization  and  protein-protein  interactions  induced  by 
GTPase-binding.  The class II PAKs, PAK4-6, are regulated very differently than class I 
PAKs discussed above.  They bind to active Cdc42, but only very weakly to active Rac 
(Abo et al., 1998; Dan et al., 2002).  This difference in specificity is likely to result from 
sequence  differences  in  the  GTPase-binding  domains  of  class  I  and  class  II  PAKs, 
which show low homology outside of the conserved CRIB motif.  In contrast to class I 
PAKs, class II PAKs are not autoinhibited and their kinase activity is not enhanced by   28 
GTPase binding.  GTPase binding is thought to regulate the activity of class I PAKs in 
the cell by regulating their localization.  PAK4, for example, is recruited to the Golgi by 
active Cdc42 where it regulates actin structures (Abo et al., 1998). 
 
IRSp53 and PIR121 are adaptor proteins and Rac effectors that link Rac activation to 
Arp2/3-dependent  actin  assembly  through  the  WAVE  proteins  (see  section  1.3.1 
below).  IRSp53 binds via its SH3 domain to the proline rich region of WAVE, and 
activates WAVE in in vitro Arp2/3-dependent actin polymerization assays.  However 
this activation is not enhanced by addition of GTP-bound Rac1, and in vivo Rac is 
thought  to  regulate  IRSp53  by  controlling  its  localization.    In  agreement  with  this 
IRSp53  localizes  to  Rac-dependent  lamellipodia  in  fibroblasts  (Miki  et  al.,  2000).  
PIR121 is another Rac effector that forms a complex with WAVE proteins, but there is 
some controversy as to how this complex is regulated.  One group found that WAVE2 
in  a  complex  including  PIR121  is  active  in  terms  of  Arp2/3-dependent  actin 
polymerization, and addition of GTP-Rac did not enhance this activity, again suggesting 
Rac  is  regulating  the  PIR121-WAVE2  complex  by  controlling  its  localization 
(Innocenti et al., 2004).  Another group found WAVE1 to be in a similar complex 
including PIR121, but in this study the complex was inactive.  Binding of GTP-Rac to 
PIR121 disrupted the complex, resulting in activation of WAVE1 (Eden et al., 2002).  
In  this  case  the  effector  protein  is  being  regulated  by  changes  in  protein-protein 
interactions induced by GTPase-binding. 
 
1.2.7 Organization of Rho GTPase signalling pathways 
 
Signal transduction pathways need to be tightly controlled to ensure the cell responds 
appropriately to signals.  This is particularly true in the case of Rho GTPases, as they 
have the potential to regulate a large number of effector proteins to control a variety of 
responses.   Coupling upstream signals with the  correct downstream effector protein 
allows for signalling specificity.  Scaffold proteins are multidomain proteins that can 
simultaneously  bind  to  multiple  proteins,  and  so  can  coordinate  signal  transduction 
pathways by biasing upstream signals to specific downstream responses.  There are an 
increasing number of examples of Rho GEFs and Rho GAPs in biochemical complexes   29 
with Rho effector proteins, which allows regulation of Rho activity to be tightly coupled 
to  specific  effector  pathways.    Rho  GEFs  and  GAPs  are  themselves  multidomain 
proteins  with  the  potential  to  act  as  scaffolds.    The  large  number  of  Rho  GEFs 
(approximately in 80 humans) and Rho GAPs (approximately 70 in humans) identified 
compared to Rho GTPases (20 in humans) is consistent with them playing a role in 
determining  signalling  specificity,  as  different  upstream  regulators  could  potentially 
couple the same GTPase to different downstream targets under different conditions. 
 
The Cdc42 GEF intersectin binds to the Cdc42 effector protein N-WASP (Hussain et 
al.,  2001).    Intersectin  regulates  clathrin-dependent  endocytosis  and  localizes  to 
clathrin-coated vesicles.  N-WASP activates the Arp2/3 complex downstream of Cdc42 
to promote actin polymerization, which is required for transport of endocytic vesicles.  
Active Cdc42 generated by intersectin is therefore coupled specifically to the N-WASP 
effector pathway to regulate endocytosis.  Interestingly CdGAP, a GAP for Cdc42, also 
interacts with intersectin, and this might be important for tightly regulating the activity 
of N-WASP (Jenna et al., 2002).  During leukocyte chemotaxis Cdc42 activates its 
effector PAK1.  PAK1 is in a complex with the Cdc42 GEF α-Pix, which allows Cdc42 
activation to be coupled to PAK1 activation (Li et al., 2003). 
 
The Rac specific GEF Tiam1 binds to the scaffold protein Par3, which is found in a 
complex with the Rac (and Cdc42) effector protein Par6 (Mertens et al., 2005).  Rac 
activation by Tiam1 in keratinocytes is required to regulate Par6 and promote tight 
junction formation (see section 1.5.1 below), and the interaction between Tiam1 and 
Par3 couples Rac activation to Par6. 
 
Activation of RhoA by its GEF p115RhoGEF leads to activation of the JNK MAPK 
pathway, which requires MLK2 (a MAPKKK) and MKK7 (a MAPKK).  p115RhoGEF, 
MLK2 and MKK7 are all found in a complex with the scaffold protein CNK1, although 
in this case the direct effector protein for RhoA in this pathway is not known (Jaffe et 
al., 2005). 
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The above examples illustrate how protein complexes involving scaffold proteins, Rho 
GEFs, Rho GAPs and Rho effectors can impart specificity on Rho GTPase signalling 
pathways to activate appropriate responses.  
 
 
1.3 Basic functions of Rho GTPases 
 
 
Rho GTPases control a number of basic cellular processes, including the organization of 
the  actin  and  microtubule  cytoskeletons,  membrane  trafficking  events  and  gene 
transcription (see Figure 1.1 in section 1.1).  The ability of Rho GTPases to regulate 
these processes is dependent on their regulation of effector proteins, as discussed in 
section 1.2.6 (above). 
 
1.3.1 Regulation of the actin cytoskeleton 
 
Early experiments in fibroblasts showed that the three best characterized Rho family 
members, RhoA, Rac1 and Cdc42, regulate the formation of distinct actin structures, 
namely stress fibres, lamellipodia and filopodia respectively (Nobes and Hall, 1995; 
Ridley and Hall, 1992; Ridley et al., 1992).  Stress fibres are bundles of actin and 
myosin II filaments, which exert tension on the cell when anchored to the extracellular 
matrix  via  integrin-dependent  focal  adhesions,  and  can  contract  when  cell-matrix 
interactions are released.  Lamellipodia and filopodia are distinct types of actin-rich 
membrane protrusions formed as a result of actin polymerization.  Lamellipodia are 
broad membrane protrusions formed by a branched actin filament network beneath the 
plasma membrane.  When lamellipodia detach from the underlying substrate they can 
move across the cell surface, and are known as membrane ruffles.  Filopodia are long 
finger-like membrane protrusions containing linear bundles of polymerized actin.  Since 
these observations were made, the Rho family GTPases have emerged as key regulators 
actin  polymerization  and  organization,  and  therefore  control  a  number  of  cellular 
processes  such  as  migration,  division  and  morphogenesis.  The  actin  cytoskeleton  is   31 
regulated  by  Rho  GTPases  in  two  principle  ways:  they  can  stimulate  actin 
polymerization or induce actin filament bundling and contraction. 
 
1.3.1a Actin polymerization  
 
There are two main ways in which actin polymerization can be stimulated: nucleation of 
new filaments or elongation of existing filaments.  Nucleation of new actin filaments 
from actin monomers is thermodynamically unfavourable, as actin dimers are unstable.  
Two  major  actin  nucleators  exist  in  cells  to  stimulate  new  filament  assembly,  the 
Arp2/3 complex and the formins.  Actin filaments have an intrinsic polarity, with a 
barbed end and a pointed end, named after their appearance in EM  studies.  Actin 
monomers, if above critical concentration, will spontaneously assemble at the barbed 
end of an existing filament in vitro, but in the cell barbed ends are normally capped by 
capping proteins.  Free barbed ends can be generated by uncapping or severing of actin 
filaments. 
 
The  Arp2/3  complex  -  The  Arp2/3  complex  is  a  7-protein  complex  that  initiates 
nucleation of new actin filaments on the side of existing filaments, leading to branched 
actin networks (Millard et al., 2004).  Two of the proteins from this complex, Arp2 and 
Arp3, are actin-related proteins.  Actin dimers are unstable, and the rate-limiting step in 
actin  filament  nucleation  is  the  formation  of  actin  trimers.    The  Arp2/3  complex 
stimulates actin filament nucleation by mimicking an actin trimer, with its two Arp 
subunits binding an actin monomer.  The complex was first isolated biochemically from 
Acanthamoeba (Machesky et al., 1994).  The human Arp2/3 complex was subsequently 
isolated from platelets as a complex capable of initiating actin comet formation on the 
pathogenic  bacterium  Listeria  monocytogenes  (Welch  et  al.,  1997).    Bacteria  are 
transported  in  host  cells  by  stimulating  actin  polymerization  at  the  surface  of  their 
membrane. The Arp2/3 complex is found localized to these actin tails of cells infected 
with pathogenic bacteria and to lamellipodia of fibroblasts.  A clear role for the Arp2/3 
complex in lamellipodia formation was first demonstrated using blocking antibodies to 
block Arp2/3 activity, which prevented EGF-induced lamellipodia formation (Bailly et 
al., 2001).   32 
 
The  Arp2/3  complex  alone  has  low  actin  polymerizing  activity  and  needs  to  be 
activated.    One  family  of  proteins  that  activates  the  Arp2/3  complex,  and  does  so 
downstream of Rho GTPases, is the WASP (Wiskott-Aldrich syndrome protein) family.  
Wiskott-Aldrich  syndrome  (WAS)  is  an  immune  disease  characterized  by  recurrent 
infections as a result of defects in T and B cell function.  Cytoskeletal and chemotactic 
defects are found in haematopoietic cells from WAS patients.  Various loss of function 
mutations were found in the WASP gene in WAS patients (Derry et al., 1994).  WASP 
is expressed exclusively in haematopoietic cells, but a homolog N-WASP was later 
found in neurons, and is ubiquitously expressed.  Three more genes in the WASP family 
have since been discovered, WAVE -1,-2 and -3 (WASP family verprolin homologous, 
also called Scar), making 5 WASP family members in total in mammals (Millard et al., 
2004).  WAVE2 is expressed ubiquitously, whereas WAVE1 and 3 are found mostly in 
brain. 
 
WASP proteins are characterized by the presence of a conserved C-terminal module 
that  activates  the  Arp2/3  complex.    This  region  contains  three  domains,  the  WH2 
domain, the central domain, and the acidic domain, and so together is referred to as the 
WCA domain.  The WH2 domain (WASP homology 2) binds to profilin-actin.  The 
central  domain  is  involved  in  autoinhibition,  by  binding  to  the  N-terminal  CRIB 
domains of WASP and N-WASP (see section 1.2.6), and might also be involved in 
activation of the Arp2/3 complex.  The acidic domain is responsible for binding to the 
Arp2/3  complex.    WASP  and  N-WASP  differ  from  WAVE  proteins  in  their  N-
terminus.  WASP and N-WASP have a conserved WH1 (WASP homology 1) domain, 
which is involved in regulatory protein-protein interactions (this domain binds to the 
inhibitor WIP, WASP interacting protein, see below); a CRIB motif (Symons et al., 
1996); and an adjacent basic region which binds to PtdInsP2 (Prehoda et al., 2000).  
WAVE proteins have at their N-terminus a SHD (Scar homology domain) and a basic 
region  of  unknown  function.    Importantly,  WAVE  proteins  do  not  contain  a  CRIB 
motif, and unlike WASP and N-WASP are not Rho GTPase effector proteins, although 
they are regulated downstream of Rho GTPases (see below).  
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As described earlier (section 1.2.6) WASP is an effector protein for Cdc42, and binding 
of  active  Cdc42  can  activate  WASP  by  relieving  an  autoinhibitory  interaction.    N-
WASP can also be activated by another Cdc42 effector protein, Toca-1 (transducer of 
Cdc42-dependent actin assembly) (Ho et al., 2004).  In the cell N-WASP is found in an 
inactive  complex  with  an  inhibitory  protein,  WIP  (WASP-interacting  protein),  and 
Toca-1, acting downstream of Cdc42, is required to activate N-WASP and stimulate the 
Arp2/3 complex, although the details are not known. 
 
N-WASP was proposed to be the effector protein linking Cdc42 to filopodia formation, 
because dominant negative N-WASP or blocking antibodies against N-WASP inhibit 
Cdc42 dependent filopodia formation (Miki et al., 1998a).  Similar results were found 
with TC10 and TCL, which induce filopodia formation that was blocked by dominant 
negative N-WASP (Abe et al., 2003).  However N-WASP null fibroblasts (which also 
lack WASP) can still form filopodia in response to growth factors, suggesting WASP 
activity is not essential for filopodia formation (Snapper et al., 2001).  N-WASP also 
does  not  seem  to  play  a  major  role  in  lamellipodia  formation,  as  N-WASP  null 
fibroblasts or HeLa cells depleted of N-WASP by RNAi both form lamelipodia and 
membrane ruffles normally when stimulated by growth factors (Innocenti et al., 2005).  
N-WASP  has  been  localized  to  lamellipodial  protrusions  though,  where  it  might 
contribute  to  lamellipodia  formation  indirectly  through  membrane  trafficking  (see 
section 1.3.3 below) (Ridley, 2006). 
 
Scar/WAVE proteins also bind to and activate the Arp2/3 complex, via their conserved 
C-terminal VPA domain.  In contrast to WASP, purified WAVE is active in in vitro 
Arp2/3-dependent actin polymerization assays (Machesky et al., 1999).  This is because 
WAVE lacks the N-terminal autoregulatory domain and is not autoinhibited.  In vivo, 
WAVE is found in a multi-protein complex containing Abi (Abl-interacting protein), 
Nap1 (sometimes called Nap125, Nck-associated protein) and PIR121, and sometimes 
HSPC300.    PIR121  is  an  effector  protein  for  Rac,  which  provides  a  potential 
mechanism for WAVE-Arp2/3-dependent actin assembly to be regulated by Rac.  As 
described earlier (section 1.2.6), there is some  disagreement in how Rac-binding to 
PIR121 results in activation of WAVE.  In one model, Rac recruits the PIR121-WAVE   34 
complex to sites of actin polymerization, such as lamellipodia (Innocenti et al., 2004), 
while in another model the PIR121-WAVE complex is inactive and Rac-binding to 
PIR121 disrupts the complex to release active WAVE (Eden et al., 2002).  A second 
Rac effector that can mediate activation of WAVE downstream of Rac is IRSp53.  Rac 
recruits the IRSp53 to sites of actin polymerization ((Miki et al., 2000). 
 
WAVE  proteins  have  a  clear  role  in  Rac-dependent  lamellipodia  formation  and 
membrane  ruffling.    WAVE  proteins  have  been  localized  to  membrane  protrusions, 
where Rac is known to be active.  Expression of a WAVE mutant lacking the WH2 
domain, expected to act as a dominant negative, blocks Rac-dependent ruffling (Miki et 
al., 1998b).  Depletion of WAVE2 from HeLa cells prevents Rac-dependent membrane 
protrusions  (Innocenti  et  al.,  2004).    Finally  WAVE2-null  fibroblasts  have  severe 
defects  in  Rac-dependent  membrane  ruffling  and  lamellipodia  formation,  with 
inhibition of PDGF-induced migration (Yan et al., 2003). 
 
Diaphonous-related formins - The second main way in which new actin filaments are 
assembled  is  through  the  formins,  which  dimerize  and  promote  nucleation  of 
unbranched filaments.  All formins contain a conserved FH2 domain, essential for actin 
filament  nucleation,  flanked  by  a  conserved  proline-rich  FH1  domain  which  binds 
profilin-actin and facilitates actin polymerization (Kovar, 2006).  Once a filament has 
been  nucleated,  the  formin  dimer  remains  attached  to  the  growing  barbed  end, 
preventing it form being capped by capping proteins and allowing the formation of long 
actin filaments.  This mode of elongation is called processive.  A subset of formins, the 
diaphonous-related formins (DRFs), are regulated by Rho GTPases (Wallar and Alberts, 
2003).  There are three mammalian DRFs, DRF1-3.  These proteins are named after the 
Drosophila protein Diaphonous, mutation of which gives rise to polyploid germ cells as 
a result of defective cytokinesis.  The mammalian Diaphonous proteins are also referred 
to as Dia1, Dia2 and Dia3.  Confusingly, mDia2 is the mouse homologue of human 
Dia3 (both of which are DRF3), while mDia3 is the mouse homologue of human Dia2 
(both of which are DRF2).  
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DRFs contain N-terminal GTPase-binding domains (GBDs) that interact with a number 
of Rho family members in a GTP-dependent manner, including RhoA, RhoD, Cdc42 
and Rif (Alberts, 2001; Gasman et al., 2003; Pellegrin and Mellor, 2005; Watanabe et 
al.,  1997).    GTPase-binding  is  thought  to  activate  DRFs  by  relieving  an  inhibitory 
intramolecular interaction between the GBD and a C-terminal domain called the DAD 
(Dia autoregulatory domain), which holds the protein in a closed inactive conformation 
(Alberts, 2001). 
 
DRFs mediate the formation of filopodia downstream of Rho GTPases.  Cdc42-induced 
filopodia are blocked by microinjection of DRF3 blocking antibodies or expression of 
dominant-negative DRF3 (Peng et al., 2003).  Similarly Rif induces filopodia in HeLa 
cells, and this is blocked by expression of dominant-negative mDia2 (Pellegrin and 
Mellor,  2005).    DRFs  have  also  been  implicated  in  lamellipodia  formation  and 
membrane  ruffling  downstream  of  RhoA.    FRET-based  probes  have  been  used  to 
localize active RhoA in migrating cells, and surprisingly some activity was found at the 
front of the cells in association with membrane protrusions, in addition to the rear of the 
cell where it plays an established role in tail retraction (Kurokawa and Matsuda, 2005).  
RhoA  at  these  membrane  protrusion  is  thought  to  be  acting  through  DRFs,  where 
mDia1 has been localized.  However it is not clear if the role of mDia1 at the leading 
edge  is  to  assemble  F-actin,  and  it  is  likely  to  be  playing  an  additional  role  in 
microtubule stabilization (see section 1.3.2 below).  Another role for DRF-dependent 
actin  polymerization  is  in  stress  fibre  formation  downstream  of  Rho.    Rho-induced 
stress fibre formation was initially thought to involve bundling of existing filaments 
rather than polymerization (Machesky and Hall, 1997).  However live imaging studies 
have shown that some stress fibres do form by actin polymerization (Hotulainen and 
Lappalainen, 2006), and this is blocked by mDia1 knockdown. 
 
Cofilin/ADF - Actin polymerization can also be stimulated by the severing of existing 
actin filaments, which generates new barbed ends.  Actin monomers will spontaneously 
assemble on the barbed end of an actin filament until the filament becomes capped by a 
capping protein.  Cofilin is a small (19kD) actin-binding protein that binds to and severs 
actin filaments leading to barbed end elongation (Desmarais et al., 2005).  Cofilin also   36 
stimulates pointed end depolymerization and is also called ADF (actin depolymerizing 
factor).  Cofilin regulates membrane protrusion at the leading edge of migrating cells by 
stimulating actin assembly, while also stimulating actin recycling by depolymerizing 
the pointed ends of filaments behind the leading edge (Chan et al., 2000).  Cofilin 
cooperates with the Arp2/3 complex to generate membrane protrusions (Bailly et al., 
2001).    Phosphorylated  cofilin  (which  is  inactive)  is  excluded  from  lamellipodia  in 
fibroblasts (Dawe et al., 2003), and expression of active LIMK to phosphorylate and 
inactivate endogenous cofilin caused defects in polarized migration.  A clear role for 
cofilin in actin assembly at the leading edge was shown using photoactivatable mutant 
of cofilin.  Activation of cofilin locally at the cortex lead to the generation of barbed 
ends, actin polymerization, and lamellipodia formation and determined the direction of 
cell migration (Ghosh et al., 2004). 
 
Cofilin  can  be  negatively  regulated  by  phosphorylation  of  serine3  downstream  of 
LIMK1/2, which in turn can be phosphorylated and activated by PAKs (p21-activated 
kinases) and ROCK, downstream of active Rac/Cdc42 and Rho respectively (Burridge 
and Wennerberg, 2004; Dan et al., 2001).  Furthermore, cofilin can be activated by 
dephosphorylation  of  serine3  by  slingshot  phosphatases  (SHH),  and  PAK4  can 
phosphorylate  and  inhibit  SHH1  (Soosairajah  et  al.,  2005).    Active  forms  of  PAK 
proteins induce similar effects on the actin cytoskeleton to active Rac and Cdc42, for 
example filopodia, membrane ruffling, and loss  of stress fibres and focal adhesions 
(Dan et al., 2001; Manser et al., 1997; Qu et al., 2001; Sells et al., 1997).  However it is 
not clear what role, if any, signaling through PAK-LIMK-cofilin plays downstream of 
Rho GTPases in these processes.  Some of the effects of active PAK4 are blocked by 
kinase-dead  LIMK,  such  as  formation  of  cytoplasmic  F-actin  clusters,  but  whether 
filopodia formation requires the LIMK-cofilin pathway has not been tested.  PAK1-
induced ruffling does not require kinase activity, so presumably is not acting through 
LIMK, and in any case cofilin needs to be activated at the leading edge to promote 
membrane protrusion, not inhibited as would happen if it was being regulated by PAK.  
Inhibition  of  cofilin  downstream  of  Rho-ROCK-LIMK  might  be  important  in  SF 
formation; inhibition of the deploymerizing activity of cofilin could help stabilize actin 
filaments (see section 1.3.1b below) (Burridge and Wennerberg, 2004).   37 
 
1.3.1b Actin filament bundling and contraction 
 
The second major way in which Rho GTPases regulate the actin cytoskeleton is by 
controlling  filament  bundling  and  contraction,  exemplified  by  Rho-dependent  stress 
fibre formation.  Stress fibres are thick bundles of actin filaments and myosin II motor 
protein that can be linked to the ECM to provide adhesion and tension, and can control 
cell shape and contraction during migration and division.  The major pathway involved 
in regulating bundling and contraction of actin filaments downstream of Rho is the 
ROCK pathway.  ROCK (Rho coiled-coil kinase) is activated by GTP-bound RhoA, 
and this leads to phosphorylation and activation of myosin light chain (MLC) through 
direct ROCK-dependent phosphorylation, and ROCK-dependent phosphorylation and 
inhibition  of    MLC  phosphatase.    Activated  myosin  binds  to  and  bundles  actin 
filaments, and through its ATPase-dependent motor activity causes bundled filaments to 
contract if they are not anchored via integrins to the extracellular matrix.  ROCK also 
phosphorylates  and  activates  LIMK,  which  inhibits  the  actin  severing  and 
deploymerizing protein cofilin and might contribute to formation of stable stress fibres 
(Burridge and Wennerberg, 2004).  
 
Another Rho effector that stimulates actomyosin contractility through phosphorylation 
of MLC is the kinase citron.  The kinase domain of citron kinase is homologous to that 
of ROCK, and outside of the kinase domain citron has a similar domain organization to 
ROCK, including a coiled-coil region with a GTPase-binding domain for RhoA.  Citron 
seems  to  function  primarily  in  cytokinesis,  a  process  that  depends  heavily  on 
actomyosin contraction (Madaule et al., 1998). 
 
1.3.2 Regulation of the microtubule cytoskeleton 
 
The  microtubule  cytoskeleton  organizes  the  interior  of  cells  by  controlling  the 
movement of vesicles and organelles, and in interphase cells has important roles in 
controlling polarization and migration.  In mitotic cells the microtubule cytoskeleton 
forms the mitotic spindle and is essential for chromosome segregation.  Microtubules   38 
are polymers of α- and β-tubulin heterodimers.  Microtubule polymers show an intrinsic 
polarity, with a stable minus end normally anchored at the centrosome, and a highly 
dynamic  plus  end  capable  of  rapidly  switching  between  polymerization  and 
depolymerization.  Microtubule dynamics can be regulated by a large family of MAPs 
(microtubule-associated proteins) (Akhmanova and Steinmetz, 2008).  These proteins 
regulate  microtubule  dynamics  in  a  number  of  ways,  including  binding  to  soluble 
tubulin heterodimers and controlling their availability for microtubule elongation (eg. 
Stathmin  and  CRMP-2),  binding  to  microtubule  plus  ends  and  regulating  plus  end 
polymerization, depolymerization, or stabilization (eg. EB1, CLIP170 and APC), and 
finally binding to the microtubule array in general and controlling its stability (eg. Tau).  
A subset of MAPs are motor proteins, such as the kinesins and dyneins, which move 
along microtubules towards the plus and minus ends respectively, and play important 
roles in trafficking of associated cargo.  Rho GTPases have been implicated in the 
regulation of microtubule polymerization and microtubule stabilization by binding to a 
number of MAPs, including tubulin dimer binding proteins and microtubule plus end 
binding proteins. 
 
Microtubule polymerization - CRMP-2 (collapsin response mediator protein) binds to 
microtubules and to tubulin dimers and enhances the rate of tubulin polymerization in 
vitro.  In cells CRMP-2 becomes incorporated in to microtubules, and is thought to 
promote  plus  end  elongation  by  binding  to  growing  plus  ends  and  enhancing 
polymerization (Fukata et al., 2002b).  The Rho effector protein ROCK phosphorylates 
CRMP-2, resulting in MT disassembly and growth cone collapse in neurons, which can 
also be induced by LPA in a Rho-ROCK-dependent manner (Arimura et al., 2000).  
Stathmin also binds to microtubule plus ends and to tubulin dimers, but in contrast to 
CRMP-2  it  depolymerizes  microtubules  and  prevents  incorporation  of  tubulin  in  to 
microtubules.  Stathmin activity can be inhibited by phosphorylation on a number of 
residues, including serine 16.  Phosphorylation of this residue occurs downstream of 
active Rac and Cdc42, and is likely to be mediated through PAK (Daub et al., 2001). 
 
Microtubule  stabilization  -  Dynamic  microtubules  can  be  stabilized  at  the  cell 
periphery by the action of capping proteins, and this is also regulated by Rho GTPases.    39 
Active Rho promotes microtubule stabilization in fibroblasts through its effector mDia1 
(Palazzo  et  al.,  2001).    Stabilization  of  microtubules  requires  the  plus  end  binding 
proteins  EB1  and  APC.    EB1  binds  to  the  plus  end  of  dynamic  microtubules  and 
stimulates their elongation, while the plus  ends  of stable microtubules are found to 
contain both EB1 and APC.  EB1 and APC interact with each other, and also interact 
with mDia1, which colocalizes with EB1 and APC at the tips of stable microtubules in 
polarized fibroblasts (Wen et al., 2004).  RhoA is known to be active at the leading edge 
of  migrating  cells,  and  its  role  there  might  be  to  activate  mDia1  and  stabilize 
microtubules in a polarized manner through EB1 and APC (Kurokawa and Matsuda, 
2005). 
 
Rac and Cdc42 have also been implicated in the stabilization of microtubules at the cell 
cortex, through their effector proteins IQGAP and Par6.  IQGAP1 binds to CLIP170, 
another  microtubule  plus  end-binding  protein,  and  this  interaction  is  enhanced  by 
binding of GTP-Rac or Cdc42 to IQGAP1 (Fukata et al., 2002a).  IQGAP1 localizes to 
the leading edge of migrating fibroblasts, and is thought to stabilize microtubules there 
through its interaction with CLIP170 and cortical actin filaments.  IQGAP1 also binds 
to APC, and both APC and IQGAP1 are required for stabilization of CLIP170-positive 
microtubule plus ends at the leading edge of fibroblasts, and for directed cell migration 
(Watanabe et al., 2004).  Par6, with its associated kinase aPCK, is recruited to the 
leading edge of astrocytes in response to Cdc42 activation, and this results in localized 
inhibition of GSK3-β (Etienne-Manneville and Hall, 2003).  This localized inhibition is 
required for the association of APC, a known substrate of GSK3-β, with EB1 at the plus 
ends of microtubules. 
 
1.3.3 Regulation of membrane trafficking 
 
Rho GTPases regulate various aspects of membrane trafficking, including the transport 
of vesicles between different organelles in both the secretory and endocytic pathways, 
and  the  membrane  fusion  and  fission  events  occurring  during  exocytosis  and 
endocytosis (Ridley, 2006). 
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Vesicle trafficking - Cdc42 is partly localized at the Golgi in many cells, and has been 
implicated in vesicle trafficking between the ER and Golgi, in both the anterograde (ie. 
ER to Golgi) (Wu et al., 2000) and retrograde (ie. Golgi to ER directions) (Luna et al., 
2002).  Transport vesicles between the ER and Golgi are coated with the COPI complex 
(coat  protein  complex  I),  including  Arf1  and  coatomer  proteins.    γ-coatomer  is  an 
effector protein for Cdc42, as it interacts specifically with GTP-bound Cdc42.  Cdc42 
has been localized to COPI vesicles associated with the Golgi complex, and might play 
a role in regulating COPI-coated vesicle formation (Wu et al., 2000). 
 
Cdc42  is  also  required  for  the  trafficking  of  vesicles  between  other  membrane 
compartments, such as the Golgi to the basolateral membrane of MDCK cells (Musch et 
al., 2001) and in the movement of secretory vesicles to the plasma membrane in PC12 
cells  (Gasman  et  al.,  2004).    Cdc42  can  regulate  the  movement  of  vesicles  by 
stimulating  Arp2/3-dependent  actin  polymerization  on  the  membrane  surface  of  the 
vesicle.  This phenomenon of actin-driven vesicle movement was first seen in cells 
infected  with  pathogenic  bacteria  such  as  Listeria  monocytogenes,  which  directly 
activate the Arp2/3 complex at their membrane resulting in the formation of an actin 
comet, which transports the bacterium inside the host cell (Welch et al., 1997).  Cdc42 
can  activate  the  Arp2/3  complex  indirectly,  through  the  WASP  family  of  adaptor 
proteins  (see  section  1.3.1  above).    N-WASP,  like  the  Arp2/3  complex,  has  been 
implicated in vesicle trafficking (Gasman et al., 2004; Luna et al., 2002). 
 
Endocytosis - Both Rac1 and RhoA negatively regulate clathrin-dependent endocytosis, 
as  expression  of  constitutively  active  mutants  prevented  internalization  of  the  EGF 
receptor (Kaneko et al., 2005; Malecz et al., 2000).  In the case of Rac, inhibition of 
endocytosis  occurs  through  its  effector  synaptojanin2,  a  PI-5  phosphatase  that 
dephosphorylates PtdIns(4,5)P2.  PtdIns(4,5)P2 stimulates endocytosis as it binds to the 
adaptor  protein  AP2  to  enhance  its  interaction  with  clathrin,  and  also  binds  to  and 
activates the GTPase dynamin, which is required for vesicle fission (Jost et al., 1998).  
Active Rac1 can therefore inhibit endocytosis by activating synaptojanin2 at the plasma 
membrane, which in turn results in decreased levels of PtdIns(4,5)P2.  In the case of 
RhoA,  inhibition  of  clathrin-dependent  endocytosis  might  occur  through  its  effector   41 
protein ROCK (Kaneko et al., 2005).  ROCK phosphorylates endophilin, an endocytic 
accessory protein that binds to lipid bilayers to regulate clathrin-coated pit formation 
and also binds to dynamin to regulate vesicle fission. 
 
Exocytosis - The exocyst complex is a conserved protein complex that regulates vesicle 
docking  and  fusion  at  the  plasma  membrane.    In  yeast,  GTPases  including  Cdc42 
regulate the localization and activity of the exocyst complex at the plasma membrane, 
which is important for establishing membrane polarity (Wu et al., 2008).  In mammals 
Cdc42 and the closely related Rho family member TC10 stimulate exocytosis (Gasman 
et al., 2004; Inoue et al., 2003), and in the case of TC10 this has been shown to involve 
recruitment of the exocyst complex component Exo70 to the plasma membrane.  The 
role  of  Rho  GTPases  is  regulating  exocyst  complex-dependent  exocytosis  therefore 
seems to be conserved in mammals. 
 
1.3.4 Regulation of gene expression 
 
Rho  GTPases  regulate  gene  expression  through  a  number  of  different  signalling 
pathways, including MAP kinase pathways and the serum response factor (SRF). 
 
MAP  kinase  pathways  -  MAPK  (mitogen-activated  protein  kinase)  signalling 
pathways  convey  cellular  signals  to  regulate  nuclear  transcription  factors  and  gene 
expression,  and  control  proliferation,  differentiation  and  survival  (Turjanski  et  al., 
2007).  MAPK signalling cassettes consist of a MAPK kinase kinase (MAPKKK), a 
MAPK kinase (MAPKK) and a  MAPK, which  are evolutionarily conserved protein 
kinases that phosphorylate and activate each other in a sequential manner.  Activated 
MAPKs  phosphorylate  and  activate  transcription  factors,  including  TCF  (ternary 
complex factor), c-Myc, c-Jun and c-Fos.  There are three main MAPK families, the 
ERK family (extracellular signal-regulated kinase, ERK1 and ERK2), the JNK family 
(c-Jun N-terminal kinase, JNK1-3, also called SAPK, stress-activated protein kinase), 
and  the  p38  family  (p38-α,-β,-γ,-δ).    Rho,  Rac  and  Cdc42  have  all  been  found  to 
activate the JNK pathway under various conditions (Coso et al., 1995; Jaffe et al., 2005; 
Minden et al., 1995), while Rac and Cdc42 also activate the p38 pathway (Bagrodia et   42 
al., 1995; Frost et al., 1997).  A number of MAPKKKs are direct effector proteins for 
Rho-family GTPases, and this is a potential mechanism for Rho GTPases to regulate 
MAPK pathways.  MLK2 and MLK3, for example, bind to active Rac and Cdc42, and 
are activated by GTPase-dependent dimerization (Leung and Lassam, 1998; Zhao and 
Manser,  2005).    MEKK1  and  MEKK4  also  bind  to  active  Rac  and  Cdc42,  and 
Rac/Cdc42-dependent JNK activation is blocked by expression of kinase-dead MEKK1 
or MEKK4 (Fanger et al., 1997).  MEKK1 is also activated by  GTP-bound RhoA, 
which could provide a mechanism for Rho to activate the JNK pathway (Gallagher et 
al., 2004).  
 
While Rho GTPases do not in general activate the ERK pathway, they have been found 
to cooperate with the Ras-Raf pathway to activate ERK in some cases.  The Rac and 
Cdc42 effector PAK1 phosphorylates MEK1, the MAPKK in the pathway, and while 
this does not affect the kinase activity of MEK1 towards ERK1, it does increase the 
affinity of MEK1 for Raf, the MAPKKK in the pathway (Frost et al., 1997). 
 
Serum response factor - A number of genes whose expression is regulated by growth 
factors or serum contain serum response elements (SRE) in their promoters, including 
c-Fos and actin (Miralles et al., 2003).  Transcription of these genes is stimulated by 
Rho acting through the serum response factor (SRF), which binds directly to the SRE.  
This regulation is thought to be mediated, at least in part, through actin polymerization.  
SRF is active when in a complex with its coactivator, MAL, which also binds to G-
actin.  Nuclear localization of MAL is regulated by cytoplasmic levels of G-actin, such 
that when actin polymerization is stimulated by Rho and G-actin levels decrease, MAL 
translocates to the nucleus.  It should be noted, however, that additional regulatory 
mechanisms must be involved, as actin polymerization does not always lead to SRF 
activation.  Rac and Cdc42, for example, are weak activators of SRF even though they 
strongly stimulate actin polymerization (Jaffe and Hall, 2005). 
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1.4 Epithelial morphogenesis and apical junctions 
 
 
The term epithelial morphogenesis refers to the complex series of events leading to the 
formation of a mature epithelial structure.  During the development of a multicellular 
organism the proliferation, differentiation, migration and adhesion of epithelial cells are 
coordinately regulated to form adult tissues and organs.  During disease states, such as 
cancer,  these  processes  are  misregulated,  leading  to  disorganization  of  epithelial 
structures and tumour formation.  
 
Epithelial  cells  are  a  specialized  cell  type  that  form  selectively  permeable  barriers 
between different compartments of a multicellular organism.  Simple epithelia consist 
of a single layer of epithelial cells that play essential roles in homeostasis by regulating 
adsorption and secretion of molecules in to and out of organs.  The ability of epithelial 
cells to form selectively permeable barriers is dependent on the formation of cell-cell 
junctions and the establishment of cell polarity.  Cell-cell junctions, including adherens 
junctions  and  tight  junctions,  are  formed  by  the  interaction  of  integral  plasma 
membrane  proteins  between  neighbouring  cells.    Adherens  junctions  are  principally 
involved  in  cell-cell  adhesion,  while  tight  junctions  provide  the  barrier  function  by 
preventing  the  diffusion  of  molecules  through  the  paracellular  space  between  cells.  
Tight  junctions  form  charge-  and  size-selective  pores,  allowing  movement  of  ions 
across epithelia in a regulated manner.  Cells within an epithelium are polarized, with an 
apical  surface  facing  a  fluid-filled  lumen  or  the  exterior,  and  a  basolateral  surface 
making  cell-cell  and  cell-matrix  contacts.    Differential  localization  of  channels  and 
transporters  on  the  apical  and  basolateral  surfaces  allows  epithelial  cells  to  control 
adsorption and secretion. 
 
1.4.1 The apical junctional complex (AJC) 
 
Epithelial junctions consist of transmembrane cell adhesion molecules that interact with 
cell  adhesion  molecules  on  neighbouring  cells  via  their  extracellular  domains,  and 
interact with soluble cytoplasmic proteins and the cytoskeleton via their cytoplasmic   44 
domains.    Epithelial  junctions  were  first  observed  in  EM  studies  of  a  number  of 
epithelia,  which  were  found  to  have  a  common  series  of  electron  dense  structures 
arranged along the cell-cell contact region (Farquhar and Palade, 1963).  The zonula 
occludens,  or  tight  junction,  is  charactrized  by  the  complete  obliteration  of  the 
intracellular space, as membranes from neighbouring cells form a tight seal.  Tight 
junctions are located at the apical end of the lateral membrane, at the boundary between 
the apical and basolateral plasma membrane domains, and form a continuous ring in the 
apex of the cell.  The zonula adherens, or adherens junction, forms just basal to the tight 
junction at the lateral membrane.  Plasma membranes of neighbouring cells are aligned 
along the length of an adherens junction but membranes do not completely seal, and a 
small paracellular space remains.  In most, but not all, epithelia adherens junctions form 
a continuous ring around the cell.  Adherens junctions and tight junctions together are 
referred to as the apical junctional complex, as they are found at the apical end of the 
lateral membrane (Figure 1.3).  A third type of intercellular junction typically found in 
epithelia is the desmosome.  Desmosomes are more varied between different epithelia, 
and can be located in discrete spots all over the basolateral membrane.  Desmosomes 
are not generally considered to be part of the apical junctional complex.   45 
  
 
Protein  Type  Junction  Function 
E-cadherin  TM  Adherens  Cell-cell adhesion 
β-catenin  adaptor  Adherens  Links cadherin complex to α-catenin 
γ-catenin  adaptor  Adherens/ 
desmosome 
Normally found in desmosomes.  Can 
substitute for β-catenin in adherens 
junctions. 
α-catenin  adaptor  Adherens  Actin filament binding 
Regulation of actin dynamics 
p120-catenin  adaptor  Adherens  Stabilization of E-cadherin at plasma 
membrane 
Nectin  TM  Adherens  Cell-cell adhesion 
Afadin  adaptor  Adherens  Actin filament binding 
Links nectin and cadherin complexes 
through α-catenin 
Claudin  TM  Tight  Tight junction strand formation 
Selective barrier functions 
Occludin  TM  Tight  Not clear 
ZO-1/2 
ZO-3 
scaffold  Tight  Facilitate claudin clustering (see text) 
Recrutiment of polarity proteins 
JAM-A  TM  Tight  Cell-cell adhesion 
Recruitment of polarity complexes 
Tricellulin  TM  Tight  Stabilization of tricellular junctions 
 
Table 1.1 Components of epithelial apical junctions.  Principal components of adherens junctions and 
tight junctions are listed, with a brief description of their function.  See text for more details.  Note that 
many junctional proteins have additional functions, not discussed, for example as components of cellular 
signalling pathways.  TM - transmembrane.   46 
1.4.2 Adherens junctions 
 
Two main types of transmembrane cell-cell adhesion proteins are found in adherens 
junctions, the cadherins and the nectins (see Table 1.1).  Cadherins are a large family of 
transmembrane glycoproteins that have essential roles in cell adhesion and sorting and 
tissue  formation  and  maintenance.    Cadherins  are  characterized  by  the  presence  of 
conserved  extracellular  (EC)  domains,  which  mediate  calcium-dependent  cell-cell 
adhesion (Nagafuchi et al., 1987).  Classical cadherins, including the epithelial adherens 
junction protein E-cadherin, contain five tandem repeats of the EC domain.  EC1, the 
furthest  EC  repeat  from  the  plasma  membrane,  mediates  trans-dimerization  of  E-
cadherin,  which  explains  why  a  gap  of  approximately  25  nm  is  observed  between 
opposing membranes at adherens junctions.  Crystal structures of a number of cadherin 
extracellular domains have revealed that calcium-binding is essential for stabilizing the 
structure of the extracellular domain and for trans-dimerization of EC1 domains (Nagar 
et al., 1996; Pokutta and Weis, 2007; Shapiro et al., 1995).  The first crystal structures 
of cadherin EC1 domains suggested two modes of dimerization were possible, leading 
to models in which cis-dimerization of cadherins on the same membrane facilitated 
subsequent trans-dimerization of cadherins on opposing membranes.  However whether 
cis-dimerization plays a role in cadherin adhesion is still uncertain (Pokutta and Weis, 
2007). 
 
The highly conserved cytoplasmic domain of E-cadherin is also essential for cell-cell 
adhesion  (Nagafuchi  and  Takeichi,  1988).    This  cytoplasmic  domain  binds  to  the 
catenin  family  of  adaptor  proteins,  which  functionally  link  cadherins  to  the  actin 
cytoskeleton.  Catenins bind via their conserved armadillo repeats to the cytoplasmic 
tail of E-cadherin.  β-catenin binds to the membrane-distal region of the E-cadherin 
cytoplasmic tail, while p120-catenin binds to the membrane-proximal region.  γ-catenin 
(plakoglobin)  is  normally  found  in  desmosomes,  but  can  substitute  for β-catenin  in 
adherens junctions.  α-catenin is also found in E-cadherin complexes, but does not bind 
directly to E-cadherin.  Instead α-catenin is recruited to the E-cadherin complex by 
interaction with β-catenin. (Jou et al., 1995).  α-catenin has regions of homology to the   47 
actin binding protein vinculin, and α-catenin binds to and bundles F-actin via its C-
terminus (Rimm et al., 1995).  α-catenin was therefore assumed to physically link the 
cadherin-catenin complex to the underlying actin cytoskeleton.  However recent work 
has shown that α-catenin can not simultaneously bind actin filaments and β-catenin 
(Yamada et al., 2005).  A number of α-catenin-binding proteins can also bind to F-
actin, including vinculin and α-actinin, but none have been shown to bind α-catenin and 
F-actin  simultaneously,  so  it  is  now  unclear  whether  the  cadherin-catenin  complex 
interacts  physically  with  F-actin  at  cell-cell  contacts.    Indeed  FRAP  and  FLIP 
experiments have shown that junctional F-actin is surprisingly dynamic, whereas E-
cadherin,  β-catenin  and  α-catenin  are  more  stable  at  cell-cell  contacts.    Instead  of 
providing a mechanical link between cadherin complexes and the actin cytoskeleton, α-
catenin  plays  an  important  role  in  regulating  cytoskeletal  dynamics  during  junction 
formation, as it recruits formin-1 and Mena/VASP to junctions and inhibits the Arp2/3 
complex (Drees et al., 2005; Kobielak et al., 2004; Vasioukhin et al., 2000) (see section 
1.4.4 below). 
 
In addition to its role in recruiting α-catenin to the cadherin complex, β-catenin is also 
important for stabilization and trafficking of E-cadherin to the basolateral membrane.  
The  E-cadherin  cytoplasmic  domain  is  structurally  disordered,  but  becomes  ordered 
when β-catenin binds.  β-catenin associates with the cytoplasmic domain of E-cadherin 
very early in the secretory pathway, while E-cadherin is still in the ER (Hinck et al., 
1994).  Mutation of the β-catenin binding domain of E-cadherin causes E-cadherin to 
accumulate in the ER and ultimately leads to its degradation.  The small amount of E-
cadherin that does leave the ER through the  secretory pathway does not get sorted 
properly to the basolateral membrane but is distributed randomly over both apical and 
basolateral plasma membrane domains (Chen et al., 1999). 
 
p120-catenin regulates E-cadherin stability at the plasma membrane.  Loss of p120-
catenin  leads  to  decreased  expression  of  E-cadherin,  and  this  reflects  increased 
degradation  rather  than  decreased  synthesis  (Davis  et  al.,  2003).    E-cadherin  is 
trafficked to the plasma membrane normally in p120-catenin-knockdown cells, but is   48 
not retained there and is internalized and degraded.  p120-catenin has therefore been 
proposed to stabilize E-cadherin at the plasma membrane by inhibiting its endocytosis. 
 
A  second  class  of  transmembrane  protein  found  in  adherens  junctions  is  the  nectin 
family  (Takahashi  et  al.,  1999).    Nectins  are  immunoglobin-like  single-span  cell 
adhesion molecules, with three extracellular immunoglobin-like loops, a transmembrane 
domain and a cytoplasmic tail.  Four mammalian nectin genes have been identified, 
each having several splice variants.  Nectins form cis-dimers, and this dimerization is 
essential  for  their  trans-interactions,  which  can  occur  in  homo-  and  heterophilic 
manners  (Ebnet,  2008).  The  cytoplasmic  tail  of  nectins  contains  a  C-terminal  PDZ 
binding  motif  that  interacts  with  the  adaptor  protein  afadin.    Nectin  and  afadin 
colocalize with E-cadherin in nascent spot-like adherens junctions and mature belt-like 
adherens junctions (Asakura et al., 1999).  Afadin can interact with F-actin, and might 
provide  a  link  between  adherens  junctions  and  the  actin  cytoskeleton.    Afadin  also 
interacts with α-catenin and might provide a link between the cadherin-catenin and 
nectin-afadin adhesion systems. 
 
Evidence for a role for nectins in adherens junction formation has come from studies in 
cells expressing exogenous nectin, which show calcium-independent aggregation and 
recruitment of E-cadherin to trans-interacting nectins at cell-cell contacts (Tachibana et 
al.,  2000;  Takahashi  et  al.,  1999).    Nectin  ligation  leads  to  activation  of  the  small 
GTPases Cdc42 and Rac1, through Src family kinases and the GEFs FRG and Vav2, 
and this might contribute to adherens junction formation by promoting filopodia and 
lamellipodia formation (see section 1.4.4 below) (Fukuhara et al., 2004; Kawakatsu et 
al., 2005; Kawakatsu et al., 2002).  However, all functional studies on nectins have been 
performed  in  cells  expressing  exogenous  nectin,  and  clear  evidence  for  a  role  for 
endogenous nectins in AJ formation is lacking.  In contrast to afadin, which is essential 
for viability and epithelial junction formation in mouse embryonic ectoderm (Ikeda et 
al.,  1999),  knockout  of  individual  nectin  genes  does  not  impair  epithelial  junction 
formation (Inagaki et al., 2006; Inagaki et al., 2005).  
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1.4.3 Tight junctions 
 
Tight  junctions,  or  zonula  occludens,  are  areas  where  the  plasma  membranes  of 
neighbouring cells are completely sealed (Farquhar and Palade, 1963).  Freeze-fracture 
EM has shown these junctions are made of networks of paired tight junction strands, 
running along the plane of the plasma membrane and sealing cells together.  These 
strands were originally speculated to be made of lipids, but are now known to be made 
of proteins polymers of the tetraspan transmembrane proteins claudin, occludin, and in 
some cases tricellulin (see Table 1.1), although a role for lipids has not been ruled out 
(Furuse et al., 1993; Furuse et al., 1998; Ikenouchi et al., 2005).  These proteins have 
similar  topologies,  consisting  of  four  transmembrane  domains  linked  by  two 
extracellular loops, and N- and C- terminal cytoplasmic tails mediating a number of 
protein-protein interactions.  However while occludin and tricellulin are homologous in 
their C-terminal tails, the claudins are unrelated to occludin and tricellulin. 
 
The  claudin  family  contains  24  members,  with  tissue  specific  expression  profiles.  
Claudins are the main protein components of tight junction strands, and expression of 
single claudin proteins is sufficient for tight junction strand formation in fibroblasts 
(Furuse et al., 1998).  Claudins regulate selective permeability to ions, and the wide 
range of selectivity exhibited by different epithelia is thought to result from expression 
of different claudin proteins.  Cell culture experiments have shown that manipulation of 
claudin  type  changes  ion  permeability,  and  this  idea  has  been  validated  by  mouse 
knockout studies and naturally occurring claudin mutations in human disease, which 
result in defects in epithelial barrier function in specific tissues (Aijaz et al., 2006).  The 
claudin  extracellular  loops  are  highly  charged  and  show  least  sequence  homology 
between different family members, and are thought to form charge- and size-selective 
pores, but the structural details of these pores have not been examined. 
 
Occludin was the first integral membrane protein to be discovered at tight junctions 
(Furuse et al., 1993), but its function remains unclear.  Occludin is incorporated in to 
claudin-positive  tight  junction  strands,  but  its  expression  is  not  sufficient,  or  even 
necessary,  for  tight  junction  strand  formation.    Functional  studies  in  cultured  cells   50 
suggested occludin plays a regulatory role in tight junction function.  For example, 
exogenous expression of occludin in MDCK cells caused an increase in transepithelial 
resistance  (TER),  reflecting  decreased  permeability  to  ions,  but  also  an  increased 
permeability to fluorescent markers, without affecting tight junction structure (Balda et 
al., 1996).  Knockout studies of occludin however have not revealed any general defects 
in  tight  junctions,  either  structurally  or  functionally.    Occludin-deficient  embryonic 
stem cells develop in to normal embryoid bodies in culture, with a structurally and 
functionally intact visceral endoderm (epithelial) layer (Saitou et al., 1998).  Occludin-
deficient  mice  develop  normally,  with  only  subtle  developmental  defects,  including 
histological abnormalities in the gastric gland and salivary glands that seem to result 
from misregulation of differentiation (Saitou et al., 2000).  Occludin therefore seems to 
play more of a signalling role rather than being involved in regulation of tight junctions, 
and  indeed  it  is  becoming  increasingly  evident  that  tight  junctions  are  signalling 
hotspots controlling many aspects of cell behaviour (Matter and Balda, 2003b). 
 
Another tetraspan transmembrane protein identified at tight junctions is tricellulin.  This 
protein is homologous to occludin in its C-terminal cytoplasmic tail, which binds the 
adaptor protein ZO-1.  In contrast to occludin and claudins, tricellulin is enriched at the 
junction between three cells, the tricellular junction.  Freeze-fracture EM analysis of 
tight  junctions  has  revealed  these  to  be  weak  points  in  the  TJ  strand  organization.  
Knockdown experiments have shown tricellulin is required to fully seal membranes at 
these points and maintain epithelial barrier function (Ikenouchi et al., 2005). 
 
Members of the CTX family of immunoglobin-like single span transmembrane proteins 
also  localize  to  tight  junctions,  including  the  JAM  (junctional  adhesion  molecule) 
proteins (Ebnet, 2008).  Of these JAM-A is the best characterized as far as epithelial 
tight junctions are concerned.  Ectopic expression of JAM-A in fibroblasts results in the 
formation of cell-cell contacts, showing JAM-A mediates homophilic cell-cell adhesion.  
JAM-A does not form tight junction strands, but is closely associated with tight junction 
strands formed by claudin expression in fibroblasts (Itoh et al., 2001).  During junction 
formation, JAM-A is one of the first tight junction proteins to be recruited and is likely 
to play a role in recruiting other tight junction proteins as junctions mature (see section   51 
1.4.4 below).  Expression of JAM-A mutants or RNAi-mediated knockdown of JAM-A 
delays  tight  junction  formation  and  results  in  reduced  TER  and  increased  dextran 
permeability in monolayers (Ebnet et al., 2001; Mandell et al., 2005). 
 
A general feature of tight junction transmembrane proteins is their ability to bind to 
cytoplasmic adaptor proteins, such as the ZO (zonula occludens) family of MAGUK 
(membrane  associated  guanylate  kinase)  proteins,  via  their  C-terminal  tails.    Three 
mammalian ZO proteins share conserved domain organization, consisting of three PDZ 
domains in their N-terminus and a SH3 and GUK domain in their C-terminus (Ebnet, 
2008).  ZO proteins bind via their PDZ domains to the C-terminal PDZ-binding motif of 
claudins.    Epithelial  cells  depleted  of  ZO-1  and  ZO-2  isoforms  fail  to  form  tight 
junctions, and rescue experiments showed this function depends on the ability of ZO 
proteins to bind to claudins and to dimerize at sites of cell-cell contact (Umeda et al., 
2006).  Based on these experiments it has been proposed that ZO-1 and ZO-2 proteins 
regulate tight junction formation by promoting claudin recruitment and clustering at 
sites of cell-cell contact.  However it is not clear if ZO proteins directly regulate claudin 
clustering at sites of cell-cell contact.  ZO proteins can also bind to actin filaments, and 
might provide a direct link between tight junctions and the actin cytoskeleton, which 
could provide an alternative explanation for the failure to form tight junctions in ZO-
depleted cells. 
 
1.4.4 Assembly of apical junctions 
 
Initiation of cell-cell contact - The assembly of adherens junctions and tight junctions 
has been extensively studied in cultured cells, which can be induced to form junctions 
synchronously by manipulation of extracellular calcium levels (the so-called ‘calcium-
switch’).  These studies have shown that apical junctions form in a stepwise manner.  
Initial cell-cell contact leads to the recruitment of E-cadherin complexes, followed by 
sequential  recruitment  of  tight  junction  proteins  and  changes  in  cell  shape  and  the 
organization of the actin cytoskeleton, resulting in the formation of polarized cells with 
mature apical junctions.  Remarkably, the sequential recruitment of junctional proteins 
seen in cultured cells mimics the formation of the first epithelial structure in the mouse   52 
pre-implantation embryo, the trophectoderm.  This epithelium forms as a result of the 
sequential  recruitment  of  adherens  junction  and  tight  junction  proteins  to  cell-cell 
contacts, starting with E-cadherin activation during compaction of the 8-cell embryo, 
and ending with the assembly of claudins in to mature tight junctions in the 32-cell 
blastocyst (Eckert and Fleming, 2008). 
 
Cell-cell adhesion is initiated when neighbouring cells in culture make contact as a 
result of membrane protrusions.  Different cells use different mechanisms to initiate 
cell-cell contact.  MDCK cells for example use transient lamellipodia to initiate cell-cell 
contact,  whereas  keratinocytes  use  filopodial  protrusions  (Adams  et  al.,  1998; 
Vasioukhin et al., 2000).  E-cadherin puncta are formed at the sites of initial contact, 
referred to as spot-like or primordial adherens junctions (Figure 1.4).  These puncta 
have  been  observed  in  a  number  of  different  epithelial  cell  types  during  junction 
formation,  and  contain  many  of  the  proteins  found  in  mature  adherens  junctions, 
including  catenins,  nectin  and  afadin  (Adams  et  al.,  1998;  Asakura  et  al.,  1999; 
Vasioukhin et al., 2000).  Live imaging studies in MDCK cells have shown that E-
cadherin  expressed  at  the  cell  surface  becomes  stabilized  at  sites  of  initial  cell-cell 
contact (Ehrlich et al., 2002).  These puncta are stabilized by association with actin 
filaments and act as landmarks for the recruitment of additional cadherin complexes as 
cell-cell contacts extend. 
 
Dramatic changes in the actin cytoskeleton are observed as junctions form.  During the 
early stages of cell-cell contact, fine actin filaments are observed emanating from the 
cortical actin ring, terminating in E-cadherin spot-like junctions (Figure 1.4).  A number 
of actin regulatory proteins localize to these nascent junctions, which are known to be 
sites of actin polymerization.  This actin polymerization provides the mechanical force 
to seal membranes together as cell-cell contacts extend (Ehrlich et al., 2002; Vasioukhin 
et al., 2000).  Treatment of cells with drugs such as cytochalasin or latrunculin to inhibit 
actin polymerization prevents junction formation, highlighting the importance of actin 
polymerization in this process (Adams et al., 1998; Ivanov et al., 2005a).  Both the 
Arp2/3 complex and the formins, the two principal actin nucleators found in eukaryotic   53 
cells (see section 1.2.1 above), as well as a number of other actin regulatory proteins, 
have important roles in junction formation. 
 
The  Arp2/3  complex  is  recruited  by  E-cadherin  to  sites  of  cell-cell  contact  during 
adherens junction formation.  As cell-cell contacts extend, it is predominantly localized 
at the margins of extending contacts where it promotes lamellipodial activity required to 
bring  opposing  membranes  together.    (Kovacs  et  al.,  2002).    Inhibition  of  Arp2/3 
function  prevents  E-cadherin  cell-cell  contact  formation  (Verma  et  al.,  2004).  
Cortactin, an activator of the Arp2/3 complex, is also recruited to cell-cell contacts by 
E-cadherin, and knockdown of cortactin prevents adherens junction formation (Helwani 
et al., 2004).  Members of the Mena/VASP family of actin regulators are also recruited 
to  nascent  cell-cell  contacts,  probably  through  indirect  interaction  with  α-catenin 
mediated by vinculin (Scott et al., 2006; Vasioukhin et al., 2000).  Interference with 
VASP  activity  prevents  adherens  junction  formation  in  keratinocytes  and  mouse 
epidermis.    The  role  of  Mena/VASP  family  proteins  in  regulating  actin  is  not 
completely clear, but they are often found enriched in lamellipodia and might cooperate 
with the Arp2/3 complex and facilitate actin polymerization by preventing actin capping 
proteins binding to the barbed end of actin filaments (Bear et al., 2002).  The Arp2/3 
complex can be inhibited by α-catenin, and this might be important for limiting Arp2/3 
activity  to  newly  contacting  membranes,  while  allowing  older  contacts  to  develop 
unbranched actin filaments found in mature junctions (Drees et al., 2005). 
 
Formin1 is recruited to nascent cell-cell contacts by interaction with α-catenin, where it 
promotes stabilization and association of cadherin puncta with actin filaments (Kobielak 
et al., 2004).  Inhibition of formin-1 function blocks adherens junction formation, while 
expression  of  an  active  mutant  of  formin-1  rescues  the  defect  in  adherens  junction 
formation seen in α-catenin-null keratinocytes, showing regulation of formin-1 activity 
is  an  important  aspect  of  α-catenin  function.    mDia1,  a  diaphanous-related  formin 
(DRF), is also required for adherens junction formation (Ryu et al., 2009).   54   55 
  
 
Maturation of apical junctions - As junctions mature, cells elongate along the apical-
basal  axis  and  generate  distinct  zonula  occludens,  containing  polymerized  claudin 
proteins, and zonula adherens (Figure 1.4).  ZO-1 and JAM-A are the first tight junction 
proteins to be recruited to cell-cell contacts, where they colocalize with E-cadherin at 
spot-like primordial junctions.  Additional tight junction proteins, including polarity 
complexes, which establish apical-basal polarity, and the transmembrane proteins that 
from tight junction strands (claudins and occludin), are recruited later, possibly through 
interactions with ZO proteins and JAM-A. 
 
Based on the observation that tight junctions do not form in epithelial cells depleted of 
ZO proteins, it has been proposed that recruitment of claudins in to tight junctions is 
dependent on ZO proteins, which bind directly to the claudin cytoplasmic tail (Umeda 
et al., 2006).  ZO-1 and ZO-2 seem to act redundantly in tight junction formation, as 
expression  of  either  protein  is  sufficient  to  rescue  the  tight  junction  defect  in  ZO-
depleted cells.  The ability of ZO-1 to promote tight junction formation depends on the 
presence of its PDZ domains, which bind to claudins, and its SH3 and GUK domains, 
which mediate dimerization and bind to adherens junction proteins.  Based on these 
observations,  it  has  been  proposed  that  ZO-1  regulates  tight  junction  formation  by 
recruiting and clustering claudins at cell-cell contacts (Umeda et al., 2006).  However it 
is not clear if the failure to form tight junctions in ZO-depleted cells reflects a direct 
role for ZO proteins in claudin clustering.  It should be noted that expression of claudin 
proteins alone is sufficient to form tight junction strands in fibroblasts (Furuse et al., 
1998), and that ZO proteins can have alternative functions in the cell, such as linking 
tight  junctions  to  junctional  actin,  which  might  explain  their  involvement  in  tight 
junction formation. 
 
The Par3 (partitioning-defective 3)/Par6/aPKC (atypical protein kinase C) complex is a 
highly conserved protein complex playing an essential role in the establishment of cell 
polarity  (Ebnet,  2008).    The  Par  proteins  were  initially  identified  in  C.elegans  as 
proteins required for asymmetric cell division in the zygote, and have since been shown   56 
to play conserved roles in cell polarity in higher eukaryotes.  Par3 and Par6 are scaffold 
proteins, which bind to and regulate the activity of aPKC (Joberty et al., 2000; Lin et 
al., 2000).  In epithelial cells, this complex localizes to tight junctions, and a number of 
studies  using  RNAi  knockdown  and  expression  of  dominant-negative  mutants  have 
shown it to be required for tight junction formation (Chen and Macara, 2005; Suzuki et 
al., 2004; Suzuki et al., 2001; Yamanaka et al., 2001).  In particular, the kinase activity 
of aPKC is required for nascent junctions to mature and for the subsequent recruitment 
of claudins to form tight junctions (Suzuki et al., 2002).  Par3 and Par6 regulate the 
localization and the kinase activity of the associated aPKC.  Par6 is an effector protein 
for Cdc42 and Rac1, and activation of these small GTPases downstream of E-cadherin 
and nectin adhesion results in activation of aPKC.  aPKC is not active when in complex 
with Par6 alone, but conformational changes induced by GTPase-binding to Par6 lead 
to  aPKC  activation  (Yamanaka  et  al.,  2001).    At  least  two  mechanisms  have  been 
proposed for the recruitment of this complex to junctions: an interaction between the 
first PDZ domain of Par3 and the C-terminal PDZ-binding motif of JAM-A (Ebnet et 
al., 2001), and an interaction between the PDZ domain of Par6 and the N-terminus of 
Pals1  (partner  of  Lin7),  which  itself  is  recruited  by  PATJ  (Pals1-associated  tight 
junction protein) and ZO-3 (Hurd et al., 2003; Roh et al., 2002).  
 
The role of aPKC in tight junction formation is not clear.  aPKC can phosphorylate tight 
junction proteins, including ZO-1, occludin and claudin-1 in vitro (Nunbhakdi-Craig et 
al., 2002), and it is known that these proteins are phosphorylated in tight junctions (see 
section 1.4.5 below), however it is not known if these are physiological substrates of 
aPKC.    Other  substrates  for  aPKC  include  the  polarity  proteins  Par1  (partitioning-
defective 1) and lgl (lethal giant larvae).  Par1, like Par3 and Par6, was discovered in 
C.elegans as a protein essential for cell polarity and is conserved in higher eukaryotes.  
It is a serine/threonine kinase, and plays a role in establishing apical-basal polarity in 
epithelial cells.  Par1 is localized to the lateral membrane in polarized epithelial cells, 
while the Par3/Par6/aPKC complex is localized apically.  Phosphorylation of Par1 by 
aPKC  causes  it  to  dissociate  from  the  membrane,  and  this  prevents  Par1  from 
associating  with  the  apical  membrane  domain  (Suzuki  et  al.,  2004),  while 
phosphorylation of Par3 by Par1, at least in Drosophila, causes Par3 to dissociate from   57 
the Par6/aPKC complex, and thus restricts the ternary complex to the apical membrane 
(Benton  and  St  Johnston,  2003).    Par1  and  the  Par3/Par6/aPKC  complex  thus  play 
antagonistic roles to establishing polarized membrane domains.  A similar antagonistic 
relationship is seen between aPKC and Lgl.  Lgl, another conserved polarity protein, is 
localized to the basolateral membrane domain in epithelial cells.  It can bind to Par6 and 
aPKC  and  prevent  Par3  from  binding  to  them,  and  so  is  thought  to  restrict  the 
Par3/Par6/aPKC complex to the apical membrane.  In turn, aPKC can phosphorylate 
Lgl to exclude it from the apical membrane (Yamanaka et al., 2003).   
 
aPKC clearly plays an important role in establishing apical-basal polarity in epithelial 
cells, but it is not clear whether its role in polarity is linked to its role in tight junction 
formation.  The fact that a number of polarity proteins discovered in lower eukaryotes 
have been found to be important for tight junction formation in vertebrates, including 
Par3 and Par6 discussed above and also Crb3 (Crumbs in Drosophila) (Fogg et al., 
2005),  Pals1  (Partner  of  lin7,  stardust  in  Drosophila)  (Straight  et  al.,  2004),  PATJ 
(Pals1-associated tight junction protein, Discs lost in Drosophila) (Shin et al., 2005), 
Dlg (Discs large in Drosophila) (Stucke et al., 2007) and Scrib (Scribble in Drosophila) 
(Qin  et  al.,  2005),  suggests  a  functional  link  between  tight  junction  formation  and 
apical-basal polarization.  In vertebrates, tight junctions are found at the border between 
the apical and basolateral membrane domains, and it is plausible that the distinction 
between these domains acts as a landmark to position tight junctions.  
 
As  junctions  mature  and  cells  elongate  along  the  apical-basal  axis,  the  actin 
cytoskeleton reorganizes to form the characteristic perijunctional actin ring found in 
polarized epithelial cells (Figure 1.4).  Cortical actin filaments contract and bundle so 
that they tightly align with the apical junctional complex.  These changes in cell shape 
and  junctional  maturation  require  myosin  II  activity  and  actin-myosin  contractility 
(Zhang et al., 2005).  Inhibition of myosin II ATPase activity does not prevent nascent 
cadherin  contacts  forming,  but  does  prevent  subsequent  tight  junction  formation, 
perijunctional actin ring formation, and cell polarization (Ivanov et al., 2005a).  Myosin 
II is activated at junctions in a Rho- and ROCK-dependent manner (Yamazaki et al., 
2008).   58 
 
1.4.5 Regulation of apical junctions 
 
Epithelial  junctions  are  highly  dynamic.    Remodelling  of  junctions  occurs  during 
normal morphogenesis as epithelial cells are organized in to tissues, and also in disease 
states such as cancer.  The formation, maintenance and disassembly of junctions can be 
regulated by a number of mechanisms, including alteration of the actin cytoskeleton, the 
availability  of  junctional  proteins  at  the  cell  surface,  and  post-translational 
modifications of junctional proteins. 
 
The perijunctional actin ring is dynamic in nature, and continual actin polymerization is 
required to maintain apical junctions in polarized monolayers (Yamada et al., 2005).  
Pharmacological inhibition of actin polymerization in epithelial monolayers results in 
loss of perijunctional actin and disruption of apical junctions (Shen and Turner, 2005; 
Yamazaki et al., 2007).  Actin-myosin contractility might also play a role in junctional 
maintenance,  although  there  is  conflicting  evidence.    Some  studies  have  found 
inhibition of myosin II disrupts junctions, while others have found myosin II activity is 
not required for the maintenance of junctions.  Hyperactivation of myosin II results in 
disassembly  of  junctions,  as  a  result  of  contraction  of  the  perijunctional  actin  ring 
(Sahai and Marshall, 2002; Shewan et al., 2005). 
 
The  membrane  proteins  forming  junctions,  such  as  E-cadherin  and  claudins,  are 
continually undergoing endocytosis, and can be targeted for degradation or recycled 
back  to  the  plasma  membrane.    Internalized  junctional  proteins  first  accumulate  in 
Rab5-positive early endosomes, and can be sorted to either Rab11-positive recycling 
endosomes  for  recycling  back  to  the  plasma  membrane,  or  to  Rab7-positive  late 
endosomes for subsequent degradation (Ivanov et al., 2005b).  Endocytosis of junctional 
proteins occurs constitutively in stable monolayers (Le et al., 1999; Matsuda et al., 
2004), where it plays important roles in junction maintenance and repair, and can also 
be stimulated by growth factors and cytokines that affect epithelial integrity and barrier 
function during morphogenesis and pathogenesis (Ivanov et al., 2005b).  Trafficking of   59 
junctional proteins thus plays an important role in the regulation of junctional integrity 
by controlling the availability of junctional proteins at the cell surface. 
 
The integrity of junctions can be regulated by phosphorylation of junctional proteins.  
Phosphorylation of E-cadherin and catenins regulates their interactions with each other, 
and thus regulates the strength of cell-cell adhesion.  Transformation of epithelial cells, 
by overexpression of oncogenes such as Src or addition of growth factors, results in 
tyrosine  phosphorylation  of  E-cadherin,  β-catenin  and  p120-catenin  (Behrens  et  al., 
1993; Hoschuetzky et al., 1994; Roura et al., 1999).  Src directly phosphorylates β-
catenin, and this weakens its interaction with E-cadherin, while Fer and Fyn, two Src-
family kinases (SFKs), directly phosphorylate β-catenin and weaken its interaction with 
α-catenin.  Disruption of the cadherin-catenin complex by SFKs contributes to their 
ability  to  transform  epithelial  cells.    On  the  other  hand,  a  positive  role  for  SFK-
dependent  tyrosine  phosphorylation  of  catenins  in  junction  formation  has  also  been 
proposed.    Fyn  is  activated  as  cell-cell  contacts  form  in  keratinocytes,  and 
phosphorylation  of  catenins  downstream  of  SFKs  is  required  for  efficient  adherens 
junction formation in these cells (Calautti et al., 2002).  The cadherin-catenin complex 
is  also  regulated  by  serine/threonine  kinases,  including  CKII  and  GSK3-β,  which 
phosphorylate the cytoplasmic tail of E-cadherin and enhance its interaction with β-
catenin (Lickert et al., 2000). 
 
The tight junction proteins occludin, claudins and ZOs are all phosphorylated in tight 
junctions,  mainly  on  serine  and  threonine  residues.    Similar  to  adherens  junction 
proteins, phoshorylation of tight junction proteins can have both positive and negative 
effects on tight junction formation and maintenance.  A number of kinases have been 
found to be both required for tight junction formation and to promote tight junction 
disassembly.    This  includes  the  PKA  and  PKC  families,  which  can  directly 
phosphorylate  tight  junction  proteins,  at  least  in  vitro.    However  the  physiological 
relevance of phosphorylation of tight junction proteins by PKA and PKC has not been 
determined.  Phosphorylation of specific claudin isoforms has also been shown to alter 
the barrier properties of tight junctions (Gonzalez-Mariscal et al., 2008). 
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1.5 Rho GTPases and apical junctions 
 
 
As described in previous sections, Rho GTPases control a number of basic processes in 
the cell, including the organization of the cytoskeleton, membrane trafficking and gene 
expression.  It is therefore not surprising that they have emerged as key regulators of 
complex  cellular  behaviours  such  as  migration,  division  and  morphogenesis.  
Experiments in cultured epithelial cells, mainly using overexpression of mutant proteins 
or  toxins  to  manipulate  the  activity  of  Rho  GTPases,  have  shown  that  Rho  family 
members regulate the assembly and maintenance of both adherens and tight junctions.  
In some cases components of the signalling pathways involved have been identified. 
 
1.5.1 Rho GTPases and the assembly of apical junctions 
 
The activity of Rho is required for epithelial junctions to form.  This has been shown by 
expression of dominant-negative RhoA or by using C3 toxin (to inhibit RhoA, B and 
C), which block recruitment of adherens junction and tight junction proteins to sites of 
cell-cell contact (Braga et al., 1997; Takaishi et al., 1997).  Recently developed FRET 
probes enable visualization of active forms of GTPases in live cells, and studies using 
these have shown RhoA is active at sites of cell-cell contact and junction formation 
(Yamada and Nelson, 2007; Yamazaki et al., 2008).  Earlier studies looking at RhoA 
activation using a biochemical approach had shown that levels of active RhoA decrease 
as epithelial junctions form (Noren et al., 2001).  However it should be noted that this 
biochemical approach looks at GTPase activation globally, whereas fluorescent probes 
allow visualization of localized pools of active GTPase.  While the overall level of 
active RhoA in the cell decreases as epithelial cells form monolayers, some Rho activity 
is required at sites of cell-cell contact for junctions to form.  The Rho GEFs ECT2 and 
GEF-H1, and the Rho GAPs ARHGAP10 and p190RhoGAP, can potentially regulate 
Rho activity at junctions.  ECT2 is best known for its role in cytokinesis in mitotic cells, 
and in interphase cells localizes predominantly in the nucleus (Kim et al., 2005; Yuce et 
al., 2005).  However some ECT2 localization has been seen at junctions in epithelial   61 
cells,  where  it  colocalizes  with  the  tight  junction  protein  ZO-1  (Liu  et  al.,  2004).  
Expression  of  dominant-negative  ECT2  prevented  lumen  formation  in  MDCK  cells 
grown in 3D cultures, a phenotype that might reflect a defect in tight junction formation 
(Liu et al., 2006).  However it is not clear if any role for ECT2 in regulating junctions is 
dependent on its ability to regulate Rho activity, and instead ECT2 can interact with the 
Par3/Par6/aPKC complex and stimulate the kinase activity of aPKC (Liu et al., 2004).  
The Rho GEF GEF-H1 also localizes to tight junctions, but is not thought to regulate 
junction  formation.    Proposed  roles  instead  include  regulation  of  junctional 
permeability, and cell density-dependent regulation of cell-cycle progression (Aijaz et 
al., 2005; Benais-Pont et al., 2003).  ARHGAP10 localizes to cell-cell contacts, and 
depletion  of  ARHGAP10  resulted  in  decreased  recruitment  of α-catenin  to  cell-cell 
contacts  in  JEG-3  epithelial  cells,  but  surprisingly  E-cadherin  localization  was  not 
affected, suggesting ARHGAP10 does not play a significant role in adherens junction 
formation (Sousa et al., 2005).  Instead ARHGAP10 is required for infection of cells by 
the  bacterium  Listeria  monocytogenes,  a  process  known  to  require  E-cadherin  as  a 
receptor.    p190RhoGAP  has  been  implicated  in  inhibition  of  Rho  downstream  of 
cadherin ligation (Noren et al., 2003).  Cadherin ligation resulted in increased tyrosine 
phosphorylation  of  p190RhoGAP  which  correlated  with  increased  activity,  and 
expression  of  dominant-negative  p190RhoGAP  prevented  cadherin-dependent 
inhibition of Rho activity.  
 
Several Rho effector proteins have been implicated in junction formation.  The actin 
nucleation activity of formins is required for junctions to form (see section 1.4.4 above), 
and a subset of formins, the DRFs (Diaphonous-related formins), are regulated by Rho, 
which provides another potential mechanism for Rho to regulate junction formation.  
Consistent with this, RNAi-mediated depletion of mDia1 prevents cell-cell adhesion in 
A431  cells  (Ryu  MCB  2009).    In  keratinocytes,  Src  family  kinases  such  as  Fyn 
phosphorylate β-,γ- and p120-catenin, which increases their affinity for E-cadherin and 
promotes adherens junction formation.  Inhibition of Rho prevents adherens junction 
formation,  and  results  in  decreased  activity  of  Fyn  kinase  and  decreased  levels  of 
tyrosine-phosphorylated catenins, suggesting Rho is promoting junction formation by 
activating Fyn (Calautti et al., 2002).  The Rho effector PRK2 is activated in these cells   62 
when junction formation is stimulated by calcium.  While expression of a constitutively 
active RhoA mutant was found to increase the speed at which E-cadherin accumulated 
at cell-cell contacts, a RhoA effector mutant Y42C that can no longer bind to PRK2 
failed to accelerate junction formation, suggesting Rho might be acting through PRK2.  
However, it should be noted that Rho GTPase effector mutants are likely to inhibit 
binding  of  multiple  Rho  effectors,  so  a  clear  role  for  PRK2  in  adherens  junction 
formation has not been demonstrated. 
 
In  some  studies  pharmacological  inhibition  of  the  Rho  effector  protein  ROCK 
prevented junction formation.  The accumulation of E-cadherin at cell-cell contacts was 
inhibited using a ROCK inhibitor in MCF7 cells (Shewan et al., 2005) and T84 cells 
(Walsh et al., 2001), but not in MDCK (Yamada and Nelson, 2007) or HCT116 cells 
(Sahai  and  Marshall,  2002).    It  is  not  clear  if  these  discrepancies  reflect  cell-type 
specific effects of ROCK inhibition, or simply differences in experimental conditions, 
and this is further confused by the fact that commonly used ROCK inhibitors are not 
very specific.  ROCK is known to activate myosin II, by direct phosphorylation of MLC 
and by inhibition of MLC phosphatase.  Myosin II-dependent contractility is required 
for epithelial junctions to mature in to distinct zonula adherens and zonula occludens 
(see section 1.4.4 above), and this could be regulated by the Rho-ROCK pathway. 
 
Rac activity is also required for junctions to form.  Expression of dominant-negative 
Rac1 or RNAi-mediated knockdown of Rac1 impairs E-cadherin recruitment to cell-cell 
contacts (Braga et al., 1997; Noritake et al., 2004).  Rac1 is activated as cell-cell contact 
is  initiated,  and  this  activation  is  thought  to  occur  as  a  direct  consequence  of  both 
cadherin and nectin homophilic ligation (Kawakatsu et al., 2002; Noren et al., 2001).  In 
the case of nectin-dependent activation of Rac1, the GEF Vav2 has been implicated, as 
expression  of  dominant-negative  Vav2  blocks  Rac1  activation  by  nectin  ligation 
(Kawakatsu et al., 2005).  It should be noted however that Vav2 has not been localized 
to  cell-cell  contacts  and  has  not  been  shown  to  play  a  functional  role  in  junction 
formation.  Active Rac1 has been visualized in MDCK cells at sites of initial cell-cell 
contact.  As cell-cell contacts extend, active Rac1 is localized predominantly at the 
edges of the contact region (Yamada and Nelson, 2007).  This localization coincides   63 
with regions of high lamellipodial activity, which seals neighbouring cells together as 
cell-cell  contacts  extend  (see  section  1.4.4  above).    The  Arp2/3  complex,  which  is 
responsible for actin polymerization to form lamellipodia, is activated downstream of 
Rac, and also localizes to the edges of extending cell-cell contacts.  Rac activates the 
Arp2/3 complex through WAVE proteins.  WAVE2 localizes to lamellipodia as cell-
cell contacts form, and colocalizes with E-cadherin in mature monolayers.  Depletion of 
WAVE2 by RNAi delays recruitment of E-cadherin to cell-cell contacts in MDCK cells 
(Yamazaki et al., 2007). 
 
IQGAP is an effector for Rac and Cdc42, and plays both positive and negative roles in 
adherens junction formation.  IQGAP1 colocalizes with E-cadherin at cell-cell contacts 
in  MDCK  cells,  and  RNAi-mediated  knockdown  of  IQGAP1  results  in  reduced 
localization of E-cadherin at cell-cell contacts (Noritake et al., 2004).  IQGAP1 binds to 
actin filaments, and might play a positive role in junction formation by stabilizing actin 
at sites of cell-cell adhesion.  IQGAP1 also binds to β-catenin and prevents β-catenin 
binding to α-catenin, resulting in decreased cell-cell adhesion.  The interaction between 
IQGAP1 and β-catenin is thought to be prevented by binding of active Rac (or Cdc42) 
to IQGAP1 (Fukata et al., 1999; Kuroda et al., 1998).  Rac could, therefore, promote 
junction formation by facilitating the interaction between β-catenin and α-catenin.  
 
Rac activity has also been implicated in apical junction maturation and the formation of 
tight junctions (Mertens et al., 2005).  Knockout of the Rac-specific GEF Tiam1 in 
keratinocytes does not prevent initial E-cadherin-dependent cell-cell contacts forming, 
but does prevent maturation in to apical tight junctions.  Tiam1 interacts with Par3, a 
component  of  the  Par3/Par6/aPKC  complex  whose  activity  is  required  for  tight 
junctions  to  form  (see  section  1.4.4  above).    Activation  of  aPCK  in  this  complex 
requires binding of active Rac or Cdc42 to the Rho effector protein Par6.  Tiam1-
activated Rac is therefore thought to promote tight junction formation by activating 
aPKC. 
 
There is conflicting data on the role of Cdc42 in junction formation.  Several studies 
have shown inhibition of Cdc42 has no effect on junction formation (Gao et al., 2002;   64 
Mertens et al., 2005; Takaishi et al., 1997), while other studies have shown Cdc42 is 
required for adherens junction and tight junction formation (Fukuhara et al., 2003; Otani 
et al., 2006; Rojas et al., 2001).  Cdc42 is activated as cell-cell contacts are initiated 
(Noren et al., 2001; Otani et al., 2006).  Cdc42 can be directly activated downstream of 
nectin ligation, and this might occur through the Cdc42 GEF FRG, as expression of 
dominant-negative FRG prevents nectin-dependent activation of Cdc42 (Fukuhara et 
al., 2004; Kawakatsu et al., 2002).  The Cdc42-specific GEF Tuba interacts with ZO-1 
and  localizes  to  apical  junctions  in  Caco-2  epithelial  cells  (Otani  et  al.,  2006).  
Depletion of Tuba resulted in a delay in adherens junction formation.  Proposed roles 
for Cdc42 in junction formation include filopodia formation, which are seen in some 
epithelial cells as cell-cell contact is initiated, regulation of IQGAP1, and activation of 
the Par3/Par6/aPKC complex. 
 
1.5.2 Rho GTPases and the maintenance of apical junctions 
 
In  addition  to  being  required  for  junctions  to  form,  Rho  GTPases  regulate  the 
maintenance and disassembly of apical junctions.  Addition of C3 toxin to inhibit Rho 
in a number of different epithelial cell lines results in loss of perijunctional F-actin and 
disruption of adherens and tight junctions (Braga et al., 1997; Nusrat et al., 1995; Sahai 
and Marshall, 2002; Takaishi et al., 1997).  The perijunctional actin ring is dynamic in 
nature, and continual actin polymerization is required to maintain apical junctions in 
polarized monolayers.  Pharmacological inhibition of actin polymerization results in 
loss of perijunctional actin and apical junctions (Shen and Turner, 2005; Yamazaki et 
al., 2007).  Rho activity is required to maintain junctions through its effector mDia, a 
DRF that promotes actin polymerization (Sahai and Marshall, 2002).  Expression of a 
dominant-negative mDia mutant that can not regulate actin polymerization phenocopies 
inhibition of Rho in HCT116 and MDCK cells, with loss of adherens junctions. 
 
Expression  of  dominant  negative  Rac1  in  epithelial  monolayers  also  results  in 
disruption of established adherens junctions and tight junctions (Braga et  al., 1997; 
Bruewer et al., 2004).  Like Rho, Rac might contribute to maintenance of junctions 
through its regulation of actin polymerization (Yamazaki et al., 2007).  Rac might also   65 
stabilize  junctions  through  its  effector  protein  IQGAP1,  which  as  described  above 
regulates the interaction between catenins and also binds to actin filaments.  A number 
of  studies  have  shown  that  expression  of  dominant-negative  Cdc42  in  epithelial 
monolayers  does  not  affect  established  junctions,  suggesting  Cdc42  activity  is  not 
required for maintenance of junctions (Bruewer et al., 2004; Takaishi et al., 1997). 
 
The activity of Rho GTPases needs to be tightly controlled for stable maintenance of 
epithelial junctions.  Overexpression of constitutively active mutants of RhoA, Rac1 
and  Cdc42  disrupts  adherens  junctions  and  tight  junctions  (Braga  et  al.,  2000; 
Kroschewski  et al., 1999; Sahai and  Marshall,  2002).  Furthermore, disassembly of 
epithelial junctions during transformation by oncogenic Ras or addition of transforming 
growth factors such as HGF and TGF-β is dependent on activation of Rho GTPases 
(Bhowmick et al., 2001; Braga et al., 2000; Ridley et al., 1995).  In the case of RhoA 
activation, disassembly of junctions occurs through activation of its effector ROCK, 
which activates myosin II, resulting in contraction of the perijunctional actin ring and 
loss of cell-cell contacts (Sahai and Marshall, 2002).   
 
 
1.6 Experimental plan 
 
 
There is considerable evidence that Rho GTPases regulate epithelial junction formation.  
The activity of Rho GTPases is controlled by a large number of regulatory proteins and 
effector proteins.  While some of the components of Rho GTPase signalling pathways 
regulating epithelial junction formation have been identified (discussed above), it seems 
likely that additional components await identification.  In this study I therefore plan to 
carry out a systematic analysis of Rho GTPase signalling pathways regulating epithelial 
junction formation by screening RNAi libraries targeting Rho GEFs, GAPs and effector 
proteins, using the human bronchial epithelial cell line 16HBE14o-. 
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CHAPTER 2 –  Materials and Methods 
 
2.1 Molecular biology 
 
2.1.1 DNA constructs 
 
The DNA constructs used in this study are listed in Table 2.1.  All constructs were 
verified by sequence analysis (MSKCC sequencing facility).  
 
Plasmid name   Description and source  
pCl2.Flag-Asef1   Flag-tagged human Asef1, from D.Billadeau 
pCMV-Tag3B-myc-
ARHGEF10 
Myc-tagged human ARHGEF10, from S.Lutz  
pCDNA3-HA-hRhoA  3xHA-tagged  (N-terminus)  human  RhoA,  from  Missouri  S&T  cDNA 
Resource Center  
pCDNA3-HA-hRhoB  3xHA-tagged  (N-terminus)  human  RhoB,  from  Missouri  S&T  cDNA 
Resource Center  
pCDNA3-HA-hRhoC  3xHA-tagged  (N-terminus)  human  RhoC,  from  Missouri  S&T  cDNA 
Resource Center 
pRK5myc-mRhoA   Myc-tagged (N-terminus) mouse RhoA.  Made by PCR using pEX_YFP-
RhoA (from ATCC) as template and the following primers: 
forward: 5’-GCGCGGGATCCATGGCTGCCATCAGGAAGAAAC-3’ 
reverse: 5’-GCGCGGAATTCTCACAAGATGAGGCACCCAGAC-3’ 
BamHI/EcoRI fragment cloned in to BamHI/EcoRI pRK5myc 
pRK5myc-mRhoC  Myc-tagged (N-terminus) mouse RhoC.  Made by PCR using pEX_YFP-
RhoC (from ATCC) as template and the following primers: 
forward: 5’-GCGCGGGATCCATGGCTGCGATCCGAAAGAAG-3'  
reverse: 5’-GCGCGGAATTCTCAGAGAATGGGACAGCCCCTC-3’ 
BamHI/EcoRI fragment cloned in to BamHI/EcoRI pRK5myc 
pRK5myc-PAK4S  Myc-tagged (N-terminus) human PAK4S (short isoform), from T.Wagner 
pBABE-HA  pBABE-HA retroviral vector with puromycin resistance 
pBABE-HA-mPRK2  HA-tagged mouse PRK2.  Made by PCR using pYX-mPRK2 (from RZPD) 
as template and the following primers: 
forward: 5’-GCGCGCAGATCTATGGCGTCCAACCCCGACCGG-3’ 
reverse: 5’-GCGCGCGAATTCTTAACACCAATCAGCAACGTAG-3’   67 
BglII/EcoRI fragment cloned in to BamHI/EcoRI pBABE-HA 
pRK5myc-RhoA(F39A)  Myc-tagged  (N-terminus)  mouse  RhoA(F39A)  mutant.    Made  by  single 
step  PCR  mutagenesis  using  pRK5myc-mRhoA  as  template  and  the 
following primers: 
forward: 5’-CTATGTGCCCACGGTGGCTGAAAACTATGTGGCG-3’ 
reverse: 5’-CGCCACATAGTTTTCAGCCACCGTGGGCACATAG-3’ 
BamHI/EcoRI fragment cloned in to BamHI/EcoRI pRK5myc 
pRK5myc-RhoA(F39V)  Myc-tagged  (N-terminus)  mouse  RhoA(F39V)  mutant.    Made  by  single 
step  PCR  mutagenesis  using  pRK5myc-mRhoA  as  template  and  the 
following primers: 
forward: 5’-CTATGTGCCCACGGTGGTTGAAAACTATGTGGCG-3’ 
reverse: 5’-CGCCACATAGTTTTCAACCACCGTGGGCACATAG-3’ 
BamHI/EcoRI fragment cloned in to BamHI/EcoRI pRK5myc 
 
pRK5myc-RhoA(E40L)  Myc-tagged  (N-terminus)  mouse  RhoA(E40L)  mutant.    Made  by  single 
step  PCR  mutagenesis  using  pRK5myc-mRhoA  as  template  and  the 
following primers: 
forward: 5’-GTGCCCACGGTGTTTCTAAACTATGTGGCGGAT-3’ 
reverse: 5’-ATCCGCCACATAGTTTAGAAACACCGTGGGCAC-3’ 
BamHI/EcoRI fragment cloned in to BamHI/EcoRI pRK5myc 
pRK5myc-RhoA(Y42C)  Myc-tagged  (N-terminus)  mouse  RhoA(Y42C)  mutant.    Made  by  single 
step  PCR  mutagenesis  using  pRK5myc-mRhoA  as  template  and  the 
following primers: 
forward: 5’-CACGGTGTTTGAAAACTGTGTGGCGGATATCCAG-3’ 
reverse: 5’-CTCGATATCCGCCACACAGTTTTCAAACACCGTG-3’ 
BamHI/EcoRI fragment cloned in to BamHI/EcoRI pRK5myc 
pBABE-HA-PAK4  HA-tagged (N-terminus) human PAK4 with 3 non-coding point mutations 
to make it resistant to PAK4 siRNA duplex 4.  Made by single step PCR 
mutagenesis  using  pLPC-PAK4  (from  A.Minden)  as  template  with  the 
following primers: 
forward:  
5’-CCAGCACGAAAACGTCGTGGAGATGTACAACAGCTACCTGGTG-3’ 
reverse:  
5’-GCTGTTGTACATCTCCACGACGTTTTCGTGCTGGTAGTCCCTC-3’ 
Followed by PCR amplification using the following primers: 
forward: 5’-GCGCGGGATCCATGTTTGGGAAGAGGAAGAAG-3’ 
reverse: 5’-GCGCGGAATTCTCATCTGGTGCGGTTCTGGCG-3’ 
BamHI/EcoRI fragment cloned in to BamHI/EcoRI pBABE-HA   68 
pBABE-HA-mPar6B  HA-tagged (N-terminus) mouse Par6B.  BamHI/EcoRI fragment  excised 
from  pK-myc-Par6B  (Addgene  plasmid  15473)  and  cloned  in  to 
BamHI/EcoRI pBABE-HA. 
pBABE-HA-PAK4S  HA-tagged (N-terminus) human PAK4S (short isoform).  Made by PCR 
using  pRK5myc-PAK4S  (T.Wagner)  as  template  and  the  following 
primers: 
forward: 5’-GCGCGGGATCCATGTTTGGGAAGAGGAAGAAG-3’ 
reverse: 5’-GCGCGGAATTCTCATCTGGTGCGGTTCTGGCG-3’ 
BamHI/EcoRI fragment cloned in to BamHI/EcoRI pBABE-HA 
 
Table 2.1.  DNA constructs used in this study.  Constructs are listed in the order in which they first 
appear in Figures presented in chapters 3-5.  All constructs were verified by sequence analysis (MSKCC 
DNA sequencing facility).  Where applicable, the sequence of PCR primers used is given.  Nucleotides in 
red indicate either restriction sites or mutations introduced. 
 
 
2.1.2 DNA agarose gel electrophoresis 
 
1% agarose gels were prepared by dissolving 1 g of agarose (Sigma) in 100 ml of TAE 
(40 mM Tris-acetate, 1 mM EDTA pH8.0).  Ethidium bromide (1µg/ml) was added 
prior  to  polymerization.    6X  DNA  loading  buffer  (30%  glycerol  (v/v),  0.25% 
bromophenol blue (w/v), 0.25% xylene cyanol (w/v)) was added to DNA samples to 
achieve a final concentration of 1X DNA loading buffer.  Samples were run at 100 V 
for approximately 1 hr.  DNA bands were visualized using a UV transilluminator. 
 
2.1.3 Polymerase chain reaction (PCR) 
 
Standard  PCR  to  amplify  fragments  for  subcloning  was  carried  out  using  100  ng 
plasmid  DNA  template,  50  pmol  each  primer  (Sigma,  see  Table  2.1  for  primer 
sequences) and 250 µM dNTPs (Sigma).  Reactions were carried out in a final volume 
of 100 µl, using 1 µl (2.5 units) of cloned Pfu DNA polymerase (Stratagene) in the 
provided buffer.  When necessary 10% DMSO (Fisher Scientific) was included in the 
reaction  mix.    Reactions  were  carried  out  in  an  Eppendorf  Mastercycler,  using  the 
following parameters: 94°C for 3 mins, followed by 25 cycles of [94°C for 1 min, 52°C 
for 2 mins, 72°C for 3 mins], followed by 72°C for 10 mins.  PCR products were   69 
partially  purified  using  QIAquick  PCR  Purification  Kit  (QIAGEN),  following  the 
manufacturer’s instructions. 
 
2.1.4 Restriction digests and ligations 
 
Plasmid DNA (5µg) or PCR products were digested in a final volume of 50 µl, using 1 
µl  of  each  restriction  enzyme  (New  England  Biolabs)  and  the  provided  buffers.  
Reactions were incubated at 37°C for 1 hr.  Digested DNA fragments were purified by 
running them in 1% agarose gels (see section 2.1.2 above), excising the appropriate 
bands,  and  extracting  the  DNA  using  QIAquick  Gel  Extraction  Kit  (QIAGEN), 
following the manufacturer’s instructions.  Ligations were carried out using a 1:4 or 1:8 
molar ratio of vector:insert in a final volume of 10 µl, using 1 µl (400 units) of T4 
ligase (New England Biolabs) in the provided buffer.  Reactions were incubated at RT 
for 1 hr and the entire volume used to transform CaCl2-competent DH5a E.coli. 
 
2.1.5 Site-directed mutagenesis 
 
Point  mutations  were  introduced  using  single  step  PCR  mutagenesis.    Forward  and 
reverse  primers  were  purchased  containing  the  desired  point  mutations  (Sigma,  see 
Table 2.1).  PCR reactions were carried out in 50 µl total volume, using 50 ng plasmid 
DNA template, 125 ng each primer, 0.5 µl 25 mM dNTPs (New England Biolabs), 1 µl 
(2.5 units) Pfu turbo DNA polymerase (Stratagene) and the provided buffer.  When 
necessary 10% DMSO (Fisher Scientific) was included in the reaction mix.  Reactions 
were carried out in an Eppendorf Mastercycler using the following parameters: 95 °C 
for 30 secs followed by 16 cycles of [95 °C for 30 secs, 55 °C for 1 min, 68 °C for 
2mins/kb plasmid].  Upon completion, the PCR mixture was treated with 1 µl (20 units) 
Dpn1 to digest template DNA.  5 µl of the reaction mix was then used to transform 
CaCl2-competent DH5a E.coli.  
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2.1.6 Preparation of CaCl2-competent E.coli 
 
A single colony of DH5a E.coli was used to innoculate 5 ml of LB (MSKCC media 
facility), and the culture was incubated overnight at 37 °C with vigorous shaking.  The 
following morning 1 ml of overnight culture was used to innoculate 100 ml LB.  The 
culture was incubated at 37 °C with vigorous shaking until it reached an OD600 of 0.5.  
The culture was then chilled on ice for 30 mins and centrifuged at 4000 rpm at 4 °C for 
10 mins.  Pelleted E.coli were resuspended in 80 ml cold sterile 100 mM CaCl2 (Sigma) 
and incubated on ice for 30 mins.  E.coli were pelleted again by centrifugation at 4000 
rpm at  4 °C for 10 mins, and resuspended in 4 ml sterile 50 mM CaCl2 containing 25% 
glycerol.  Aliquots of 200 µl were prepared and stored at -80 °C. 
 
 
2.1.7  Transformation of CaCl2-competent E.coli 
 
CaCl2-competent DH5a E.coli were thawed on ice.  50 µl of E.coli was mixed with 
DNA (10 µl ligation mix or 100 ng plasmid DNA) and incubated on ice for 30 mins.  
Samples  were  incubated  at  42  °C  for  2  mins  to  induce  DNA  uptake,  followed  by 
addition of 1 ml LB (MSKCC media facility) and incubation at 37 °C for 30 mins.  
Samples  were  centrifuged  at  4000  rpm  for  3  mins  and  the  pelleted  E.coli  were 
resuspended  in  50-100  µl  LB.    Transformants  were  streaked  on  to  LB-agar  plates 
(MSKCC media facility) containing either ampicillin (100 µg/ml) or kanamycin (50 
µg/ml) (both from Sigma). 
 
2.1.8 Purification of plasmid DNA 
 
Plasmid DNA was purified using either QIAprep Spin Miniprep Kit (QIAGEN) (typical 
yield  10  µg)  or  QIAfilter  Plasmid  Maxi  Kit  (QIAGEN)  (typical  yield  500  µg), 
following the manufacturer’s instructions. 
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2.2 Cell culture and transfection 
 
2.2.1 Cell lines and culture conditions 
 
2.2.1a 16HBE14o- cells 
 
16HBE14o- cells, abbreviated here to 16HBE cells, were provided by the Gruenert lab 
(California  Pacific  Medical  Center),  in  which  this  cell  line  was  generated  by 
transforming  normal  human  bronchial  epithelial  cells  with  SV40  large  T-antigen.  
16HBE  cells  were  grown  in  MEM  +  GlutaMAX  +  Earle’s  salts  (Gibco,  catalogue 
number 41090), supplemented with 10% fetal bovine serum (FBS) (BenchMark, lot 
number  A27A00X)  and  a  mixture  of  penicillin  (100  U/ml)  and  streptomycin  (100 
µg/ml) antibiotics (Gibco).  Cells were grown in a humidified incubator at 37 °C with 
5% CO2.  Cells were passaged when 50-75% confluent, every 3-4 days. 
 
2.2.1b HEK293T cells 
 
HEK293T cells were obtained from ATCC.  Cells were grown in DME + L-glutamine + 
sodium pyruvate (MSKCC media facility) supplemented with 10% fetal bovine serum 
(FBS) (Omega Scientific, lot number 104021) and a mixture of penicillin (100 U/ml) 
and streptomycin (100 µg/ml) antibiotics (Gibco). Cells were grown in a humidified 
incubator at 37 °C with 5% CO2.  Cells were passaged when 80% confluent, every 2-3 
days. 
 
2.2.2  Transfection of 16HBE cells with plasmid DNA 
 
3x10
4 cells were seeded in each well of a  sterile 24-well cell culture plate (Nunc), 
corresponding to approximately 1.5x10
4 cells/cm
2.  Cells were thoroughly resuspended 
prior to seeding to avoid aggregation.  Cells were allowed to adhere overnight, and were 
transfected the following day when at a confluency of 10-20%.  Cells were transfected 
with  100  ng  plasmid  DNA,  using  1  µl  of  lipofectamine  LTX  transfection  reagent   72 
(Invitrogen)  and  following  the  manufacturer’s  instructions.    16HBE  cells  were 
incubated with the transfection mix for 6 hours,  before the media was changed to fresh 
growth media. 
 
2.2.3 Transfection of 16HBE cells with siRNA 
 
3x10
4 cells were seeded in each well of a  sterile 24-well cell culture plate (Nunc), 
corresponding to approximately 1.5x10
4 cells/cm
2.  Cells were thoroughly resuspended 
prior to seeding to avoid aggregation.  Cells were allowed to adhere overnight, and were 
transfected the following day when at a confluency of 10-20%.  Cells were transfected 
with 25 pmol RNA in a final volume of 500 µl  (corresponding to a concentration of 50 
nM), using 1 µl of lipofectamine LTX transfection reagent (Invitrogen) and following 
the manufacturer’s instructions.  16HBE cells were incubated with the transfection mix 
overnight (12-16 hours),  before the media was changed to fresh growth media.  See 
Table 2.2 for a list of siRNA duplexes used. 
 
siRNA duplex  Target sequence 
siLamin  ACCAGGUGGAGCAGUAUAA 
siControl  GGAAAUUAUACAAGACCAA 
RhoA siRNA duplex 1  AUGGAAAGCAGGUAGAGUU 
RhoA siRNA duplex 2  GAACUAUGUGGCAGAUAUC 
RhoA siRNA duplex 3  GAAAGACAUGCUUGCUCAU 
RhoA siRNA duplex 4  GAGAUAUGGCAAACAGGAU 
Cdc42 siRNA duplex 1  GGAGAACCAUAUACUCUUG 
Cdc42 siRNA duplex 2  GAUUACGACCGCUGAGUUA 
Cdc42 siRNA duplex 3  GAUGACCCCUCUACUAUUG 
Cdc42 siRNA duplex 4  CGGAAUAUGUACCGACUGU 
Asef siRNA duplex 1  GCACAAAGAUGGAGUCAAG 
Asef siRNA duplex 2  GAAAGGAGGCUGCACAUAG 
Asef siRNA duplex 3  ACACCAAGCUCAGCAAGUA 
Asef siRNA duplex 4  GCUCAGAACUCAUCUACUC 
ARHGEF10 siRNA duplex 1  GAACCUUACCUAAAUAAUG 
ARHGEF10 siRNA duplex 2  GAAUACGGAUGGAGUUCGA 
ARHGEF10 siRNA duplex 3  GACGAUGGGAAUCACAUUA   73 
ARHGEF10 siRNA duplex 4  GACCUAACCCGUUUAAAGG 
ITSN2 siRNA duplex 1  GAUCAAACGUGACAAGUUG 
ITSN2 siRNA duplex 2  GACAGGAGCUUCUCAAUCA 
ITSN2 siRNA duplex 3  CCAAACAUGUGGGCUAUUA 
ITSN2 siRNA duplex 4  AAACUCAGCUGGCUACUAU 
Par6B siRNA duplex 1  GGAAUAAUGUUGUGAGGAA 
Par6B siRNA duplex 2  AGACAUCCAUGGAGACUUA 
Par6B siRNA duplex 3  CGAAGAAGAUGACAUUAUC 
Par6B siRNA duplex 4  GGGUACGUCUUUACAAAUA 
PRK2 siRNA duplex 1  GACAGAAGAUCUCAGCAAA 
PRK2 siRNA duplex 2  GGAGCGCUCUGAUGGACAA 
PRK2 siRNA duplex 3  UAGACAGCCUGAUGUGUGU 
PRK2 siRNA duplex 4  GUACGCAUCCCUCAACUAG 
PAK4 siRNA duplex 1  GGAUAAUGGUGAUUGAGAU 
PAK4 siRNA duplex 2  GGGUGAAGCUGUCAGACUU 
PAK4 siRNA duplex 3  AGAAUGUGGUGGAGAUGUA 
PAK4 siRNA duplex 4  CCAUGAAGAUGAUUCGGGA 
 
Table 2.2.  siRNA duplexes used in this study.  All duplexes were purchased from Dharmacon. 
 
 
2.2.4 Sequential transfection of 16HBE cells with plasmid DNA and siRNA 
 
In some rescue experiments 16HBE cells were transfected with plasmid DNA followed 
by siRNA.  In these experiments, cells were seeded as described in sections 2.2.2 and 
2.2.3 (above).  The following day, cells were transfected with 100 ng plasmid DNA, as 
described    in  section  2.2.2  (above).    After  6  hours  the  DNA  transfection  mix  was 
removed, cells were washed once with sterile PBS, and the siRNA transfection mix was 
added, as described in section 2.2.3 (above).  Cells were left overnight, before the media 
was changed to fresh growth media. 
 
2.2.5 Transfection of HEK293T cells with plasmid DNA 
 
3x10
5  cells  were  seeded  in  each  well  of  a  sterile  6-well  cell  culture  plate  (Nunc), 
corresponding to approximately 3x10
4 cells/cm
2, and allowed to adhere overnight.  The   74 
following day cells were transfected while at a confluency of approximately 50%.  Cells 
were transfected with 1 µg of DNA, using 5 µl lipofectamine 2000 transfection reagent 
(Invitrogen) and following the manufacturer’s instructions.  Cells were incubated with 
the transfection mix overnight (12-16 hours),  before the media was changed to fresh 
growth media.   
 
2.2.6 Sequential transfection of HEK293T cells with siRNA and plasmid DNA 
 
In some cases the ability of siRNA duplexes to downregulate expression of their target 
gene was determined by expressing exogenous protein in HEK293T cells.  3x10
5 cells 
were seeded in each well of a sterile 6-well cell culture plate (Nunc), corresponding to 
approximately 3x10
4 cells/cm
2, and allowed to adhere overnight.  The following day 
cells were transfected while at a confluency of approximately 50%.  Cells were first 
transfected with 100 pmol siRNA in a final volume of 2 ml, corresponding to a final 
concentration of 50 nM, using 5 µl lipofectamine 2000 transfection reagent (Invitrogen) 
and following the manufacturer’s instructions.  6 hours later, the RNA transfection mix 
was removed from cells and was replaced with DNA transfection mix, containing 1 µg 
of DNA, using 5 µl lipofectamine 2000 transfection reagent (Invitrogen) and following 
the manufacturer’s instructions.  Cells were incubated overnight before the media was 
changed to fresh growth media. 
 
2.2.7 Infection of 16HBE cells with retrovirus 
 
Retroviral  particles  were  produced  by  triply  transfecting  HEK293T  cells  with  1 µg 
retroviral expression vector (pBABE), 1 µg VSV-G expression vector and 1 µg Gag/Pol 
expression  vector,  using  5  µl  lipofectamine  2000  transfection  reagent  and  the 
transfection  protocol  described  in  section  2.2.5  (above).    The  following  day,  the 
transfection mix was removed, cells were washed once in sterile PBS (MSKCC media 
facility) and 2 ml of 16HBE growth media was added.  HEK293T cells were incubated 
in 16HBE growth media for 24 hours to collect secreted viral particles.  The media was 
then collected and filtered through a 0.45 µm filter (Sarstedt), and supplemented with 8   75 
µg/ml polybrene (hexadimethrine bromide, Sigma).  This mix was added to 16HBE 
cells, which had been seeded at a density of 1.5x10
4 cells/cm
2 in a 6-well cell culture 
dish the previous day.  16HBE cells were incubated overnight with the virus-containing 
media,  which  was  then  removed  and  fresh  growth  media  added.    48  hours  after 
infection,  infected  cells  were  selected  using  growth  media  containing  1.5  µg/ml 
puromycin (Invitrogen).  
 
2.2.8 Calcium-switch in 16HBE cells 
 
Junction formation was induced in 16HBE cells using the calcium-switch technique.  
16HBE  monolayers  were  washed  3  times  in  PBS  without  calcium  (MSKCC  core 
facility) to remove all traces of calcium.  Cells were then incubated for 4 hours in 
DMEM without calcium chloride (Gibco catalogue number 21068) supplemented with 
10%  calcium-depleted  FBS  (BenchMark,  lot  number  A27A00X)  and  a  mixture  of 
penicillin (100 U/ml) and streptomycin (100 µg/ml) antibiotics (Gibco).  Calcium was 
depleted from FBS by chelation using Chelex 100 Resin (Bio-Rad).  80 g Chelex resin 
was dissolved in 2 L water and the pH adjusted to 7.4 using hydrochloric acid.  The 
resin was then removed from solution by filtering through Whatman no. 1 filter paper 
and incubated with 200 ml FBS at RT for 3 hours.  Calcium-depleted FBS was purified 
by filtering through Whatman no. 1 filter paper and sterilized by filtering through a 0.2 
µm  filter  (Sarstedt).    Following  incubation  in  calcium-depleted  media,  junction 
assembly  was  induced  by  changing  cells  back  to  normal  16HBE  growth  media 
containing calcium (see section 2.2.1a). 
 
 
2.3 Protein biochemistry 
 
2.3.1 Preparation of cell lysates 
 
Total cell lysates were prepared by adding protein sample buffer (2% (v/v) SDS, 0.1 M 
DTT, 50 mM Tris-HCl pH6.8, 10% (v/v) glycerol, 0.1% (v/v) bromophenol blue) to   76 
cells on ice, and scraping using a cell scraper or a pipette tip.  HEK293T cells grown in 
6-well plates were lysed in 250 µl protein sample buffer, while 16HBE cells grown in 
24-well plates were lysed in 100 µl protein sample buffer.  The lysate was boiled at 100 
°C for 5 mins to denature proteins, then sonicated in a sonicating waterbath for 1 min to 
shear DNA. 
 
Soluble fractions were prepared by adding 100 µl of 0.1% NP40 lysis buffer (0.1% 
(v/v)  NP-40  (Igepal  CA630,  Sigma),  50  mM  Tris-HCl  pH  8.0,  150  mM  NaCl, 
supplemented with 0.5 mM PMSF (Fluka, stock solution 100 mM in methanol) and 
Complete protease inhibitor cocktail tablet (Roche)) to 16HBE cells grown in a 24-well 
plate.  Cells were scraped on ice with a pipette tip to aid solubilization.  The lysate was 
transferred to a 1.5 ml microcentrifuge tube and centrifuged at 13000 rpm at 4 °C for 10 
mins.  The supernatant was transferred to a fresh microcentrifuge tube and 25 µl 5X 
protein sample buffer added (to give a final concentration of 1X protein sample buffer).  
The sample was boiled at 100 °C for 5 mins to denature proteins, then sonicated in a 
sonicating waterbath for 1 min to shear DNA. 
 
2.3.2 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Protein samples were prepared in protein sample buffer (see section 2.3.1 above) and 
loaded on to 1.5 mm thick polyacrylamide gels.  Separating gels were prepared by 
diluting a stock solution of 30% acrylamide/0.8% bis-acrylamide (National Diagnostics) 
to a final concentration of 7.5%-15% (w/v) acrylamide (depending on the molecular 
weight of the protein of interest) in 350 mM Tris-HCl pH8.6, 0.1% SDS, and adding 
0.1%  (w/v)  ammonium  persulphate  (Amersham  Biosciences)  and  0.001%  (v/v) 
tetramethylethlyenediamine (TEMED, Fisher scientific) to polymerize.  Stacking gels 
were prepared by diluting a stock solution of 30% acrylamide/0.8% bis-acrylamide to a 
final concentration of 4% (w/v) acrylamide in 130 mM Tris-HCl pH6.8, 0.1% SDS, and 
adding 0.2% (w/v) ammonium persulphate and 0.002% (v/v) TEMED to polymerize.  A 
full-range rainbow protein marker (Amersham) was included to allow determination of 
protein size.  Proteins were resolved by running gels at 120 V for approximately 90   77 
minutes  in  a  Bio-Rad  minigel  apparatus,  in  a  running  buffer  containing  200  mM 
glycine, 25 mM Tris base and 0.05% (w/v) SDS.  Proteins were transferred to a PVDF 
membrane to allow protein visualization (see section 2.3.3, below). 
 
2.3.3 Western blot analysis 
 
Proteins  were  resolved  by  SDS-PAGE  (see  section  2.3.2,  above).    Proteins  were 
transferred to methanol-activated PVDF membrane (0.45 µm pore size, Millipore) using 
a Bio-Rad minitransfer apparatus, in a transfer buffer containing 125 mM glycine, 25 
mM Tris base, 0.1% (w/v)  SDS and 10% (v/v) methanol.  The transfer was carried out 
at 40V in a 4 °C cold room for 2 hours.  Following protein transfer membranes were 
blocked with a solution of 5% milk in TBS-T (50 mM Tris-HCl pH8.0, 150 mM NaCl, 
0.1%  Tween20  (Sigma))  for  30  mins  at  RT.    Primary  antibody  incubations  were 
performed overnight in 5% milk in TBS-T at 4 °C (see Table 2.3 for a list of antibodies 
used).    Membranes  were  washed  3  x  10  mins  in  TBS-T.    Secondary  antibody 
incubations  were  carried  out  using  HRP-conjugated  secondary  antibodies 
(DakoCytomation) diluted 1:5000 in 5% milk in TBS-T, for 1 hour at RT.  Membranes 
were  washed  4  x  10  mins  in  TBS-T.    Proteins  were  detected  using  ECL  Western 
Blotting  Detection  Reagents  (Amersham),  following  the  manufacturer’s  instructions, 
and visualized by exposing Fuji medical X-ray film (Crystalgen). 
 
Antibody  Host  Clone  Source  Cat. #  Stock 
(µg/ml) 
IF 
(µg/ml) 
WB 
(µg/ml) 
LaminA/C  mouse  636  Santa Cruz  sc-7292  200  2  0.2 
α-tubulin  rat  YL1/2  Serotec  MCA77S  n/a  -  1:1000 
β-actin  mouse  AC-74  Sigma  A5316  1700  -  0.085 
flag  mouse  M2  Sigma  F3165  3000  -  3 
myc  mouse   9E10  CRUK  n/a  1200  6  1.2 
HA  mouse  12CA5  CRUK  n/a  800  -  0.8 
HA  rat  3F10  Roche  1867423  100  1  0.1 
RhoA  mouse  26C4  Santa Cruz  sc-418  200  -  0.4 
RhoA/C  rabbit  poly  Santa Cruz  sc-179  200  -  1 
RhoB  rabbit  poly  Santa Cruz  sc-180  200  -  1 
Rac1  mouse  23A8  Upstate  05-389  1000  -  1   78 
Cdc42  mouse  44  BD Transduction  610929  250  -  0.25 
ITSN2  mouse  poly  Abnova  H0005061
8-A01 
n/a  -  1:1000 
p115RhoGEF  goat  poly  Santa Cruz  sc-8492  200  -  0.2 
Par6B  rabbit  poly  Santa Cruz  sc-67392  200  2  0.2 
PRK1  mouse  49  BD Transduction  610687  250  -  0.25 
PRK2  mouse  22  BD Transduction  610795  250  2.5  0.25 
PAK4  rabbit  poly  Cell Signaling  3242  n/a  1:100  1:1000 
E-cadherin  mouse  34  BD Transduction  610405  250  -  0.25 
E-cadherin  rat  ECCD-2  Invitrogen  13-1900  500  5  - 
β-catenin  mouse  14  BD Transduction  610154  250  1.25  - 
β-catenin  rabbit  poly  Invitrogen  71-2700  250  2.5  - 
Occludin  rabbit  poly  Zymed  71-1500  250  2.5  0.25 
Occludin  mouse  OC-3F10  Zymed  33-1500  500  5  - 
ZO-1  mouse  1A12  Zymed  33-9100  400  2  - 
ZO-1  rabbit  poly  Zymed  61-7300  250  2.5  0.25 
 
Table 2.3 Antibodies used in this study.  All primary antibodies used for western blot analysis and 
immunofluorescence  microscopy  are  listed,  with  working  concentrations.    In  some  cases  the 
concentration is not known, and the working dilution is given.  Poly - polyclonal. 
 
 
 
2.4 Immunofluorescence microscopy 
 
2.4.1 Preparation of coverslips 
 
13 mm glass coverslips (Fisher Scientific) were treated with 70% nitric acid for 15 mins 
with gentle agitation.  Coverslips were washed for 20 mins under a flowing deionized 
water tap.  Coverslips were then washed several times in methanol to remove all traces 
of water, and transferred to a glass petri dish.  Once dry, coverslips were sterilized by 
baking for 30 minutes at 180 °C. 
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2.4.2 Fixing and immunostaining  
 
16HBE cells were seeded on glass coverslips in 24-well cell culture plates.  Following 
experimental manipulation, cells were washed once in PBS (MSKCC media facility) 
and  fixed.    Unless  otherwise  stated,  cells  were  fixed  by  incubating  in  3.7%  (v/v) 
formaldehyde (Sigma), diluted in PBS, for 20 mins at RT.  Following formaldehyde 
fixation, coverslips were washed 5 times in PBS, and cells were permeabilized with 
0.5% (v/v) Triton X-100 in PBS for 5 mins at RT.  In some cases cells were fixed by 
incubating in ice cold methanol for 5 mins at -20 °C.  Following methanol fixation, cells 
were washed 5 times in PBS at RT. 
 
Coverslips were incubated with primary antibodies diluted in PBS for 1 hour at RT (see 
Table 2.3 for a list of antibodies used).  Coverslips were then washed 5 times in PBS.  
Secondary  antibody  incubations  were  carried  out  using  Alexa488-  or  Alexa568- 
conjugated secondary antibodies (Invitrogen) diluted 1:500 in PBS, incubating for 45 
mins at RT.  In some experiments, rhodamine-conjugated phalloidin (Invitrogen, stock 
solution prepared in methanol according to manufacturer’s instructions, diluted 1:250 in 
PBS) was added to the secondary antibody mix, to allow visualization of filamentous 
actin.  Coverslips were then washed 5 times in PBS.  Hoechst (Sigma) was included in 
the  first  PBS  wash  at  a  concentration  of  1  µg/ml,  to  visualize  DNA.    Following 
immunostaining, coverslips were mounted on glass microscope slides (Fisher Scientific) 
using Dako fluorescent mounting medium (DakoCytomation).  Mounting solution was 
allowed to set by incubating coverslips at 37 °C for 1 hour or at RT overnight. 
 
2.4.3 Immunofluorescence microscopy 
 
Stained  cells  were  visualized  using  a  Zeiss Axio  inverted  fluorescence  microscope.  
Images were captured using a Hamamatsu ORCA-ER digital camera and AxioVision 
computer software.  In each experiment the camera exposure time was optimized for 
each  fluorescence  channel  using  the  control  sample,  and  all  further  images  were 
captured  with  the  same  camera  settings,  making  fluorescence  intensity  comparisons 
possible.    Captured  images  were  saved  as  TIFFs  to  allow  further  analysis  in  other   80 
software programmes.  For presentation purposes, images were processed using Adobe 
photoshop.    In  some  experiments,  brightness  and  contrast  settings  were  changed  to 
improve image quality.  In most experiments, images were cropped to increase image 
size and facilitate visualization.  In all cases, all images within an experiment were 
processed in an identical manner, allowing comparison of image intensity and size. 
 
2.4.4 Quantification of tight junction formation 
 
Tight junction formation in 16HBE cells was quantified after staining cells with anti-
occludin or anti-ZO-1 antibody.  12 random non-overlapping images were taken at 40X 
magnification  (see  section  2.4.3  above),  containing  approximately  400-500  cells.  
Images  were  saved  in  TIFF  format  and  later  opened  in  Metamorph  image  analysis 
software.  For each cell, tight junction integrity was assessed.  Cells with a continuous 
staining of occludin or ZO-1 at cell-cell contacts were defined as having intact tight 
junctions, whereas cells with punctate discontinuous staining or no staining at cell-cell 
contacts  were  defined  as  not  having  intact  tight  junctions.    In  control  monolayers 
mitotic  cells  (approximately  3-5%  of  total  cells),  identified  by  DNA  staining, 
sometimes  exhibit  disruptions  in  their  tight  junction  staining.    Mitotic  cells  were 
therefore not included in our analysis of tight junction integrity.  Cells were counted 
manually using the Metamorph manual count option.  The percentage of cells with 
intact tight junctions was calculated and represented in bar charts, in which error bars 
correspond  to  the  SEM  (Standard  Error  of  the  Mean)  of  at  least  3  independent 
experiments.    SEM  was  calculated  by  the  following  formula:  SEM  =  standard 
deviation/√n. 
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CHAPTER3 - Results 
 
RNAi  screens  to  identify  Rho  GEFs,  GAPs  and  effector  proteins 
required for tight junction formation. 
 
3.1 Overview 
 
16HBE14o- human bronchial epithelial cells (abbreviated to 16HBE) were chosen as a 
model  epithelial  cell  line  to  study  the  signalling  pathways  regulating  tight  junction 
formation.  16HBE cells cultured on glass coverslips form tight junctions, which can be 
analysed  by  immunofluorescence  microscopy  using  antibodies  against  tight  junction 
proteins  such  as  ZO-1  and  occludin.    16HBE  cells  seeded  at  low  density  can  be 
transfected with siRNA with high efficiency, such that 72 hours post-transfection cells 
are  approaching  confluence  and  have  formed  tight  junctions,  defined  here  as  a 
continuous ring of ZO-1 or occludin protein localized at cell-cell contacts.  As expected, 
downregulation of RhoA or Cdc42 prevented tight junction formation in this assay, and 
served as positive controls in screens to identify components of Rho GTPase signalling 
pathways  required  for tight  junction  formation.   These  screens  identified  three  Rho 
GEFs, namely Asef, ARHGEF10 and ITSN2, and three Rho effector proteins, namely 
PAK4, PRK2 and Par6B, as potential regulators of tight junction formation. 
 
Screens were carried out using SMARTpool siRNA reagents (Dharmacon) consisting of 
a pool of 4 distinct siRNA duplexes targeting each gene.  To assess the specificity of the 
observed  tight  junction  defects,  the  siRNA  duplexes  making  up  each  pool  were 
transfected individually.  The ability of each siRNA duplex to knockdown expression of 
its target protein was determined by western blot analysis, and was compared with its 
ability to prevent tight junction formation.  Based on this analysis, we concluded that 
the tight junction defect observed after transfection of Asef, ARHGEF10 or ITSN2 
siRNA is likely to be caused by a non-specific mechanism, whereas the tight junction 
defect observed after transfection of PAK4, PRK2 or Par6B siRNA is likely to be a 
specific consequence of downregulation of these proteins.   82 
 
3.2 16HBE cells as a model for tight junction formation 
 
16HBE14o-  cells  (abbreviated  here  to  16HBE  cells)  are  SV40  large  T-antigen-
transformed  human  bronchial  epithelial  cells.    When  cultured  in  vitro  they  form 
monolayers  with  many  of  the  properties  of  normal  epithelial  cells,  including  the 
presence of tight junctions and cilia detected by transmission EM, and the generation of 
transepithelial electrical resistance (TER) (Cozens et al., 1994).  This is in contrast to 
most  transformed  epithelial  cell  lines,  which  do  not  retain  these  properties.    We 
therefore decided to assess the suitability of 16HBE cells for RNAi-based screens. 
 
16HBE cells were seeded on glass coverslips at low density (1.5 x 10
4 cells/cm
2) and 
allowed to adhere overnight.  The following day cells were transfected with siRNA 
targeting laminA/C (siLamin) at a concentration of 50 nM using lipofectamine LTX 
transfection  reagent.    72  hours  later  knockdown  efficiency  was  determined  by 
immunofluorescence  microscopy  and  western  blot  analysis  with  an  anti-laminA/C 
antibody  (Figure  3.1).    Typically  80-90%  of  cells  showed  a  clear  knockdown  of 
laminA/C  expression.    The  ability  of  16HBE  cells  to  form  tight  junctions  after 
transfection with siRNA was determined by comparing untransfected cells with cells 
transfected with a control siRNA (siControl, not known to knockdown expression of 
any genes) and cells transfected with siLamin.  72 hours post-transfection tight junction 
formation was assessed by staining with an anti-occludin antibody.  Untransfected cells 
are approaching confluence by this time, and the majority of cells have a continuous 
ring of occludin staining at cell-cell contacts (Figure 3.2).  siControl- and siLamin-
transfected  cells  were  indistinguishable  from  untransfected  cells,  showing  that  the 
transfection protocol itself does not have any adverse effects on cell behaviour.  The 
percentage of cells forming tight junctions, defined as the presence of a continuous ring 
of occludin staining at cell-cell contacts, was determined by taking 12 random non-
overlapping images at 40X magnification (typically 400-500 cells in total) and scoring 
cells for the presence of a continuous ring of occludin staining at cell-cell contacts.  
Cells  with  discontinuous  punctate  occludin  staining  at  cell-cell  contacts,  or  cells 
completely lacking occludin staining at cell-cell contacts, do not have tight junctions.     83   84 
16HBE cells consistently form tight junctions in this assay, and this is not affected by 
transfection with control siRNA duplexes (Figure 3.2).  The high transfection efficiency 
of these cells together with their ability to reproducibly form tight junctions that can be 
readily assessed by immunofluorescence microscopy makes them a suitable model cell 
line for RNAi screens to identify proteins required for tight junction formation.   
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3.3 RhoA and Cdc42 are required for tight junction formation 
 
The  three  best-characterized  members  of  the  Rho  family,  namely  RhoA,  Rac1  and 
Cdc42, have each been implicated in tight junction formation (see introduction, section 
1.5.1).  However these experiments have mainly been carried out in MDCK cells and 
keratinocytes,  two  established  cell  culture  models  for  studying  epithelial 
morphogenesis.  To examine  whether these GTPases  are required for tight junction 
formation in 16HBE cells, cells were transfected with SMARTpool siRNA targeting 
RhoA, Rac1 and Cdc42.  72 hours post-transfection many cells transfected with siRhoA 
or siCdc42 did not have tight junctions, seen as a failure to localize occludin at cell-cell 
contacts (Figure 3.3).  This defect in tight junction formation was not a result of loss of 
expression  of  junctional  proteins  as  occludin  and  E-cadherin  expression  were  not 
affected by knockdown of RhoA or Cdc42 (Figure 3.3G).  Cells transfected with siRac1 
were indistinguishable from control cells.  Protein expression level was determined by 
western blot analysis, which revealed that RhoA and Cdc42 expression was strongly 
reduced by transfection of siRhoA and siCdc42 respectively (Figure 3.3F).  siRac1 only 
partially reduced expression of Rac protein, which might explain why siRac1 does not 
affect tight junction formation (discussed further below, section 3.6). 
 
To assess the specificity of the tight junction defect observed after transfection of RhoA 
and  Cdc42  SMARTpool  siRNA,  the  4  duplexes  comprising  the  SMARTpool  were 
transfected individually.  Transfection of all 4 RhoA siRNA duplexes resulted in the 
same tight junction defect observed after transfection of the RhoA SMARTpool, and in 
each case RhoA protein level was reduced (Figure 3.4).  RhoA siRNA duplex 1 was 
particularly efficient at knocking down RhoA expression, and resulted in a more severe 
defect  in  tight  junction  formation,  as  far  as  number  of  cells  affected  is  concerned.  
Transfection of 3 out of 4 Cdc42 siRNA duplexes resulted in the same tight junction 
defect  observed  after  transfection  of  the  Cdc42  SMARTpool,  with  a  corresponding 
decrease in Cdc42 expression (Figure 3.5).  Cdc42 siRNA duplex 1 did not knockdown 
expression of Cdc42, and did not affect tight junction formation.  For both RhoA and 
Cdc42 the phenotype observed after transfection of siRNA is therefore likely to be a 
specific consequence of loss of the target protein, as in each case multiple distinct    86   87   88   89 
siRNA duplexes impair tight junction formation.  These experiments show that RhoA 
and Cdc42 are required for tight junction formation in 16HBE cells, as expected based 
on experiments carried out in other cell types. 
 
 
3.4 Screening of Rho GEFs and Rho GAPs 
 
To identify upstream regulators of Rho GTPases required for tight junction formation, 
we screened SMARTpool siRNA libraries targeting 82 known human Rho GEFs and 66 
known human Rho GAPs (see Tables 3.1 and 3.2 for a complete list of genes targeted), 
using  the  assay  described  above  with  siRhoA  and  siCdc42  as  positive  controls.  
Transfection of three Rho GEF SMARTpool reagents resulted in a failure to form tight 
junctions, phenocopying knockdown of RhoA or Cdc42, while none of the Rho GAP 
SMARTpool reagents generated this phenotype.  The 3 hits from the Rho GEF screen 
were  Asef  (ARHGEF4),  ARHGEF10  and  ITSN2  (intersectin2)  (Figure  3.6).    This 
screen therefore identified these proteins as potential regulators of tight junctions. 
 
 
 
 
Table 3.1 (below) Rho GEF genes targeted with siRNA.  All siRNA reagents used are siGENOME 
SMARTpool siRNA purchased from Dharmacon. 
 
 
Number  Gene name  Accession #  Alternative names 
1  SWAP70  NM_015055   
2  SGEF  NM_015595   
3  PREX1  NM_020820   
4  GEFT  NM_133483  p63 RhoGEF 
5  ARHGEF10  NM_014448  NBR, neuroblastoma 
6  FLJ10521  NM_018125  GrinchGEF 
7  FGD6  XM_370702   
8  DNMBP  NM_015221  Tuba 
9  MCF2  NM_005369  Dbl 
10  MCF2L  NM_024979  Dbs, ARHGEF14 
11  DOCK4  NM_014705   
12  DOCK5  NM_024940   
13  DOCK6  NM_020812   
14  DOCK7  NM_033407     90 
15  DOCK8  NM_203447   
16  NGEF  NM_019850  Ephexin 
17  FGD2  NM_173558   
18  SPATA13  NM_153023  Asef2 
19  MCF2L2  NM_015078   
20  DEF6  NM_022047  IBP 
21  FGD4  NM_139241  Frabin 
22  ARHGEF19  NM_153213   
23  FGD3  NM_033086   
24  DOCK10  XM_371595   
25  PLEKHG5  NM_020631   
26  DOCK9  NM_015296   
27  AKAP13  NM_006738  Lbc 
28  LOC351864  XM_302177   
29  ECT2  NM_018098   
30  FARP1  NM_005766  CDEP 
31  FARP2  XM_376193  FRG 
32  ABR  NM_001092   
33  ALS2  NM_020919  Alsin 
34  ARHGEF3  NM_019555   
35  ARHGEF4  NM_015320  Asef 
36  ARHGEF10  NM_014629   
37  ARHGEF15  NM_173728  Vsm-RhoGEF 
38  BCR  NM_004327   
39  PLEKHG2  NM_022835  Clg 
40  DOCK1  NM_001380  DOCK180 
41  DOCK2  NM_004946   
42  DOCK3  NM_004947   
43  FLJ10665  NM_018173   
44  NET1  NM_005863   
45  C9ORF100  NM_032818   
46  FLJ20148  NM_017700   
47  ITSN1  NM_003024  Intersectin1 
48  ITSN2  NM_006277  Intersectin2 
49  ARHGEF12  NM_015313  Larg 
50  ARHGEF2  NM_004723  GEF-H1 
51  KIAA1639  XM_290923  Obscurin 
52  ARHGEF18  NM_015318  p114-RhoGEF 
53  ARHGEF1  NM_004706  p115-RhoGEF 
54  ARHGEF17  NM_014786  p164-RhoGEF 
55  ARHEGF11  NM_014784  PDZ-RhoGEF 
56  ARHGEF9  XM_377014  h-PEM2, collybistin 
57  ARHGEF6  NM_004840  α-PIX 
58  ARHGEF7  NM_003899  β-PIX 
59  RASGRF1  NM_002891   
60  RASGRF2  NM_006909   
61  SOS1  NM_005633   
62  SOS2  NM_006939   
63  TIAM1  NM_003253   
64  TIAM2  NM_012454   
65  ARHEGF5  NM_005435  TIM 
66  TRIO  NM_007118   
67  VAV1  NM_005428   
68  VAV2  NM_003371     91 
69  VAV3  NM_006113   
70  FGD5  XM_371619   
71  PLEKHG1  XM_027307   
72  RGNEF  XM_371755   
73  FLJ10357  XM_370737   
74  PLEKHG4B  NM_052909   
75  PLEKHG7  NM_001004330   
76  LOC401147  XM_376334   
77  LOC345930  XM_294019   
78  DOCK11  NM_144658   
79  FGD1  NM_004463   
80  KALRN  NM_003947  Duet 
81  PLEKHG4  NM_015432   
82  PLEKHG3  NM_015549   
 
Table  3.1  (above)  Rho  GEF  genes  targeted  with  siRNA.    All  siRNA  reagents  are  siGENOME 
SMARTpool siRNA purchased from Dharmacon. 
 
 
 
 
 
 
 
 
Table  3.2  (below)  Rho  GAP  genes  targeted  with  siRNA.    All  siRNA  reagents  are  siGENOME 
SMARTpool siRNA purchased from Dharmacon. 
 
Number  Gene name  Accession #  Alternative names 
1  7H3  NM_033025  SYDE1 
2  ARHGAP1  NM_004308   
3  ARHGAP10  NM_024605  GRAF2 
4  ARHGAP11A  NM_014783   
5  ARHGAP12  NM_018287   
6  ARHGAP15  NM_018460   
7  ARHGAP17  NM_018054  RICH1 
8  ARHGAP18  NM_033515   
9  ARHGAP19  NM_032900   
10  ARHGAP20  NM_020809   
11  ARHGAP21  NM_020824   
12  ARHGAP22  NM_021226   
13  ARHGAP23  XM_290799   
14  ARHGAP24  NM_031305   
15  ARHGAP25  NM_014882   
16  ARHGAP26  NM_015071  GRAF 
17  ARHGAP28  NM_030672   
18  ARHGAP4  NM_001666   
19  ARHGAP5  NM_001173   
20  ARHGAP6  NM_001174   
21  ARHGAP8  NM_001017526   
22  ARHGAP9  NM_032496   
23  BNIP2  NM_004330   
24  C5ORF5  NM_016603     92 
25  CDGAP  NM_020754   
26  CENTD1  NM_015230  ARAP2 
27  CENTD2  NM_015242  ARAP1 
28  CENTD3  NM_022481  ARAP3 
29  CHN1  NM_001822  chimaerin-1 
30  CHN2  NM_004067  chimaerin-2 
31  DEPDC1  NM_017779   
32  DEPDC1B  NM_018639   
33  DLC1  NM_006094  STARD12, p112-RhoGAP 
34  FKSG42  NM_032032   
35  FLJ13815  XM_086186  SYDE2 
36  FLJ30058  NM_144967   
37  FLJ32810  XM_370651   
38  GMIP  NM_016573   
39  GRLF1  NM_004491  p190-RhoGAP 
40  HA-1  NM_012292   
41  INPP5B  NM_005540   
42  KIAA0672  NM_014859   
43  KIAA1688  NM_025251   
44  LOC201176  NM_199282  ARHGAP27 
45  LOC257106  NM_181720  ARHGAP30 
46  LOC285101  XM_210411   
47  LOC343578  XM_293123   
48  LOC389211  XM_371697   
49  MYO9A  NM_006901   
50  MYO9B  NM_004145   
51  OCRL  NM_000276  INPP5F 
52  OPHN1  NM_002547   
53  PARG1  NM_004815  ARHGAP29 
54  PIK3R1  NM_181504  p85-alpha 
55  PIK3R2  NM_005027  p85-beta 
56  RACGAP1  NM_013277  Mgc-RacGAP 
57  RALBP1  NM_006788   
58  RICS  NM_014715  GRIT, p200-RhoGAP 
59  SH3BP1  NM_018957   
60  SNX26  NM_052948  TCGAP 
61  SRGAP1  NM_020762   
62  SRGAP2  NM_015326   
63  SRGAP3  NM_014850   
64  STARD13  NM_052851  DLC2 
65  STARD8  NM_014725  DLC3 
66  TAGAP  NM_054114   
 
Table  3.2  (above)  Rho  GAP  genes  targeted  with  siRNA.    All  siRNA  reagents  are  siGENOME 
SMARTpool siRNA purchased from Dharmacon. 
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To assess the specificity of the tight junction defect observed after transfection of these 
SMARTpool  siRNA  reagents,  the  4  duplexes  making  up  the  SMARTpool  were 
transfected  individually.    Transfection  of  16HBE  cells  with  Asef  siRNA  duplex  2 
resulted in the same tight junction defect seen after transfection of Asef SMARTpool 
siRNA, while transfection of Asef siRNA duplexes 1, 3 and 4 had no effect (Figure 
3.7).  We were not able to detect Asef expression in 16HBE cells using an anti-Asef 
antibody (data not shown).  To check which Asef duplexes can knockdown expression 
of Asef, HEK293T cells were transfected with Asef siRNA duplexes followed by a 
flag-tagged human Asef cDNA, and expression of exogenous Asef was determined by 
western blot using an anti-flag antibody.  Several bands were detected after expression 
of Asef, presumably as a result of post-translational modifications (Figure 3.7).  Asef 
siRNA duplexes 1 and 3 were able to downregulate Asef expression, but Asef siRNA 
duplexes 2 and 4 were not.  The inability of Asef siRNA duplex 2 to downregulate 
expression of Asef suggests that the defect in tight junction formation in 16HBE cells 
caused by transfection of this duplex is not a  specific consequence of loss of Asef 
protein. 
 
Transfection of 16HBE cells with ARHGEF10 siRNA duplex 3 resulted in the same 
tight junction defect seen after transfection of ARHGEF10 SMARTpool siRNA, while 
transfection of ARHGEF10 siRNA duplexes 1,  2 and 4 had no effect (Figure 3.8).  
There  is  currently  not  an  antibody  against  ARHGEF10  protein,  so  to  check  which 
ARHGEF10 siRNA duplexes can knockdown expression of ARHGEF10, HEK293T 
cells were transfected with ARHGEF10 siRNA duplexes followed by a myc-tagged 
human ARHGEF10 cDNA, and expression of exogenous ARHGEF10 was determined 
by western blot using an anti-myc antibody.  All 4 ARHGEF10 siRNA duplexes were 
able to downregulate expression of ARHGEF10 protein (Figure 3.8).  The observation 
that ARHGEF10 siRNA duplexes 1, 2 and 4 are able to downregulate expression of 
ARHGEF10 as efficiently as ARHGEF10 siRNA duplex 3 and yet do not impair tight 
junction formation suggests that the defect in tight junction formation observed after 
transfection  of  ARHGEF10  siRNA  duplex  3  is  not  caused  by  knockdown  of 
ARHGEF10 protein. 
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Transfection of 16HBE cells with ITSN2 siRNA duplex 3 resulted in the same tight 
junction defect seen after transfection of ITSN2 SMARTpool siRNA, while transfection 
of ITSN2 siRNA duplexes 1, 2 and 4 had no effect (Figure 3.9).  To check which 
ITSN2 siRNA duplexes can downregulate expression of ITSN2, lysates from 16HBE 
cells were analysed by western blot with an anti-ITSN2 antibody.  All 4 ITSN2 siRNA 
duplexes were able to knockdown expression of endogenous ITSN2 protein isoforms to 
a similar extent (Figure 3.9).  The observation that ITSN2 siRNA duplexes 1, 2 and 4 
are able to downregulate expression of ITSN2 as efficiently as ITSN2 siRNA duplex3 
and yet do not impair tight junction formation suggests that the defect in tight junction 
formation  observed  after  transfection  of  ITSN2  siRNA  duplex  3  is  not  caused  by 
specific knockdown of ITSN2 protein. 
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3.5 Screening of Rho effector proteins 
 
To identify Rho effector proteins required for tight junction formation, we screened a 
SMARTpool siRNA library targeting known Rho effector proteins (Table 3.3).  In the 
light of our failure to identify any Rho GEFs or GAPs using this approach, we decided 
to  screen  our  effector  proteins  individually  and also  in  families  of  related  proteins.  
Redundancy amongst closely related proteins could result in failure to identify proteins 
required for tight junction formation when only one family member is targeted.   
 
16HBE cells were transfected with the 92 SMARTpool siRNA reagents listed in Table 
3.3, and tight junction formation was assessed 72 hours post-transfection by staining 
with  an  anti-occludin  antibody.   This  screen  identified  PAK4,  Par6B  and  PRK2  as 
potential regulators of tight junction formation.  Transfection of SMARTpool siRNA 
targeting these genes resulted in a large number of cells without tight junctions (Figure 
3.10a).  PAK4 belongs to a family of proteins including PAK5 and PAK6 (the class II 
PAK family).  In this screen transfection of PAK6 SMARTpool siRNA resulted in a 
partial decrease in tight junction formation, while transfection of PAK5 SMARTpool 
siRNA had no effect (Figure 3.10a, red bars in G).  Par6B belongs to a family of 
proteins  including  Par6A  and  Par6G,  however  transfection  of  Par6A  or  Par6G 
SMARTpool siRNA had no effect on tight junction formation (Figure 3.10a, green bars 
in G).  PRK2 belongs to a family of proteins including PRK1 and PRK3.  Transfection 
of PRK1 SMARTpool siRNA resulted in a slight decrease in tight junction formation, 
while transfection of PRK3 SMARTpool siRNA had no effect (Figure 3.10a, yellow 
bars in G). 
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Table 3.3 (below) Rho effector genes targeted with  siRNA.  All siRNA reagents are siGENOME 
SMARTpool siRNA purchased from Dharmacon. 
 
Number  Gene name  Gene ID  Alternative names 
1  ARFIP2  23647  Arfaptin 
2  BAIAP2  10458  IRSp53 
3  CCM2  83605   
4  CDC42BPA  8476  MRCKα 
5  CDC42BPB  9578  MRCKβ 
6  CDC42EP1  11135  Borg5 
7  CDC42EP2  10435  Borg1 
8  CDC42EP3  10602  Borg2 
9  CDC42EP4  23580  Borg4 
10  CDK5R1  8851  Cdk5 regulatory subunit 1 
11  CDKN1B  1027  kip1/p27 
12  CIT  11113  Citron kinase 
13  CNKSR1  10256   
14  CNKSR2  22866   
15  CNKSR3  154043   
16  CYFIP1  23191  SRA1 
17  DAAM1  23002   
18  DGKG  1608  Diacylglycerol kinase-γ 
19  DGKQ  1609  Diacylglycerol kinase-θ 
20  DIAPH1  1729  DRF1, Dia1 
21  DIAPH2  1730  DRF2, Dia2 
22  DIAPH3  81624  DRF3, Dia3 
23  ELMO1  9844   
24  ELMO2  63916   
25  ELMO3  79767   
26  EXOC7  23265  Exo70 
27  FHOD1  29109   
28  FLNA  2316  Filamin-A 
29  FMNL1  756  Formin-like 1 
30  GNB2  2783   
31  GOPC  57120  PIST 
32  HSMDPKIN  55561  CDC42BPG, MRCKγ 
33  IQGAP1  8826   
34  IQGAP2  10788   
35  KTN1  3895  Kinectin 
36  MAP3K1  4214  MEKK1 
37  MAP3K10  4294  MLK2 
38  MAP3K11  4296  MLK2 
39  MAP3K4  4216  MEKK4 
40  MAP3K5  4217  MEKK5 
41  M-RIP  23164   
42  NCF2  4688  p67PHOX 
43  NOX1  27035  NADPH oxidase 1 
44  NOXA1  10811  NADPH oxidase activator 1 
45  PAK1  5058   
46  PAK2  5062   
47  PAK3  5063     101 
48  PAK4  10298   
49  PAK6  56924   
50  PAK7  57144  PAK5 
51  PARD6A  50855  Par6A 
52  PARD6B  84612  Par6B 
53  PARD6G  84552  Par6G 
54  PDE6D  5147  Phosphodiesterase 6D 
55  PIK3R1  5295  p85α 
56  PIK3R2  5296  p85β 
57  PIK4CB  5298   
58  PIP5K1A  8394   
59  PIP5K1B  8395   
60  PIP5K1C  23396   
61  PITPNM1  9600   
62  PKN3  29941  PRK3 
63  PLCB2  5330  PhospholipaseC-β2 
64  PLCB3  5331  PhospholipaseC-β3 
65  PLCE1  51196  PhospholipaseC-ε1 
66  PLCG1  5335  PhospholipaseC-γ1 
67  PLD1  5337  PhospholipaseD 
68  PLXNA1  5361  plexinA1 
69  PLXNB1  5364  plexinB1 
70  PLXNB2  23654  plexinB2 
71  PPP1R12A  4659  Protein phosphatase 1 
72  PRKCL1  5585  PRK1, PKN1 
73  PRKCL2  5586  PRK2, PKN2 
74  RCC2  55920   
75  RHPN1  114822  Rhophilin1 
76  RHPN2  85415  Rhophilin2 
77  ROCK1  6093  ROK1 
78  ROCK2  9475  ROK2 
79  RPS6KB1  6198   
80  RTKN  6242  Rhotekin 
81  SH3RF1  57630  POSH 
82  SMURF1  57154   
83  SPRED1  161742   
84  SYNJ1  8867  Synaptojanin1 
85  SYNJ2  8871  Synaptojanin2 
86  TNK1  8711   
87  TNK2  10188  ACK1 
88  FNBP1L  54874  TOCA 
89  TRIP10  9322  CIP4 
90  USP6  9098   
91  WAS  7454  WASP 
92  WASL  8976  N-WASP 
 
Table 3.3 (above) Rho effector genes targeted with  siRNA.  All siRNA reagents are siGENOME 
SMARTpool siRNA purchased from Dharmacon. 
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In  a  parallel  screen,  16HBE  cells  were  transfected  with  the  combinations  of 
SMARTpool siRNA reagents listed in Table 3.4.  Where two genes were targeted, each 
siRNA was transfected at a concentration of 25 nM.  Where three genes were targeted, 
each  siRNA  was  transfected  at  a  concentration  of  16.7  nM.    The  total  siRNA 
concentration was thus maintained at 50 nM for all experiments.   
 
Number  SMARTpool siRNAs co-transfected 
1  MRCKα + MRCKβ 
2  CDC42BP1 + CDC42BP2 + CDC42BP3 
3  CDC42BP2 + CDC42BP3 + CDC42BP4 
4  DGKG + DGKQ 
5  Dia1 + Dia2 
6  Dia1 + Dia3 
7  Dia2 + Dia3 
8  Dia1 + Dia2 + Dia3 
9  ELMO1 + ELMO2 + ELMO3 
10  IQGAP1 + IQGAP2 
11  PAK1 + PAK2 
12  PAK1 + PAK3 
13  PAK2 + PAK3 
14  PAK1 + PAK2 + PAK3 
15  PAK4 + PAK5 
16  PAK4 + PAK6 
17  PAK5 + PAK6 
18   PAK4 + PAK5 + PAK6 
19  PIK3R1 + PIK3R2 
20  PIP5K1A + PIP5K1B + PIP5K1C 
21  PRK1 + PRK2 
22  PRK1 + PRK3 
23  PRK2 + PRK3 
24  PRK1 + PRK2 + PRK3 
25  PlexinB1 + PlexinB2 
26  Rhophilin1 + Rhophilin2 
27  ROCK1 + ROCK2 
28  Synaptojanin1 + Synaptojanin2 
29  TNK1 + TNK2 
30  WASP + N-WASP 
 
Table  3.4    Combinations  of  Rho  effector  genes  targeted  with  siRNA.    The  combinations  of 
SMARTpool siRNA reagents listed, targeting closely related genes were, were co-transfected.  
 
Co-transfection of PAK4 and PAK6 SMARTpool siRNA resulted in a strong defect in 
tight  junction  formation  (Figure  3.10b).    Co-transfection  of  PAK4  and  PAK5 
SMARTpool siRNA also resulted in a clear defect in tight junction formation, although 
the  number  of  cells  that  formed  tight  junctions  was  slightly  higher  than  after  co-
transfection of PAK4 and PAK6 SMARTpool siRNA (Figure 3.10b).  Co-transfection    104   105 
of PAK5 and PAK6 SMARTpool siRNA had no effect on tight junction formation.  
These  results,  together  with  the  results  of  transfecting  single  SMARTpool  siRNA 
reagents  in  Figure  3.10a,  suggest  PAK4  is  a  potential  regulator  of  tight  junction 
formation, with the related protein PAK6 possibly contributing to this function. 
 
Co-transfection of PRK1 and PRK2 SMARTpool siRNA resulted in a strong defect in 
tight  junction  formation  (Figure  3.10b).    Co-transfection  of  PRK2  and  PRK3 
SMARTpool siRNA also resulted in a clear defect in tight junction formation, although 
the number of cells that formed tight junctions was higher than after co-transfection of 
PRK1 and PRK2 SMARTpool siRNA (Figure 3.10b).  Co-transfection of PRK1 and 
PRK3 SMARTpool siRNA had no effect on tight junction formation.  These results, 
together with the effects of transfecting single SMARTpool siRNA reagents in figure 
3.10a, suggest PRK2 is a potential regulator of tight junction formation, with the related 
protein PRK1 possibly contributing to this function. 
 
To assess the specificity of the phenotypes observed in these screens using SMARTpool 
siRNA reagents, the effect of transfection of individual siRNA duplexes making up the 
SMARTpool was analysed.  16HBE cells were transfected with 4 distinct Par6B siRNA 
duplexes and tight junction formation was assessed by staining cells with an anti-ZO1 
antibody  72  hours  after  transfection.    Transfection  of  all  4  Par6B  siRNA  duplexes 
phenocopied the tight junction defect observed after transfection of Par6B SMARTpool 
siRNA,  although  to  varying  degrees  (Figure  3.11).    Transfection  of  Par6B  siRNA 
duplex 3 gave the strongest defect in tight junction formation, while duplexes 1 and 4 
gave intermediate phenotypes, and duplex 2 gave a mild phenotype, as far as number of 
cells affected is concerned.  The ability of the Par6B siRNA duplexes to knockdown 
expression  of  Par6B  was  determined  by  western  blot  analysis  using  an  anti-Par6B 
antibody.    All  duplexes  were  able  to  knockdown  expression  of  Par6B  to  varying 
degrees, and the level of knockdown correlated well with the severity of the defect 
observed in tight junction formation (Figure 3.11).  These results strongly suggest that 
the impaired tight junction formation observed after transfection of Par6B siRNA is a 
specific consequence of loss of Par6B protein. 
   106   107 
16HBE  cells  were  transfected  with  two  siRNA  duplexes  targeting  PRK1  and  two 
targeting  PRK2  alone  or  in  combination  (Figure  3.12).    All  siRNA  duplexes  were 
transfected at a concentration of 25 nM.  Where only one PRK duplex was transfected, 
siControl duplex was co-transfected to keep the total siRNA concentration at 50 nM in 
all  experiments.    Both  PRK1  siRNA  duplexes  downregulated  expression  of  PRK1 
protein, while both PRK2 siRNA duplexes downregulated expression of PRK2 protein 
(Figure 3.12E).  Transfection of 16HBE cells with either PRK2 siRNA duplex 1 or 
PRK2  siRNA  duplex  3  resulted  in  a  clear  defect  in  tight  junction formation,  while 
transfection of either PRK1 siRNA duplex 2 or PRK1 siRNA duplex 3 had no effect on 
tight junction formation.  The defect in tight junction formation caused by knockdown 
of PRK1 and PRK2 together was similar to that caused by knockdown of PRK2 alone, 
suggesting  that  if  PRK1  makes  any  contribution  to  tight  junction  formation  it  is 
minimal. 
 
16HBE  cells  were  transfected  with  two  siRNA  duplexes  targeting  PAK4  and  two 
targeting PAK6 alone or in combination (Figure 3.13).  In these experiments, all siRNA 
duplexes were transfected at a concentration of 25 nM.  Where only one PAK siRNA 
duplex was transfected, siControl duplex was co-transfected to keep the total siRNA 
concentration 50 nM in all experiments.  Transfection of 16HBE cells with either PAK4 
siRNA duplex 3 or PAK4 siRNA duplex 4 alone resulted in a clear defect in tight 
junction formation, while transfection of either PAK6 siRNA duplex 2 or PAK6 siRNA 
duplex 3 alone had minimal effect (Figure 3.13).  Co-transfection of PAK4 and PAK6 
siRNA duplexes together resulted in a slightly increased tight junction defect compared 
to  transfection  of  PAK4  siRNA  duplexes  alone,  but  the  increase  was  minimal.  
Transfection of PAK4 siRNA duplex 3 and duplex 4 both resulted in downregulation of 
PAK4 expression in 16HBE cells, determined by western blot analysis using an anti-
PAK4 antibody (Figure 3.13).  Together these results suggest that the defect in tight 
junction formation observed after transfection of PAK4 siRNA duplexes is a specific 
consequence  of  loss  of  PAK4  protein.    PAK6  does  not  seem  to  make  a  major 
contribution to tight junction formation in these cells, however as I have not been able 
to detect expression of PAK6 in 16HBE cells using the available antibody reagents or    108   109   110 
determine whether it is downregulated by the PAK6 siRNA duplexes used in these 
experiments, a contribution can not be ruled out. 
 
16HBE cells depleted of Par6B, PRK2 or PAK4 express the junctional proteins ZO-1 
and  E-cadherin  at  similar  levels  to  control cells  (Figures  3.11H,  3.12F  and  3.13F), 
showing that the observed defects in tight junction formation are not simply due to loss 
of expression of junctional proteins. 
 
 
3.6 Discussion 
 
To analyse the signalling pathways through which Rho GTPases regulate tight junction 
formation, an assay was established to quantitatively assess tight junction formation in 
16HBE cells.  16HBE cells can be transfected with control siRNAs with high efficiency 
and under conditions that do not affect tight junction formation (Figures 3.1 and 3.2).  
72  hours  after  transfection  tight  junction  formation  can  be  assessed  by  fixing  and 
staining cells with anti-occludin or anti-ZO-1 antibodies.   
 
I have demonstrated a clear role for two Rho family GTPases in tight junction formation 
in 16HBE cells, namely RhoA and Cdc42.  Transfection of multiple siRNA duplexes 
targeting each gene resulted in downregulation of their target protein and caused the 
observed defect in tight junction formation, suggesting these phenotypes are likely to be 
specific and not caused by off-target mechanisms (Figures 3.4 and 3.5).  These results 
are consistent with studies in other cell types showing that Rho and Cdc42 activity are 
required  for  tight  junction  formation  (Braga  et  al.,  1997;  Otani  et  al.,  2006)  (see 
introduction, section 1.5.1). 
 
Transfection  of  SMARTpool  siRNA  targeting  Rac1  had  no  effect  on  tight  junction 
formation in 16HBE cells, which is surprising given the considerable evidence that Rac 
is required for epithelial junction formation (see introduction, section 1.5.1).  However, 
western blot analysis revealed that the Rac1 SMARTpool used in these experiments 
only partially reduced Rac expression (Figure 4.3).  Rac3 is likely to be expressed in   111 
16HBE  cells  and  might  act  redundantly  with  Rac1.    I  have  not  determined  the 
specificity of the Rac1 antibody used in these experiments.  The residual protein seen 
after transfection of Rac1 SMARTpool siRNA is likely to be either Rac1 that has not 
been downregulated efficiently or Rac3 that has cross-reacted with the Rac1 antibody.  
In either case, there is a considerable amount of Rac protein left in 16HBE cells after 
transfection of Rac1 siRNA, which is likely to explain why no defect in tight junction 
formation was observed.  
 
To identify upstream GEFs and GAPs and downstream effector proteins required for 
tight  junction  formation,  RNAi  libraries  were  screened.    Unfortunately  I  failed  to 
identify any GEFs and GAPs using this approach.  Three GEF SMARTpool siRNA 
reagents  prevented  tight  junction formation,  but  subsequent  analysis  found  this  was 
likely to be due to non-specific effects.  There are at least 3 potential reasons for not 
identifying any Rho GEFs or GAPs regulating tight junction formation. 
 
Firstly, tight junction formation in 16HBE cells might not require any Rho GEF or Rho 
GAP function.  This is unlikely, as RhoA and Cdc42 are required for tight junction 
formation in these cells.  Rho GTPases require Rho GEFs for their activation, and so it 
is highly likely that any Rho-dependent process will also be Rho GEF-dependent.  Rho 
GAPs  terminate  Rho  GTPase  signalling.    Often  Rho-dependent  processes  require 
precise regulation of the level of Rho activity, both spatially and temporally, and Rho 
GAP activity is important for achieving this.  Overexpression of either constitutively 
active  or  dominant  negative  mutants  of  Rho  GTPases  results  in  disruption  of  tight 
junctions (Braga et al., 2000; Braga et al., 1997; Kroschewski et al., 1999; Otani et al., 
2006; Sahai and Marshall, 2002), highlighting the importance of precisely regulating 
the level of Rho activity.  It therefore seems likely that Rho GAPs will also be required 
for tight junction formation. 
 
Secondly,  the  level  of  knockdown  achieved  after  transfection  of  siRNA  targeting  a 
particular gene varies.  Not all siRNAs efficiently downregulate expression of their 
target gene.  I might therefore have failed to identify Rho GEFs and GAPs required for 
tight junction formation because their expression was not reduced sufficiently.   112 
 
Thirdly, I might have failed to identify Rho GEFs and GAPs required for tight junction 
formation because of redundancy.  Most Rho GEFs and GAPs in the human genome 
have closely related homologues which can potentially have redundant functions.  It 
might therefore be necessary to simultaneously downregulate expression of more than 
one closely related GEF or GAP for a defect in tight junction formation to become 
apparent. 
 
Three  Rho  effector  proteins  were  identified  as  being  required  for  tight  junction 
formation, namely Par6B, PAK4 and PRK2.  RNAi-mediated knockdown of Par6B, 
using multiple siRNA duplexes, resulted in a defect in tight junction formation that 
correlated with knockdown of Par6B expression, indicating that this phenotype is likely 
to be a specific consequence of Par6B downregulation (Figure 3.11).  Transfection of 
SMARTpool siRNA targeting Par6A or Par6G did not affect tight junction formation 
(Figure 3.10a).  This suggests that either Par6B is the main Par6 isoform expressed in 
16HBE cells, or that Par6 isoforms have distinct functions.  It is known that Par6A is 
not detectably expressed in 16HBE cells using a Par6A specific antibody (D.Jin and 
A.Hall,  unpublished  data),  however  it  is  not  known  whether  Par6G  is  expressed  in 
16HBE cells due to lack of an antibody that recognizes Par6G.   
 
Initial experiments using SMARTpool siRNA reagents suggested PAK4 is required for 
tight  junction  formation  in  16HBE  cells,  with  PAK6  perhaps  contributing  to  this 
function, and PAK5 playing no role (Figure 3.10).  Further experiments using multiple 
siRNA duplexes targeting PAK4 and PAK6 individually or in combination confirmed 
that PAK4 is required for tight junction formation, but suggested that PAK6 makes 
minimal  contribution  to  this  function  (Figure  3.13).    The  apparent  requirement  for 
PAK4 but not PAK5 or PAK6 for tight junction formation in 16HBE cells is consistent 
with the reported tissue distribution of PAK expression.  Within the class II PAKs, 
PAK4 is expressed ubiquitously, PAK5 is expressed specifically in the brain, and PAK6 
shows high expression in the brain but also limited expression in several other tissues 
including placenta, testis and prostate (Callow et al., 2002; Pandey et al., 2002).  PAK5 
and  PAK6  are  therefore  not  expected  to  be  expressed  in  bronchial  epithelial  cells.    113 
However a role for PAK5 or PAK6 in 16HBE cells can not be ruled out, as I have not 
determined their expression level in these cells and do not know how efficiently the 
siRNA  reagents  used  in  these  experiments  downregulate  expression  of  PAK5  and 
PAK6. 
 
Initial results using SMARTpool siRNA reagents suggested PRK2 is required for tight 
junction formation in 16HBE cells, with PRK1 perhaps contributing to this function and 
PRK3 playing no role (Figure 3.10).  Subsequent experiments using multiple siRNA 
duplexes  targeting  PRK1  and  PRK2,  transfected  individually  or  in  combination, 
confirmed that PRK2 is required for tight junction formation, but showed that PRK1 
does not contribute to this function (Figure 3.12).  PRK1 and PRK2 are both expressed 
ubiquitously (Mukai, 2003), and I have detected expression of both proteins in 16HBE 
cells (Figure 3.12).  It is therefore surprising that PRK1 does not contribute to tight 
junction  formation  in  these  cells.    It  should  be  noted,  however,  that  I  have  not 
determined the relative expression levels of PRK1 and PRK2 in 16HBE cells.  The 
failure to detect any defect in tight junction formation after depletion of PRK1 might 
therefore simply be because PRK1 expression is lower than that of PRK2 and does not 
make a significant contribution to the total PRK pool in 16HBE cells.  PRK3 expression 
has only been detected in cancer cells and not in normal tissues (Mukai, 2003).  It is 
therefore unlikely that PRK3 is expressed in 16HBE cells, which is likely to explain 
why transfection of siRNA against PRK3 has no effect on tight junction formation in 
these  cells.    However  as  I  have  not  analysed  PRK3  expression  in  16HBE  cells  or 
determined how efficiently the PRK3 siRNA used downregulates PRK3 expression I 
can not rule out a role for PRK3. 
 
Par6B is a scaffold protein and an effector protein for Cdc42, and has previously been 
implicated in tight junction formation through the regulation of aPKC (see introduction, 
section 1.4.4).  PAK4 is a serine/threonine kinase belonging to the STE family and an 
effector protein for Cdc42.  PRK2 is a serine/threonine kinase belonging to the AGC 
family and an effector protein for RhoA.  PAK4 and PRK2 have not been previously 
implicated  in  tight  junction  formation.    Chapter  4  will  further  analyse  a  potential 
signalling  pathway  involving  RhoA  and  its  effector  protein  PRK2  regulating  tight   114 
junction formation, while chapter 5 will further analyse a potential signalling pathway 
involving Cdc42 and its effector proteins Par6B and PAK4 in regulating tight junction 
formation (Figure 3.14). 
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CHAPTER 4 – Results  
 
Regulation of Epithelial Junctions by RhoA and its Effector PRK2 
 
 
4.1 RhoA and RhoC can act redundantly to control tight junction formation 
 
The  data  presented  in  chapter  3  shows  that  RhoA  expression  is  necessary  for  tight 
junction formation in 16HBE cells.  RhoA belongs to a subfamily of Rho GTPases 
containing the highly related RhoB and RhoC proteins.  To determine whether RhoB or 
RhoC  also  regulate  tight  junction  formation,  16HBE  cells  were  transfected  with 
SMARTpool siRNA targeting these genes and tight junction formation was analysed.  
Transfection  of  either  RhoB  or  RhoC  SMARTpool  siRNA  had  no  effect  on  tight 
junction formation, while transfection of RhoA SMARTpool resulted in a clear defect 
in tight junction formation (Figure 4.1).  There are several possible explanations for the 
lack of phenotype caused by transfection of RhoB or RhoC siRNA in this assay.  The 
RhoB and RhoC SMARTpool siRNA used in these experiments might not efficiently 
downregulate  expression  of  their  target  proteins.    RhoB  and  RhoC  might  not  be 
expressed in 16HBE cells, or might be expressed at lower levels than RhoA, and so 
might not make a contribution to tight junction formation in these cells.  Finally, RhoB 
and RhoC might have distinct functions from RhoA, despite high sequence similarity. 
 
To determine whether RhoB and RhoC are expressed in 16HBE cells, and to assess the 
ability of the transfected siRNA reagents to knockdown expression of RhoB and RhoC, 
several Rho antibodies were first characterized.  HEK293T cells were transfected with 
HA-tagged human RhoA, RhoB and RhoC expression vectors, and protein lysates were 
analysed by western blot.  An anti-HA antibody was used to determine the relative 
amount of RhoA, RhoB and RhoC in the HEK293T lysates.  RhoA and RhoC were 
expressed  at  similar  levels  in  the  HEK293T  lysates,  while  RhoB  was  expressed  at 
considerably higher levels (Figure 4.2A, HA blot).  These lyastes were used to assess 
the ability of several Rho antibodies to bind to Rho proteins.     116   117 
An anti-RhoA antibody specifically binds to RhoA with no cross-reactivity with RhoB 
or RhoC (Figure 4.2A, RhoA blot).  An anti-RhoA/C antibody binds to both RhoA and 
RhoC, but has higher affinity for RhoC (Figure 4.2A, RhoA/C blot).  An anti-RhoB 
antibody binds with a strong preference to RhoB, with minimal cross-reactivity with 
RhoA or RhoC (Figure 4.2A, RhoB blot).     118 
 
 
 
These antibodies were used to detect endogenous Rho GTPase proteins expressed in 
16HBE cells and to check downregulation of expression after transfection of siRNA.  
As  shown  in  chapter  3  RhoA  can  be  detected  in  16HBE  cells  with  the  anti-RhoA 
antibody,  and  RhoA  expression  is  downregulated  by  RhoA  siRNA  (Figure  4.2B).  
RhoB expression can be detected using the anti-RhoB antibody, and RhoB expression is 
downregulated after transfection of RhoB siRNA (Figure 4.2C).  Surprisingly a large 
increase  in  RhoB  expression  is  seen  after  downregulation  of  either  RhoA  or  RhoC 
(Figure 4.2C).  While the reason for this is not clear, it has recently been described that 
the total levels of Rho GTPase proteins in cells can be limited by the availability of 
RhoGDIs (Keith Burridge, personal communication).  RhoGDIs bind to inactive forms 
or  Rho  GTPases  and  sequester  them  in  the  cytosol,  and  are  typically  thought  to 
negatively regulate Rho GTPase signalling, however they might also have an additional 
role in stabilizing Rho GTPases.  The increase in RhoB expression after knockdown of 
RhoA or RhoC might therefore reflect an increase in the availability of RhoGDI.  RhoC 
expression can be detected using the RhoA/C antibody.  RhoA and RhoC proteins are 
both 193 amino acids in length, but RhoC has a slightly higher molecular weight, 22.0 
kDa compared to 21.8 kDa.  RhoC protein runs at a slightly higher molecular weight 
than RhoA on a 15% polyacrylamide gel, and this allowed differential detection of 
RhoA  and  RhoC  in  16HBE  cell  lysates  (Figure  4.2B).    RhoC  expression  is 
downregulated  after  transfection  of  RhoC  siRNA  (Figure  4.2B).    The  above 
experiments show that RhoB and RhoC are expressed in 16HBE cells and expression of 
these proteins is downregulated after transfection of corresponding siRNA.  The lack of 
phenotype caused by transfection of RhoB or RhoC siRNA could therefore be because 
RhoB  and  RhoC  have  distinct  roles  from  RhoA  and  do  not  regulate  tight  junction 
formation, or could be because RhoB and RhoC are functionally redundant with RhoA 
but are expressed at lower levels than RhoA in 16HBE cells, and so do not make a 
detectable contribution to tight junction formation in these cells. 
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The relative expression levels of RhoA and RhoC in 16HBE cells can be estimated 
using the RhoA/C antibody.  This antibody binds considerably more strongly to RhoC 
than to RhoA when these proteins are expressed at similar levels in HEK293T cells 
(Figure 4.2A).  Endogenous RhoA and RhoC proteins in 16HBE cells are detected by 
this antibody to a similar level (Figure 4.2B).  Together this suggests that RhoA protein 
is expressed at considerably higher levels than RhoC in 16HBE cells.  The observation 
that RhoC is expressed at considerably lower levels than RhoA means that RhoC might 
contribute to tight junction formation in 16HBE cells redundantly with RhoA, and the 
failure  to  detect  a  defect  in  tight  junction  formation  after  knockdown  of  RhoC 
expression might simply be because RhoC does not contribute significantly to the total 
RhoA/C pool in these cells.  To address this, rescue experiments were carried out using 
expression vectors encoding mouse RhoA and RhoC proteins, which are not expected to 
be targeted by the human RhoA siRNA duplexes used in these experiments.  16HBE 
cells were seeded at low density on glass coverslips and allowed to adhere overnight.  
The following day, cells were transfected with 50 ng of expression vectors encoding 
myc-tagged  mouse  RhoA,  myc-tagged  mouse  RhoC,  or  myc-tagged  PAK4  as  an 
unrelated control protein.  6 hours later cells were transfected with siControl siRNA or 
RhoA siRNA duplex1, which gives the strongest knockdown of RhoA out of the 4 
RhoA duplexes used in our experiments (Figure 3.4 in chapter 3).  72 hours later tight 
junction formation was analysed by immunofluorescence microscopy, using an anti-
occludin antibody.  Exogenous expression of RhoA, RhoC or PAK4 did not affect tight 
junction formation (Figure 4.3, A-I), as the majority of myc-positive cells showed a 
continuous ring of occludin staining at cell-cell contacts after transfection of siControl 
siRNA.  Transfection of RhoA siRNA resulted in the expected tight junction defect in 
cells  expressing  the  control  myc-tagged  protein  (myc-PAK4,  Figure  4.3  P-R).  
Expression of mouse RhoA rescued the tight junction defect caused by knockdown of 
endogenous RhoA, as expected, with most myc-positive cells showing a continuous 
ring of occludin staining at cell-cell contacts (Figure 4.3, J-L).  Interestingly expression 
of  mouse  RhoC  also  rescued  the  tight  junction  defect  caused  by  knockdown  of 
endogenous  RhoA  (Figure  4.3,  M-O).    Similar  results  were  obtained  when  RhoA 
siRNA duplex 2 or duplex 3 were used instead of RhoA siRNA duplex1 (data not 
shown).  These experiments confirm that the defect in tight junction formation caused   120 
by transfection of RhoA siRNA duplexes is a specific consequence of loss of RhoA 
protein, and show that RhoC is able to act redundantly with RhoA in regulating tight 
junction formation.    121 
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4.2  Expression  of  mouse  PRK2  rescues  the  tight  junction  defect  caused  by 
transfection of PRK2 siRNA. 
 
The results presented in chapter 3 show that transfection of siRNA targeting PRK2 
results in a defect in tight junction formation in 16HBE cells.  Two distinct siRNA 
duplexes  targeting  PRK2  generated  this  phenotype,  suggesting  it  is  likely  to  be  a 
specific consequence of loss of PRK2 expression.  To confirm this, an attempt was 
made to rescue this phenotype by expressing exogenous mouse PRK2, which should be 
resistant to the human PRK2 siRNA duplexes used in these experiments.  In contrast to 
the mouse RhoA and RhoC expression constructs used above, mouse PRK2 constructs 
did not express well after transient transfection.  Mouse PRK2 was therefore subcloned 
in to pBABE-HA retroviral expression vector, and retroviral particles were made by 
transfecting pBABE-HA empty vector or pBABE-HA-mPRK2 in to HEK293T cells, 
along with VSV-G and Gag/Pol.  Retroviral particles were collected from the growth 
medium and used to infect 16HBE cells.  Infected cells were selected with puromycin 
for at least one week.  Following selection, stably-expressing cells were seeded on glass 
coverslips at low density, and transfected with siControl or siRNA targeting PRK2.  72 
hours post-transfection tight junction formation was assessed by immunofluorescence 
microscopy using an anti-ZO-1 antibody.  16HBE-pBABE-HA control cells transfected 
with siControl siRNA formed tight junctions normally, shown by a continuous ring of 
ZO-1 staining at cell-cell contacts (Figure 4.4, A-C).  16HBE-pBABE-HA control cells 
transfected with PRK2  siRNA duplex 1 or duplex 3 showed a clear defect in tight 
junction formation, with many cells showing no ZO-1 staining or discontinuous ZO-1 
staining at cell-cell contacts (Figure 4.4, D-F and G-I).  16HBE-pBABE-HA-mPRK2 
cells transfected with siControl siRNA formed tight junctions normally, showing that 
exogenous expression of mPRK2 does not affect tight junction formation (Figure 4.4, J-
L).  16HBE-pBABE-HA-mPRK2 cells transfected with PRK2 siRNA duplex 1 did not 
show any defect in tight junction formation (Figure 4.4, M-O), showing that expression 
of mouse PRK2, which is resistant to knockdown by PRK2 siRNA duplex 1, is able to 
rescue the tight junction defect caused by transfection of PRK2 siRNA duplex 1.  This 
provides strong evidence that the defect in tight junction formation caused by PRK2 
siRNA duplex 1 is a specific consequence of loss of PRK2 expression.     123 
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Surprisingly,  PRK2  siRNA  duplex  3  was  able  to  knockdown  expression  of  mouse 
PRK2  in  16HBE-pBABE-HA-mPRK2  cells,  determined  by  western  blot  and 
immunofluorescence microscopy using an anti-HA antibody (Figure 4.4, P and S - note 
that the PRK2 antibody used in S does not cross-react with mouse PRK2 (data not 
shown)).  The human sequence targeted by PRK2 siRNA duplex 3 has only 1 mismatch 
with the corresponding mouse sequence, and in this case 1 mismatch is not sufficient to 
prevent downregulation of mouse PRK2 expression.   Accordingly, 16HBE-pBABE-
HA-mPRK2  cells  transfected  with  PRK2  siRNA  duplex  3  showed  the  same  tight 
junction defect as 16HBE-pBABE-HA control cells transfected with this siRNA duplex, 
as both endogenous and exogenous PRK2 expression was downregulated (Figure 4.4, 
P-R). 
 
4.3  Multiple  Rho  effector  proteins  are  likely  to  contribute  to  tight  junction 
formation downstream of RhoA 
 
As discussed in chapter 1, a large number of proteins have been identified as effector 
proteins  for  Rho  GTPases,  and  several  have  already  been  implicated  in  epithelial 
junction formation.  PRK2 was the only effector protein for RhoA identified in the 
screen for Rho effector proteins required for tight junction formation (chapter 3).  A 
reasonable hypothesis therefore is that RhoA regulates tight junction formation through 
PRK2.    To  analyse  more  directly  the  signalling  pathway  downstream  of  RhoA 
regulating tight junction formation, point mutations were made in the effector-binding 
loop of RhoA to selectively impair binding to certain downstream effector proteins.  
Structural changes occurring upon activation of Rho GTPases are limited to two short 
loops exposed on the surface of the protein, called switch regions.  Residues within 
these  loops  are  known  to  bind  directly  to  effector  proteins  and  to  contribute  to 
specificity.  Residues within switch I of RhoA have been mutated, and the ability of the 
mutant  GTPases  (known  as  effector  loop  mutants)  to  bind  to  several  Rho  effector 
proteins has been assessed (Sahai et al., 1998).  RhoA(F39A) has reduced affinity for 
PRK and for ROCK.  RhoA(F39V) and RhoA(Y42C) bind to ROCK normally but have 
reduced affinity for PRK.  RhoA(E40L) binds to PRK normally but has reduced affinity 
for ROCK.  Importantly, all proteins can still bind to mDia and to upstream GEFs,   126 
showing that these mutations do not simply cause the GTPase to misfold.  These point 
mutations were introduced in to wild-type mouse RhoA, with the intention of using the 
mutant  proteins  in  rescue  experiments.    However  overexpression  of  these  proteins 
resulted in a similar tight junction defect to that caused by knockdown of RhoA (Figure 
4.5,  note  that  overexpression  of  wild-type  RhoA  does  not  affect  tight  junction 
formation), making rescue experiments impossible with these constructs.   
 
When  overexpressed  these  mutant  proteins  are  likely  to  act  in  a  dominant-negative 
manner, as they will compete with endogenous Rho proteins for binding to upstream 
GEFs,  thus  preventing  activation  of  endogenous  Rho  proteins,  but  can  not  regulate 
certain downstream effector pathways.  RhoA(F39A), RhoA(F39V) and RhoA(Y42C) 
have  impaired  binding  to  PRK,  and  when  overexpressed  are  expected  to  inhibit 
endogenous RhoA signalling through PRK as they will compete for upstream activators 
of RhoA.  The defect in tight junction formation observed after overexpression of these 
mutants  (Figure  4.5)  is  consistent  with  the  hypothesis,  based  on  RNAi-mediated 
depletion of PRK2, that RhoA promotes tight junction formation by acting through 
PRK2.  Surprisingly, overexpression of RhoA(E40L) also resulted in a defect in tight 
junction formation (Figure 4.5).  This mutant is able to bind to PRK normally, but has 
impaired binding to ROCK.  Overexpression of this protein is therefore expected to 
inhibit endogenous RhoA signalling through ROCK but not through PRK.  The defect 
in  tight  junction  formation  seen  after  overexpression  of  this  mutant  suggests  that 
regulation of ROCK by RhoA is also required for RhoA to function in tight junction 
formation.  Transfection of ROCK1 and ROCK2 siRNA, either alone or together, did 
not prevent tight junction formation in the RNAi screens carried (chapter 3).  However I 
have not determined how efficiently ROCK is downregulated by the siRNA used.  It 
should also be noted that the point mutations used to prevent binding of Rho to its 
effector proteins might not be very specific, as only binding of Rho to certain effectors 
was tested when these mutants were first described and the interaction with many other 
effector proteins has not been tested.  The E40L mutation could potentially prevent 
RhoA from binding to other effectors in addition to ROCK.  Together these experiments 
show that at least two Rho effector proteins are required downstream of RhoA for tight   127 
junction formation, and that regulation of PRK2 by RhoA is not the sole mechanism 
through which RhoA regulates tight junctions.   128 
4.4 RhoA and PRK2 are required for the formation of mature adherens junctions 
and the organization of junctional F-actin 
 
In  addition  to  tight  junctions,  epithelial  cells  are  characterized  by  the  presence  of 
adherens junctions and junctional actin filaments.  Epithelial adherens junctions are 
formed by the transmembrane cell adhesion molecule E-cadherin, which associates via 
its  cytoplasmic  tail  with  β-catenin.    Adherens  junctions  can  be  analysed  by 
immunofluorescence  microscopy  using  antibodies  against  E-cadherin  or  β-catenin.  
16HBE monolayers stained  with an anti-E-cadherin antibody show two pools of E-
cadherin at cell-cell contacts.  A sharp line of E-cadherin along contacting membranes 
is seen in cells with mature cell-cell contacts (Figure 4.6, closed arrowheads in panel 
B).  This E-cadherin staining often overlaps, at least partly, with tight junction proteins 
such as ZO-1 (Figure 4.6, panel C) and occludin (not shown).  Additionally, E-cadherin 
is  also  localized  in  a  more  broad  and  diffuse  pattern  at  the  plasma  membrane.    In 
cultured epithelial cells some adherens junction proteins, including E-cadherin and β-
catenin, are localized along the lateral membrane and are not restricted to such a narrow 
plane as tight junction proteins.  Lateral membranes are often dynamic, with membrane 
protrusions from one cell extending beneath a neighbouring cell.  This results in the 
broad membrane staining of E-cadherin seen in some cells (Figure 4.6, open arrowheads 
in panel B).  In control monolayers most cells contain both pools of E-cadherin at cell-
cell contacts (Figure 4.6, panel B).  16HBE cells depleted of RhoA or PRK2 show 
abnormal E-cadherin staining (Figure 4.6, panels E, H and K).  Most cells are still in 
contact with neighbouring cells, and some E-cadherin is localized to cell-cell contacts.  
However mature adherens junctions do not form, seen as a failure to concentrate E-
cadherin in to the sharp line observed in control monolayers. 
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Actin is reorganized as epithelial cells form monolayers.  Thick cortical actin bundles 
are found in isolated cells and along non-contacting plasma membranes, and when cell-
cell contacts form this actin is reorganized to form the characteristic junctional F-actin 
associated with apical junctions.  16HBE monolayers stained with fluorescently labelled 
phalloidin, which binds to F-actin, show actin filaments tightly associated with cell-cell 
contacts,  as  well  as  cytoplasmic  staining  and  in  some  cells  prominent  stress  fibres 
(Figure 4.7, arrowheads in panel A indicate junctional actin filaments).  16HBE cells 
depleted of RhoA or PRK2 do not organize F-actin normally between contacting cells.  
Prominent cortical F-actin bundles are seen in both neighbouring cells, and this actin 
has failed to reorganize in to the actin filaments tightly associated with mature junctions 
found in control monolayers (Figure 4.7, panels D, G and J). 
 
The  organization  of  tight  junction  proteins,  adherens  junction  proteins  and  F-actin 
observed in 16HBE monolayers depleted of RhoA or PRK2 is similar to that of control 
cells at early stages of junction formation.   Junction formation can be monitored over 
time  using  the  calcium-switch  technique.    Incubation  of  epithelial  monolayers  in 
medium that has been depleted of calcium results in disassembly of adherens junctions 
and tight junctions, because E-cadherin-mediated adhesion is calcium-dependent.  Upon 
re-addition  of  calcium,  adherens  junctions  and  tight  junctions  re-form.    Figure  4.8 
shows 16HBE monolayers at 1 hour after calcium-switch, a time at which cell-cell 
contacts are in the process of forming.  The organization of tight junction proteins (ZO-
1 in Figure 4.8), adherens junction proteins (β-catenin in Figure 4.8) and F-actin at this 
time are similar to that of 16HBE cells in monolayers depleted of RhoA or PRK2.  
Adherens junction proteins are localized diffusely to cell-cell  contacts but have not 
matured  in  to  the  continuous  line  found  in  control  monolayers,  and  tight  junction 
proteins are absent from cell-cell contacts or show a punctate staining pattern.  F-actin 
is  present  in  prominent  cortical  bundles  that  have  not  reorganized  yet  to  form  the 
thinner actin filaments found closely associated with mature junctions.  In summary, 
RhoA and PRK2 are required for the formation of mature epithelial apical junctions, 
comprising adherens junctions and tight junctions and the associated junctional F-actin.  
Cells depleted of RhoA or PRK2 are able to undergo early stages of cell-cell contact   131 
formation, in which adherens junction proteins are localized at cell-cell contacts, but 
can not form mature junctions. 
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4.5 PRK2 colocalizes with ZO-1 at tight junctions 
 
16HBE  monolayers  were  stained  with  the  anti-PRK2  antibody  and  analysed  by 
immunofluorescence microscopy to determine the localization of PRK2.  Most cells 
showed a diffuse cytoplasmic staining, with a clear enrichment at cell-cell contacts in 
some cells that overlaps with the tight junction protein ZO-1 (Figure 4.9, panels A-C).  
This staining pattern is likely to be specific because 16HBE cells transfected with an 
expression vector encoding HA-tagged PRK2 show the same localization at cell-cell 
contacts (Figure 4.9, G-L). The PRK2 staining at cell-cell contacts also partly overlaps 
with the adherens junction protein β-catenin (Figure 4.9, panels D-F).  Under these 
culture conditions, tight junction proteins and adherens junction proteins do not fully 
separate along the lateral membrane.  Adherens junction proteins such as E-cadherin 
and β-catenin localize all along the lateral membrane, while tight junction proteins such 
as ZO-1 and occludin are localized in a more discrete plane.  Tight junction proteins 
overlap  with  the  adherens  junction  proteins  located  at  the  apical-most  edge  of  the 
adherens junction (for examples, see Figure 4.6, panels A-C).  Our observation that 
PRK2 protein localizes in a discrete plane that colocalizes with ZO-1, rather than in a 
more diffuse pattern all along the lateral membrane, suggests that PRK2 is localized at 
the tight junction and not the adherens junction.  However this should be confirmed 
under conditions where tight junctions fully separate from adherens junctions along the 
lateral membrane.  Such conditions might be provided by growing 16HBE cells on 
transwell filters, which are thought to facilitate the final steps in polarization along the 
apical-basal axis, or by using other cell types such as Caco-2 or MDCK, which separate 
adherens  junction  and  tight  junction  proteins  more  readily  when  cultured  on  glass 
coverslips.  Furthermore, due to the narrow width of tight junction structures (typically 
100-200 nm), it is not possible to conclusively localize a protein at tight junctions based 
on  colocalization  with  tight  junction  proteins  in  fluorescence  microscopy  studies.  
Instead ultrastructural studies are required to resolve tight junctions (Matter and Balda, 
2003a).  We have not performed such experiments as they are technically challenging. 
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Only a minority of cells in a monolayer show PRK2 localization at cell-cell contacts, 
suggesting PRK2 is localized transiently at cell-cell contacts.  This is consistent with 
PRK2 playing a regulatory role in junction formation. 
 
4.6 Discussion 
 
I have demonstrated that RhoA is required for tight junction formation in 16HBE cells 
(see chapter 3).  Two closely related Rho family members, RhoB and RhoC, are also 
expressed in 16HBE cells, but RNAi-mediated downregulation of RhoB or RhoC does 
not affect tight junction formation (Figure 4.1 and 4.2).  This raises the possibility that 
RhoB and RhoC have distinct functions from RhoA and do not regulate tight junction 
formation.  Using an antibody that recognizes RhoA and RhoC, I estimated that RhoA 
is  expressed  at  considerably  higher  levels  than  RhoC  in  16HBE  cells  (Figure  4.2).  
Furthermore exogenous expression of RhoC is able to rescue the tight junction defect 
caused by knockdown of RhoA in 16HBE cells (Figure 4.3).  Together this suggests 
that RhoC does in fact act redundantly with RhoA during tight junction formation, and 
the failure to observe a defect in tight junction formation after knockdown of RhoC 
simply reflects the fact that RhoC does not make a significant contribution to the total 
RhoA/C levels in 16HBE cells.  I have not yet attempted to rescue the tight junction 
defect  caused  by  RNAi-mediated  depletion  of  RhoA  with  exogenous  expression  of 
RhoB.    RhoA,  RhoB  and  RhoC  proteins  show  a  high  level  of  sequence  similarity.  
RhoA and RhoB are 83% identical and 94% homologous, while RhoA and RhoC are 
91%  identical  and  96%  homologous.    However  RhoB  acquires  different  post-
translational modifications than RhoA and RhoC, as a result of sequence differences at 
the C-terminus.  All three proteins undergo prenylation at their C-terminus but with 
different moieties; RhoA and RhoC are geranylgeranylated but RhoB is farnesylated.  
RhoB  can  also  be  palmitoylated,  whereas  RhoA  and  RhoC  are  not (Ridley,  2006).  
These differences in lipid modification affect GTPase localization, as RhoA and RhoC 
localize  to  the  plasma  membrane  but  RhoB  to  endosomes.    It  will  therefore  be 
interesting to determine whether RhoA and RhoB are functionally distinct in 16HBE 
cells by attempting to rescue the RhoA phenotype with exogenous RhoB. 
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PRK2 belongs to a family of mammalian serine/threonine kinases, the PRKs (PKC-
related kinase; also called PKN, protein kinase novel), which were first identified on the 
basis of their similarity to PKC.  Three PRK genes exist in mammals, encoding proteins 
characterized  by  the  presence  of  3  conserved  domains:  HR1  (homology  region  1) 
(subsequently shown to bind to Rho GTPases), HR2 (a C2-like domain similar to the 
lipid-binding  C2  domain  found  in  PKC),  and  a  serine/threonine  kinase  domain 
homologous to the kinase domain of PKC (Figure 4.10).   
 
 
While the biological role of PRKs is not clear, there is some evidence they regulate 
epithelial morphogenesis. A PRK homologue, PKN, has been described in Drosophila 
and plays a role in morphogenesis during development.  Null mutations of PRK in flies 
are  lethal,  and  embryos  show  defects  in  dorsal  closure  (Lu  and  Settleman,  1999).  
Dorsal closure is a process that occurs at a late stage of Drosophila development in 
which leading edge cells of the epidermis elongate along the dorsal-ventral axis until 
they meet at the dorsal midline.  Cell shape changes during dorsal closure require actin-
myosin contractility, and PRK has been proposed to regulate this downstream of Rho,   137 
but the details are not known (Betson and Settleman, 2007).  In cultured keratinocytes, 
PRK2 has been suggested to play a role in adherens junction formation, although the 
evidence  is  not  strong.    PRK2  activity  increases  during  calcium-induced  cell-cell 
adhesion in keratinocytes.  Overexpression of V14RhoA, a constitutively-active mutant, 
results in increased E-cadherin localization at cell-cell contacts in these cells, while 
overexpression of V14RhoA(Y42C), a constitutively active mutant of RhoA that has 
reduced affinity for PRK proteins, does not increase E-cadherin localization at cell-cell 
contacts (Calautti et al., 2002), suggesting that active RhoA promotes adherens junction 
formation through a PRK family member.  However, as noted earlier, Rho effector-loop 
mutants are likely to inhibit binding of Rho to more than one effector protein, and so the 
Y42C mutation might affect binding to proteins other than PRKs.  We have clearly 
demonstrated that PRK2 is required for apical junction formation in 16HBE cells, using 
RNAi-mediated  knockdown  and  rescue  experiments.    Depletion  of  PRK2  does  not 
inhibit  the  early  stages  of  cell-cell  adhesion,  during  which  E-cadherin  starts  to 
accumulate at cell contacts, but does prevent mature junctions, consisting of adherens 
junctions, tight junctions and perijunctional F-actin, from forming. 
 
Based on the observation that RNAi-mediated depletion of RhoA phenocopies depletion 
of PRK2, I propose that PRK2 acts downstream of RhoA to regulate junction formation.  
PRK was identified as a Rho GTPase effector protein using biochemical approaches to 
isolate proteins that bind to active RhoA.  Initial experiments on PRK1 and PRK2 found 
they interact specifically with GTP-bound RhoA (and RhoB and RhoC), but not with 
GTP-bound Rac1 or Cdc42 (Amano et al., 1996; Quilliam et al., 1996; Watanabe et al., 
1996).  However it has since been reported that PRK1 and PRK2 can both bind to active 
Rac1,  in  contrast  to  the  earlier  studies (Owen  et  al.,  2003;  Vincent  and  Settleman, 
1997).  The N-terminus of PRK contains 3 leucine-rich repeats, called HR1 (homology 
region 1) domains  (HR1a-c), which have been defined biochemically as the GTPase-
binding domains.  The HR1a and HR1b domains of PRK1, but not the HR1c domain, 
bind to active RhoA (Flynn et al., 1998).  A crystal structure of the HR1a domain of 
PRK1 in complex with RhoA has been solved, showing that the HR1a domain forms an 
antiparallel coiled-coil, and that a number of hydrophobic and charged residues make   138 
direct contact with the GTPase (Maesaki et al., 1999).  Many of these residues are not 
conserved in HR1c, which might explain why it does not bind to RhoA. 
 
In  vitro  the  kinase  activity  of  PRK  is  enhanced  by  GTPase-binding,  and  relief  of 
autoinhibition has been proposed as the mechanism (Amano et al., 1996; Quilliam et al., 
1996; Watanabe et al., 1996).  The N-terminal regulatory domain and the C-terminal 
kinase domains of PRK1 interact, suggesting PRK1 exists in a closed conformation 
(Kitagawa et al., 1996).  A small peptide corresponding to a region overlapping with 
HR1a  inhibits  the  kinase  activity  of  PRK1.    The  N-terminus  of  PRK1  is  therefore 
thought to act as an autoinhibitory pseudosubstrate, and relief of autoinhibition occurs 
upon GTPase-binding, although the structural details are not known.  In addition to 
relieving autoinhibition, GTPase-binding to PRK1 and PRK2 allows them to interact 
with  PDK-1  (3-phosphoinositide  dependent  protein  kinase-1)  (Flynn  et  al.,  2000).  
PDK-1 phosphorylates many AGC kinases (including PKC and PRK) in their conserved 
activation loop, and this phosphorylation is required for kinase activity. 
 
To  investigate  whether  PRK2  acts  downstream  of  RhoA  to  regulate  tight  junction 
formation  in  16HBE  cells,  I  overexpressed  mutants  of  RhoA  that  are  defective  in 
binding to certain effector proteins and therefore act as selective dominant-negatives to 
inhibit  signalling  from  endogenous  RhoA  to  specific  downstream  effectors. 
Overexpression of either RhoA(F39V) or RhoA(Y42C) phenocopies RNAi-mediated 
knockdown of RhoA, resulting in a defect in tight junction formation (Figure 4.5).  As 
discussed above, both mutants have reduced affinity for PRK and when overexpressed 
are  expected  to  inhibit  activation  of  PRK  by  endogenous  RhoA  without  affecting 
activation of ROCK or mDia.  These results are therefore consistent with the idea that 
RhoA  acts  through  PRK2  to  regulate  tight  junction  formation  in  16HBE  cells.  
However, as noted previously, although these point mutations in RhoA do not affect 
binding to ROCK or mDia they might affect binding to other Rho effectors in addition 
to PRK.  
 
PRK2  colocalizes  with  ZO-1  in  a  subset  of  cells,  suggesting  it  localizes  at  tight 
junctions (Figure 4.9).  As discussed earlier (section 4.5), more experiments are needed   139 
to conclude that PRK2 is a tight junction.  It seems likely that the localization of PRK2 
at cell-cell contacts is important for its function in junction formation.  In a monolayer 
only a subset of cells show cell-cell contact localization, suggesting that PRK2 localizes 
transiently at cell-cell contacts.  This is consistent with the idea that PRK2 regulates 
junction formation.  The localization of endogenous Rho proteins in 16HBE cells has 
not  been  determined,  as  the  Rho  antibodies  do  not  work  for  immunostaining.  
Overexpressed  RhoA  and  RhoC  show  cytosolic  localization,  and  do  not  localize 
appreciably at cell-cell contacts (Figure 4.3 and 4.5).  However studies using FRET-
based probes to look specifically at active RhoA have found some RhoA activity at 
epithelial  cell-cell  contacts  during  junction  formation  (Yamada  and  Nelson,  2007; 
Yamazaki et al., 2008).  It will be interesting to see if PRK2 localization at cell-cell 
contacts is GTPase-dependent, by assessing the localization of HR1 mutants (discussed 
further in chapter 6).  It should be noted of course that PRK2 localization and PRK2 
activity might not necessarily be regulated by the same upstream signals. 
 
In summary, I have found that RhoA and its effector PRK2 are required for apical 
junction formation in 16HBE cells.  Depletion of either protein does not prevent the 
initial stages of cell-cell contact formation, during which E-cadherin accumulates at 
cell-cell  contacts,  but  does  prevent  junctional  maturation,  during  which  F-actin  is 
remodelled, E-cadherin is reorganized and tight junctions form.  PRK2 localizes partly 
at cell-cell contacts, and this is likely to be important for its role in regulating junction 
formation.  Based on the fact that PRK2 is a known effector protein for RhoA, it is 
reasonable  to  speculate  that  RhoA  regulates  junction  formation  through  PRK2.  
Experiments using RhoA effector-loop mutants are consistent with this model, but do 
not prove it.  Potential experiments to test this hypothesis further will be discussed in 
chapter 6. 
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CHAPTER 5 – Results 
 
Regulation of epithelial junctions by Cdc42 and its effectors PAK4 and 
Par6B 
 
 
5.1 Expression of RNAi-resistant PAK4 rescues the tight junction defect caused by 
transfection of PAK4 siRNA. 
 
The results presented in chapter 3 show that transfection of siRNA targeting PAK4 
caused a defect in tight junction formation in 16HBE cells.  Two distinct PAK4 siRNA 
duplexes downregulated the expression of PAK4 protein and caused the defect in tight 
junction formation, suggesting this effect is likely to be a specific consequence of loss 
of PAK4 protein (see Figure 3.13 in chapter 3).  To confirm this an attempt was made to 
rescue  this  phenotype  by  expressing  exogenous  PAK4  protein.    Three  non-coding 
mutations were introduced in to a human PAK4 cDNA such that it would no longer be 
targeted by PAK4 siRNA duplex 4 (Figure 5.1).  RNAi-resistant PAK4 was subcloned 
in to pBABE-HA retroviral expression vector.  Retroviral particles were produced by 
transfecting  HEK293T  cells  with  pBABE-HA-PAK4  or  pBABE-HA  empty  vector, 
along  with  plasmids  encoding  VSV-G  and  Gag/Pol,  and  retroviral  particles  were 
collected  from  the  growth  medium.    16HBE  cells  were  infected  with  pBABE-HA-
PAK4 or pBABE-HA empty vector, and infected cells were selected with puromycin 
for at least one week.  Immunofluorescence microscopy using an anti-HA antibody 
showed that, while the expression level varied from cell to cell, almost all cells were 
expressing a detectable level of exogenous PAK4 (Figure 5.2, panels G and J).  Stably-
expressing cells were seeded at low density, transfected with siControl or PAK4 siRNA 
duplex  4,  and  tight  junction  formation  was  analysed  by  immunofluorescence 
microscopy using an anti-ZO-1 antibody.  16HBE-pBABE-HA cells transfected with 
siControl  formed  tight  junctions  normally,  with  the  majority  of  cells  showing  a 
continuous ring of ZO-1 staining at cell-cell contacts (Figure 5.2, panels A-C).  16HBE-
pBABE-HA cells transfected with PAK4 siRNA duplex 4 showed a clear defect in tight   141 
junction formation, as expected, with about half the cells showing no ZO-1 staining or 
discontinuous ZO-1 staining at cell-cell contacts (Figure 5.2, panels D-F).  16HBE-
pBABE-HA-PAK4  cells  transfected  with  siControl  formed  tight  junctions  normally, 
showing that exogenous expression of PAK4 does not affect tight junction formation 
(Figure  5.2,  panels  G-I).    16HBE-pBABE-HA-PAK4  cells  transfected  with  PAK4 
siRNA  duplex  4,  which  downregulates  expression  of  endogenous  PAK4  but  is  not 
expected to downregulate expression of exogenous RNAi-resistant PAK4, also showed 
normal tight junction formation (Figure 5.2, panels J-L).  Western blot analysis (Figure 
5.1B)  and  immunofluorescence  microscopy  (Figure  5.2,  panel  J)  confirmed  that 
exogenous PAK4 was resistant to knockdown by PAK4 siRNA duplex 4.  The fact that 
the tight junction defect caused by transfection of PAK4 siRNA duplex 4 is no longer 
seen when exogenous RNAi-resistant PAK4 is expressed strongly suggests that the tight 
junction defect is a specific consequence of downregulation of PAK4 expression. 
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5.2 Expression of mouse Par6B does not rescue the tight junction defect caused by 
transfection of Par6B siRNA. 
 
The results presented in chapter 3 show that transfection of siRNA targeting Par6B 
caused a defect in tight junction formation.  4 distinct Par6B siRNA duplexes used 
generated this phenotype, and the severity of the phenotype correlated well with the 
degree  of  Par6B  knockdown,  indicating  this  phenotype  is  likely  to  be  a  specific 
consequence of loss of Par6B protein (See Figure 3.11 in chapter 3).  To confirm this, 
an attempt was made to rescue this phenotype by expressing exogenous Par6B protein.  
An  expression  vector  encoding  mouse  Par6B  (mPar6B)  was  available  and,  as  this 
cDNA is naturally resistant to the human siRNA duplexes used in our experiments, we 
used  this  for  our  rescue  experiments  (Figure  5.3A).    mPar6B  was  subcloned  in  to 
pBABE-HA expression vector, and retroviral particles were produced by transfecting 
HEK293T cells with either pBABE-HA-mPar6B or pBABE-HA empty vector, along 
with VSV-G and Gag/Pol.  Retroviral particles were collected from the growth medium 
and used to infect 16HBE cells.  Infected cells were selected using puromycin for at 
least one week.  Immunofluorescence microscopy using an anti-HA antibody showed 
that  almost  all  cells  were  expressing  detectable  levels  of  mPar6B,  although  the 
expression level varied from cell to cell (Figure 5.4, panel J).  Stably-expressing cells 
were  seeded  at  low  density,  transfected  with  siControl,  Par6B  siRNA  duplex  3,  or 
Par6B  siRNA  duplex  4,  and  tight  junction  formation  was  analysed  by 
immunofluorescence microscopy using an anti-ZO-1 antibody.  16HBE-pBABE cells 
transfected with siControl formed tight junctions normally, while 16HBE-pBABE-HA 
cells transfected with either Par6B siRNA duplex 3 or duplex 4 showed a clear defect in 
tight junction formation (Figure 5.4, panels A-I).  16HBE-pBABE-HA-mPar6B cells 
transfected  with  siControl  formed  tight  junctions  normally,  showing  that  exogenous 
expression  of  mPar6B  does  not  affect  tight  junctions  (Figure  5.4,  panels  J-L).  
Surprisingly,  16HBE-pBABE-HA-Par6B  cells  transfected  with  either  Par6B  siRNA 
duplex 3 or duplex 4 showed the same tight junction defect seen in 16HBE-pBABE-HA 
cells (Figure 5.4, panels M-O and P-R).  Par6B siRNA duplexes 3 and 4 both contain 4 
mismatches compared to the corresponding sequences in the mouse Par6B gene (Figure 
5.3A) and are therefore not expected to downregulate expression of mouse Par6B.     145   146 
HA  ZO-1  merge   147 
HA  ZO-1  merge   148 
Western blot analysis (Figure 5.3B) and immunofluorescence microscopy (Figure 5.4, 
panels  M  and  P)  confirmed  that  the  mouse  Par6B  cDNA  is  indeed  resistant  to  the 
human  Par6B  siRNA  duplexes  used.    Exogenous  expression  of  mouse  Par6B  was 
therefore not able to rescue the tight junction defect caused by transfection of Par6B 
siRNA duplexes.  There are at least 4 possible explanations for this.   
 
The phenotype caused by transfection of Par6B siRNA duplexes might be caused by 
non-specific mechanisms such as off-target downregulation of other genes.  This is 
highly unlikely, as all 4 Par6B siRNA duplexes used result in a defect in tight junction 
formation  (see  Figure  3.11).    Over  250  SMARTpool  siRNA  reagents  have  been 
screened in this assay, and only 8 were found to give a tight junction defect (see chapter 
3 - RhoA, Cdc42, Asef, ARHGEF10, ITSN2, PRK2, PAK4 and Par6B).  Non-specific 
effects of siRNA transfection therefore do not often result in a defect in tight junction 
formation in this assay.  The probability of 4 distinct siRNA duplexes targeting the 
same gene, Par6B, all causing a tight junction defect by non-specific mechanisms is 
therefore extremely low. 
 
A second possible explanation is that the exogenous Par6B protein does not seem to 
localize properly.  Several studies have reported that Par6 localizes to tight junctions.  
Furthermore, an antibody against Par6B gives tight junction staining in 16HBE cells 
(Figure 5.11, below).  In 16HBE-HA-mPAR6 cells exogenous Par6B shows cytosolic 
localization and does not localize at tight junctions.  Overexpression can cause a protein 
to mislocalize, however even cells expressing low levels of HA-mPAR6B do not show 
tight junction localization.  It is possible that the N-terminal HA epitope interferes with 
Par6B localization, which would obviously interfere with its function. 
 
A third possible explanation is that in 16HBE-HA-mPar6B cells mPar6B might not be 
expressed  at  a  sufficient  level  to  rescue  the  phenotype  caused  by  knockdown  of 
endogenous Par6B.  Conveniently, HA-tagged mouse Par6B runs at a slightly higher 
molecular  weight  than  endogenous  human  Par6B,  allowing  the  bands  to  be 
distinguished from each other in western blot analysis (Figure 5.3B).  When lysates 
from  16HBE-pBABE-HA-mPar6B  cells  are  analysed  in  this  way,  the  band   149 
corresponding to exogenous mouse Par6B is approximately half as intense as the band 
corresponding to endogenous human Par6B, suggesting that the exogenous Par6B is 
expressed at a lower level than the endogenous Par6B (Figure 5.3B).  It should be noted 
however that this antibody was raised using an antigen corresponding to amino acids 
309-372  of  human  Par6B,  and  there  are  several  non-conserved  amino  acids  in  the 
corresponding region of the mouse Par6B protein.  The antibody might therefore bind 
more strongly to human Par6B than to mouse Par6B, which would mean the expression 
of mouse Par6B is underestimated when compared to human Par6B.  As the relative 
expression levels of mouse and human Par6B in 16HBE-pBABE-HA-mPar6B can not 
be  conclusively  estimated  it  is  not  possible  to  comment  on  whether  the  exogenous 
Par6B  expression  is  sufficient  to  rescue  the  phenotype  caused  by  knockdown  of 
endogenous Par6B. 
 
A final possible explanation for the failure of the exogenous Par6B protein to rescue the 
Par6B phenotype is that mouse Par6B might not be sufficiently similar to human Par6B.  
However this is unlikely as mouse and human Par6B proteins show a high degree of 
sequence similarity (91% identity and 94% homology).  The mouse Par6B construct 
used in these experiments was found to interact with human aPKC, a known interacting 
partner of Par6B, in coimmunoprecipation experiments (data not shown), confirming 
the high degree of similarity between mouse and human Par6B proteins. 
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5.3 Cdc42, PAK4 and Par6B are required for the formation of adherens junctions 
and the organization of junctional F-actin 
 
As described earlier, epithelial cells form adherens junctions which can be analysed by 
immunofluorescence microscopy using antibodies against E-cadherin or β-catenin, and 
organize  F-actin  in  to  the  characteristic  perijunctional  ring  closely  associated  with 
junctions.  In addition to preventing tight junction formation, knockdown of Cdc42, 
PAK4 or Par6B was found to result in abnormal E-cadherin staining.  Some E-cadherin 
was  localized  at  cell-cell  contacts,  but  it  was  not  concentrated  in  the  sharp  line 
indicative of mature adherens junctions found in control monolayers (Figure 5.5 and 
5.6).  F-actin, visualized by phalloidin staining, was found in prominent cortical bundles 
and did not reorganize in to the junctional actin filaments found in control monolayers 
(Figure 5.7 and 5.8).  As described for knockdown of RhoA and PRK2 earlier (section 
4.4), the junctions in 16HBE monolayers depleted of Cdc42, PAK4 or Par6B are similar 
to those in control cells at early times of calcium-induced junction formation.  Cdc42, 
PAK4 and Par6B are required for the formation of mature epithelial apical junctions, 
comprising adherens junctions and tight junctions and the associated junctional F-actin.  
Cells depleted of Cdc42, PAK4 or Par6B are able to undergo early stages of cell-cell 
contact  formation,  in  which  adherens  junction  proteins  are  localized  at  cell-cell 
contacts, but can not form mature junctions. 
   151 
ZO-1  E-cadherin  merge   152 
ZO-1  E-cadherin  merge   153 
F-actin  occludin  merge   154 
F-actin  ZO-1  merge   155 
5.4 PAK4 and Par6B colocalize with ZO-1 at tight junctions 
 
16HBE  monolayers  were  stained  with  the  anti-PAK4  antibody  to  determine  the 
localization of PAK4 protein.  PAK4 staining was detected at cell-cell contacts where it 
colocalized with the tight junction protein ZO-1 (Figure 5.9 above, panels A-C), and 
also in the nucleus (Figure 5.9 above, panels A and D).  The PAK4 signal at cell-cell 
contacts is likely to be specific, because HA-tagged PAK4 also colocalized with ZO-1 
at cell-cell contacts (Figure 5.10, panels D-F).  Interestingly, a PAK4 splice variant has 
been  identified,  PAK4-short,  and  when  expressed  exogenously  in  16HBE  cells  it 
localizes to the nucleus (Figure 5.10, panels G-I), raising the possibility that the nuclear 
staining  seen  with  the  PAK4  antibody  might  be  endogenous  PAK4-short  protein.  
However, a band was not seen corresponding to the PAK4-short isoform when 16HBE 
cell lysates are analysed by western blot using the PAK4 antibody, despite the fact that 
the PAK4-short isoform is recognized by the PAK4 antibody used (data not shown), 
suggesting that if PAK4-short is expressed in 16HBE cells it is at a significantly lower 
level than the long isoform of PAK4.  
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The PAK4 staining at cell-cell contacts also partly overlaps with the adherens junction 
protein  β-catenin  (Figure  5.9,  panels  D-F).    As  discussed  earlier  (section  4.5)  with 
regard to PRK2 localization, tight junction proteins and adherens junction proteins do 
not fully separate along the lateral membrane under these culture conditions.  Adherens 
junction  proteins  such  as  E-cadherin  and  β-catenin  localize  all  along  the  lateral 
membrane, while tight junction proteins such as ZO-1 and occludin are localized in a 
more  discrete  plane.    Tight  junction  proteins  colocalize  with  the  adherens  junction 
proteins located at the apical-most edge of the adherens junction (for examples, see 
Figures 5.5 panels A-C and 5.6 panels A-C).  The observation that PAK4 localizes in a 
discrete plane that colocalizes with ZO-1, rather than in a more diffuse pattern all along 
the lateral membrane, suggests that PAK4 is localized at the tight junction and not the 
adherens junction.  However this should be confirmed under conditions where tight 
junctions  fully  separate  from  adherens  junctions  along  the  lateral  membrane. 
Furthermore, due to the narrow width of tight junction structures (typically 100-200 
nm), it is not possible to conclusively localize a protein at tight junctions based on 
colocalization with tight junction proteins in fluorescence microscopy studies.  Instead 
ultrastructural studies are required to resolve tight junctions (Matter and Balda, 2003a).  
We have not performed such experiments as they are technically challenging.   
 
In contrast to ZO-1, which is localized in a continuous ring around the cell-cell contact 
in  the  majority  of  cells,  PAK4  protein  is  only  localized  to  the  cell-cell  contact  in 
approximately 25% of cells, and some of those cells only have PAK4 localized at a part 
of the cell-cell contact.  This partial localization at junctions would be consistent with 
PAK4 playing a regulatory role in junction formation, in contrast to ZO-1, which is a 
structural component of the tight junction. 
 
16HBE monolayers were stained with the Par6B antibody to determine the localization 
of Par6B protein.  As discussed in Chapter 1 (section 1.4.4), Par6 localizes to the tight 
junction in epithelial cells, where it forms a complex with Par3 and aPKC and regulates 
tight junction formation.  As expected, endogenous Par6B colocalized with ZO-1 at 
cell-cell contacts in 16HBE cells (Figure 5.11, A-C).  As observed for PAK4, Par6B 
does not colocalize exclusively with ZO-1, and some overlap  can be seen with the   157 
adherens junction protein  β-catenin (Figure 5.11 D-F).  As discussed above, this is 
likely to reflect the fact that under these culture conditions tight junction and adherens 
junction proteins do not fully segregate along the lateral membrane. 
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5.5 Discussion 
 
 
Three mammalian Par6 genes have been cloned, Par6A-C (Joberty et al., 2000).  Par6 
isoforms  show  high  sequence  identity,  particularly  in  the  known  protein-protein 
interaction domains, including the PB1 domain (which binds to aPKC), the semi-CRIB 
domain (which binds to active forms of the GTPases Cdc42, TC10 and Rac), and the 
PDZ domain (which binds to Par3 and PALS1, and contributes to GTPase-binding) 
(Figure 5.12).  Areas outside these domains, and in particular at the C-terminus, show 
more sequence divergence, but these areas do not have any known binding partners.  
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Par6 is one of many polarity proteins to be discovered using genetic approaches in 
C.elegans and Drosophila.  The Par (partitioning-defective) genes were discovered in a 
screen to identify genes required for asymmetric cell division in the C.elegans zygote, 
and have since been found to be conserved in higher organisms.  In general, polarity 
genes encode scaffold proteins that form multiprotein complexes through a network of 
protein-protein interactions and associate with discrete plasma membrane domains to 
define  plasma  membrane  identity  and  to  establish  and  maintain  cell  polarity  (see 
introduction, section 1.4.4).  Epithelial cells exhibit apical-basal polarity, with distinct 
apical and basolateral membrane domains.  Par6, in a complex with Par3 and aPKC, is 
localized apically, where it activates aPKC in a spatially restricted manner.  aPKC in 
turn phosphorylates basolateral proteins including Par1 and Lgl and restricts them to the 
basolateral  domain.    The  Par3/Par6/aPKC  complex  is  therefore  a  key  regulator  of 
apical-basal polarity in epithelial cells.  In vertebrate epithelial cells tight junctions, 
consisting of strands of claudin proteins, form at the boundary between the apical and 
basolateral membrane domain.  Many of the polarity proteins required for apical-basal 
polarization are also required for tight junction formation in vertebrate epithelial cells, 
including the Par3/Par6/aPKC complex.  Par6 is localized at tight junctions, where it 
colocalizes with Par3 and aPKC (Johansson et al., 2000; Yamanaka et al., 2001).  At   160 
least two mechanisms have been proposed for the localization of this complex at tight 
junctions: Par3 binding to JAM and Par6 binding to PALS1 (see introduction, section 
1.4.4).    Evidence  that  Par6  regulates  tight  junction  formation  has  come  from 
overexpression studies.  Overexpression of full-length Par6B (Joberty et al., 2000), or 
Par6A or Par6B mutants lacking the N-terminal PB1 domain that binds to aPKC (Gao 
et al., 2002; Yamanaka et al., 2001), resulted in disruption of tight junctions in MDCK 
cells.  However it is difficult to draw conclusions about the physiological role of Par6 
based on these studies, as overexpressed Par6 proteins are likely to sequester binding 
partners with known roles in tight junction formation, including Par3, aPKC, Cdc42 and 
PALS1.    I  have  demonstrated  a  clear  role  for  Par6B,  one  of  the  mammalian  Par6 
homologues, in tight junction formation. 
 
Regulation of tight junction formation in 16HBE cells by Par6B is likely to involve 
aPKC.  aPKC has been shown to be required for tight junction formation using RNAi-
mediated knockdown and overexpression of dominant-negative mutants, and this role is 
dependent  on  aPKC  kinase  activity  (Suzuki  et  al.,  2002;  Suzuki  et  al.,  2001).    In 
addition to phosphorylating Par1 and Lgl and establishing apical-basal polarity, aPKC 
isoforms  can  also  directly  phosphorylate  tight  junction  proteins  including  ZO-1, 
occludin and claudin-1, at least in vitro, and this might contribute to aPKC function in 
tight junction formation (Nunbhakdi-Craig et al., 2002).  Depletion of aPKC in 16HBE 
cells using siRNA duplexes targeting both aPKCι and aPKCζ isoforms prevents tight 
junction  formation,  phenocopying  knockdown  of  Par6B  (J.  Durgan  and  A.Hall, 
unpublished data). 
 
Based  on  the  observation  that  RNAi-mediated  knockdown  of  Par6B  phenocopies 
knockdown  of  Cdc42,  it  is  reasonable  to  speculate  that  Par6B  acts  downstream  of 
Cdc42  in  tight  junction  formation  in  16HBE  cells.    Par6  is  an  effector  protein  for 
Cdc42, as it binds specifically to the active GTP-bound form of Cdc42.  Binding of 
active Cdc42 to Par6 results in activation of the associated aPKC, and this is thought to 
involve relief of inhibition of aPKC by Par6.  aPKC in complex with Par6 has low 
kinase activity compared to isolated aPKC, and binding of active Cdc42 restores aPKC 
kinase activity to basal levels (Yamanaka et al., 2001).  Polarized localization of Par6 in   161 
the  C.elegans  zygote  and  in  Drosophila  epithelial  cells  requires  Cdc42.    RNAi-
mediated depletion of Cdc42 in C.elegans phenocopies loss of Par6, resulting in loss of 
asymmetric cell division, and this results from a failure to restrict Par6 localization to 
the anterior cortex (Gotta et al., 2001).   After cellularization of the Drosophila embryo 
Par6  localizes  apically  in  the  newly-formed  epithelial  cells,  and  this  is  blocked  by 
expression of dominant-negative Cdc42.  A mutant of Par6 that can no longer bind to 
Cdc42 but still binds to Par3 and aPKC can not rescue the polarity defect in Par6-null 
embryos (Hutterer et al., 2004).  Cdc42 therefore regulates Par6 function in two ways, 
by controlling its localization and by activating the associated aPKC.  In vertebrate 
epithelial  cells  Cdc42  partly  localizes  at  tight  junctions,  and  Cdc42  is  activated  in 
response to cell-cell adhesion (Otani et al., 2006), both of which are consistent with the 
idea  that  Cdc42  activates  the  Par3/Par6/aPKC  complex  to  promote  tight  junction 
formation.  However there is some disagreement in the literature about whether Cdc42 
activity  is  required  for  tight  junction  formation.    Some  studies  have  found  that 
expression of dominant-negative Cdc42 has no effect on junction formation (Gao et al., 
2002; Mertens et al., 2005; Takaishi et al., 1997), while other studies have shown that 
inhibition of Cdc42 signalling prevents junction formation (Fukuhara et al., 2003; Otani 
et al., 2006; Rojas et al., 2001).  Par6 is also an effector for the GTPase Rac1, which 
also localizes partly at tight junctions where it is activated by the GEF Tiam1 (Mertens 
et  al.,  2005).    Tiam1  binds  to  Par3,  and  in  keratinocytes  at  least  activation  of  the 
Par3/Par6/aPKC  complex  during  tight  junction  formation  is  Rac-dependent  and  not 
Cdc42-dependent.  I have found that Cdc42 is required for apical junction formation in 
16HBE cells, and a reasonable model is that it is acting through Par6B.  However it is 
not known whether Rac activity is also required for apical junction formation in 16HBE 
cells (see section 3.6).  It therefore remains possible that regulation of the Par6 complex 
in 16HBE cells is Rac- and not Cdc42-dependent. 
 
PAK4 belongs to the p21-activated kinase (PAK) family, consisting of 6 members in 
mammals, which are divided in to class I PAKs (PAK1, 2 and 3) and class II PAKs 
(PAK4, 5 and 6), based on sequence similarity and mode of regulation.  PAKs belong to 
the STE family of kinases, named after one of the yeast PAK proteins STE20.  Genetic 
analysis  in  yeast  has  shown  that  PAK  regulates  the  actin  cytoskeleton  and  MAPK   162 
signalling pathways, and these functions are conserved in higher organisms (Hofmann 
et al., 2004).  The 6 mammalian PAKs contain a conserved C-terminal serine/threonine 
kinase domain and  a conserved N-terminal GTPase-binding domain including a CRIB 
motif (Figure 5.13 above).  Apart from these conserved domains, class I and class II 
PAKs do not show sequence similarity.   
 
 
PAK4  homologues  have  been  described  in  Drosophila  and  Xenopus,  and  there  is 
evidence they regulate epithelial morphogenesis.  The Drosophila PAK4 homologue 
Mbt  (mushroom  body  tiny)  was  identified  as  a  gene  required  for  normal  brain 
development.    Mbt  mutant  flies  have  unusually  small  mushroom  bodies  (structures 
involved in learning and memory analogous to the hippocampus) with reduced numbers 
of Kenyan cells, suggesting Mbt is required for proliferation, differentiation or survival 
(Melzig et al., 1998).  The eyes of mutant flies also develop abnormally, with variable 
numbers  of  photoreceptor  cells  missing,  and  the  remaining  photoreceptor  cells 
exhibiting morphological defects (Schneeberger and Raabe, 2003).  Drosophila eyes 
develop from the eye imaginal disc, which is a simple epithelial sheet.  Mbt protein is 
localized at adherens junctions in differentiating photoreceptor cells in the eye imaginal   163 
disc, and Mbt mutants show fragmented localization of adherens junction proteins.  Mbt 
is therefore thought to regulate photoreceptor morphogenesis through the regulation of 
adherens junctions.  Interestingly, expression of constitutively active Mbt also disrupts 
adherens junctions in photoreceptor cells (Menzel et al., 2007), suggesting Mbt levels 
need to be tightly regulated.  Mbt can directly phosphorylate armadillo (the Drososphila 
homologue of β-catenin) in vitro, and this weakens the interaction between armadillo 
and DE-cadherin, which could contribute to the disruption of adherens junctions seen 
when constitutively active Mbt is overexpressed (Menzel et al., 2008).  In developing 
Xenopus  embryos,  X-PAK5  (the  Xenopus  PAK4  homologue)  localizes  to  adherens 
junctions in animal cap cells and dorsal marginal zone (DMZ) cells.  Expression of 
either  kinase-dead  X-PAK5,  which  is  expected  to  act  as  a  dominant-negative,  or 
constitutively active X-PAK5 in DMZ cells interferes with convergence extension (CE) 
movements, during which cells elongate and intercalate between each other (Faure et 
al., 2005).  CE movements require dynamic rearrangements of cell-cell adhesion.  The 
finding that activation or inhibition of X-PAK5 prevents CE movements is consistent 
with the observation that loss of Mbt or overexpression of active Mbt in Drosophila 
photoreceptor cells both result in adherens junction defects. 
 
Mammalian PAK4 has not been studied in the  context of epithelial morphogenesis.  
PAK4 knockout mice have been generated, but die during embryogenesis with defects 
in multiple tissues, making it difficult to draw conclusions about PAK4 function (Qu et 
al., 2003).  Cell culture studies have focused on overexpression of PAK4 in fibroblasts, 
showing  that  PAK4  regulates  cell  morphology  and  allows  anchorage-independent 
growth, a sign of cellular transformation (Qu et al., 2001).  This is interesting as PAK4 
is overexpressed in many cancer cell lines (Callow et al., 2002).  However it is unclear 
if  these  effects  reflect  physiological  functions  of  PAK4.    I  have  demonstrated  that 
PAK4 is required for the formation of apical junctions in epithelial cells, using RNAi-
mediated knockdown and rescue experiments.  16HBE cells depleted of PAK4 undergo 
initial  stages  of  cell-cell  adhesion,  but  do  not  form  mature  junctional  structural 
structures  consisting  of  adherens  junctions,  tight  junctions  and  the  associated 
perijunctional F-actin.  Based on the observation that RNAi-mediated knockdown of 
Cdc42 phenocopies knockdown of PAK4, I propose that PAK4 acts downstream of   164 
Cdc42 to regulate tight junction formation in 16HBE cells.  PAK was the first kinase to 
be identified as an effector protein for Rho GTPases, and the regulation of PAK1 by 
Rac and Cdc42 has been extensively studied.  Active forms of Rac and Cdc42 bind to 
the GTPase-binding domain of PAK1 and enhance its kinase activity.  Deletion of the 
N-terminus  of  PAK1,  including  the  GTPase-binding  domain,  leads  to  constitutive 
activation of PAK1, suggesting that the N-terminus acts in an autoinhibitory fashion 
(Xhao et al 1998).  Mutational analysis defined an autoinhibitory region that overlapped 
with  the  GTPase-binding  domain,  and  structural  studies  showed  this  autoinhibitory 
region binds to the kinase domain and blocks the catalytic site (Lei et al., 2000).  These 
studies lead to a general model in which PAKs are activated by binding of Rac or 
Cdc42 to the GTPase-binding domain resulting  in dissociation of the autoinhibitory 
region from the kinase domain.  However important differences have been found in 
class II PAKs, including PAK4.  Class II PAKs bind preferentially to active Cdc42 and 
only  weakly  to  Rac  (Abo  et  al.,  1998;  Dan  et  al.,  2002).    Class  II  PAKs  lack  the 
autoinhibitory region found in class I PAKs and show relatively high kinase activity in 
vitro  in  the  absence  of  GTPase.    Addition  of  GTP-bound  Cdc42  does  not  further 
increase the kinase activity of class II PAKs.  Deletion of the N-terminus including the 
GTPase-binding domain does lead to a modest enhancement of kinase activity though, 
suggesting alternative autoinhibitory interactions might exist in class II PAKs.   
 
It has been proposed that Cdc42 regulates PAK4 activity by controlling its cellular 
localization.  When PAK4 is overexpressed in fibroblasts it is recruited to the Golgi by 
constitutively  active  Cdc42  (Abo  et  al.,  1998).    The  Drosophila  Mbt  homologue 
localizes at adherens junctions in photoreceptor cells and this requires an intact CRIB 
motif.  Point mutations in the CRIB motif that prevent Cdc42-binding prevent adherens 
junction localization and fail to rescue the defect in adherens junctions seen in Mbt 
mutants  (Schneeberger  and  Raabe,  2003).    In  mammalian  epithelial  cells  Cdc42 
localizes  partly  at  tight  junctions  and  is  activated  in  response  to  cell-cell  adhesion 
(Otani et al., 2006).  I have found that PAK4 is localized partly to tight junctions in 
16HBE cells, where it colocalizes with the tight junction protein ZO-1, consistent with 
it playing a regulatory role in tight junction formation.  Activation of Cdc42 at tight 
junctions might provide a mechanism for recruitment of PAK4 to tight junctions.     165 
 
PAK4 is a serine/threonine kinase and several substrates have been identified.  Most 
notably PAK4 phosphorylates LIMK (LIM kinase) and SHH (slingshot phosphatase) to 
control  the  activity  of  the  actin  regulatory  protein  cofilin/ADF  (Dan  et  al.,  2001; 
Soosairajah et al., 2005).  LIMK phosphorylates cofilin to inactivate it, while SHH 
dephosphorylates the same residue in cofilin to activate it.  PAK4 phosphorylation of 
LIMK activates it, while PAK4 phosphorylation of SHH inactivates it.  PAK4 thus 
inhibits cofilin activity by these two complementary pathways.  Cofilin stimulates actin 
polymerization by severing actin filaments, which generates free barbed ends for actin 
assembly,  and  also  stimulates  depolymerization  of  actin  filaments  at  pointed  ends 
(Desmarais et al., 2005) (see introduction, section 1.3.1a).  There is some evidence that 
cofilin  activity  contributes  to  the  disassembly  of  epithelial  junctions  (Ivanov  et  al., 
2004).  Cultured epithelial cells depleted of calcium rapidly disassemble their junctions, 
as they are no longer able to maintain E-cadherin at the cell surface in a competent state 
for  trans-dimerization.    Junction  disassembly  is  associated  with  contraction  of  the 
perijunctional  actin  ring,  which  exacerbates  junction  disassembly.    Cofilin  activity 
increases as junctions disassemble, seen as a decrease in phosphorylated cofilin, and 
active non-phosphorylated cofilin is found associated with the contracting actin ring.  
Contraction of the perijunctional actin ring clearly requires myosin II motor activity, but 
it has been proposed that the actin depolymerizing activity of cofilin might also be 
important during this process, as pharmacological inhibition of actin depolymerization 
prevents contraction of perijunctional actin filaments in calcium-depleted cells (Ivanov 
et al., 2004).  It is therefore possible that inhibition of cofilin downstream of PAK4 is 
required  for  the  formation  of  stable  perijunctional  actin  filaments  found  in  mature 
epithelial monolayers, analogous to the proposed role for cofilin inhibition downstream 
of Rho-ROCK-LIMK to stabilize actin filaments that form stress fibres (Burridge and 
Wennerberg,  2004).    On  the  other  hand,  one  study  suggested  cofilin  activity  to  be 
important  for  tight  junction  formation  (Chen  and  Macara,  2006).    RNAi-mediated 
depletion of Par3 in MDCK cells delays tight junction formation, and also leads to 
increased  levels  of  phosphorylated  inactive  cofilin.    The  defect  in  tight  junction 
formation could be partially rescued by expressing an active non-phosphorylatable form 
of cofilin or by downregulating expression of LIMK2.  Furthermore, Par3 binds to   166 
LIMK2 and inhibits its kinase activity.  Par3 might therefore promote tight junction 
formation,  at  least  in  part,  by  inhibiting  LIMK2  and  preventing  cofilin  from  being 
inactivated.  However, RNAi-mediated downregulation of cofilin itself had no effect on 
tight junction formation in this study, so it remains unclear whether cofilin activity is 
required  for  tight  junction  formation.    Inhibition  of  cofilin  downstream  of  PAK4 
therefore remains a potential mechanism for PAK4-dependent tight junction formation.  
Another interesting PAK4 substrate is β-catenin, an important component of adherens 
junctions.    As  mentioned  above  the  Drosophila  PAK4  homologue,  Mbt,  directly 
phosphorylates the Drosophila β-catenin homologue, armadillo (Menzel et al., 2008).  
However,  this  phosphorylation  weakens  the  interaction  between  β-catenin  and  E-
cadherin, and is thought to contribute to the disruption of adherens junctions caused by 
overexpression of active Mbt.  It is therefore unlikely that phosphorylation of β-catenin 
by PAK4 would contribute to junction formation. 
 
In summary, I have found that Cdc42 and its effector proteins Par6B and PAK4 are 
required for apical junction formation in 16HBE cells.  Depletion of any one of these 
proteins results in a similar phenotype, in which cells undergo the initial stages of cell-
cell adhesion during which E-cadherin accumulates at cell-cell contact, but do not form 
mature  apical  junctions.    Par6B  and  PAK4  both  colocalize  with  ZO-1  at  cell-cell 
contacts, and this is likely to be important for their function in junction formation.  
Par6B and PAK4 are both known to be effector proteins for Cdc42, and I therefore 
propose that Cdc42 controls junction formation by regulating Par6B and PAK4.  
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CHAPTER 6 – Final Discussion 
 
 
6.1 Thesis overview 
 
Rho GTPases control many different cellular processes by regulating the activity of a 
large number of downstream effector proteins.  Rho GTPases are themselves regulated 
by upstream signalling pathways acting through Rho GEFs and Rho GAPs.  The human 
genome contains 20 Rho GTPases and approximately 80 GEFs, 70 GAPs and at least 90 
effectors.  An outstanding question is therefore how the components of Rho GTPase 
signalling  pathways  are  organized  during  diverse  processes  to  generate  specific 
responses.   
 
Substantial evidence exists in the literature for a role for Rho GTPases in epithelial 
junction formation (see section 1.5.1 above).  I have confirmed that two Rho family 
proteins, RhoA and Cdc42, are required for apical junction formation in 16HBE cells, 
using a microscopy-based assay.  RNAi screens carried out to identify components of 
the  signalling  pathways  through  which  these  GTPases  regulate  apical  junction 
formation have identified 3 Rho effector proteins, namely PRK2, PAK4 and Par6B.  
RNAi-mediated  depletion  of  these  proteins  phenocopies  depletion  of  the  upstream 
GTPases, with cells undergoing the early stages of cell-cell adhesion, during which E-
cadherin  is  recruited  to  nascent  cell-cell  contacts,  but  failing  to  undergo  junctional 
maturation,  during  which  mature  adherens  and  tight  junctions  and  the  associated 
perijunctional actin filaments form.   
 
It is likely that additional Rho GTPase effector signalling pathways, not identified in 
these screens, play a role in regulating junction formation in 16HBE cells.  The Rho 
family consists of 20 members, only a small number of which were investigated in this 
study.  A number of well-characterized Rho effector proteins have described roles in 
junction formation, including ROCK, mDia and IQGAP (discussed earlier in section 
1.5.1) and yet were not identified in the effector RNAi screens in 16HBE cells.   While   168 
this might in some cases reflect differences in cell types, it is likely that some Rho 
effector proteins were not identified here due to insufficient protein knockdown with the 
SMARTpool siRNA reagents used in these experiments. 
 
In this study I have used a microscopy-based assay to look at junction formation. As 
discussed  in  the  introduction  (section  1.4.3),  tight  junction  strands,  the  structural 
components of tight junctions seen in EM studies, are composed principally of claudin 
proteins.  I have used the localization of ZO-1 and occludin at cell-cell contacts to 
assess  tight  junction  formation,  due  to  the  availability  of  good  antibodies  for  these 
proteins and the large number of claudin proteins known to exist (at least 24 isoforms) 
(Aijaz et al., 2006).  ZO proteins are essential for tight junctions formation and localize 
to  the  cytoplasmic  face  of  tight  junctions  in  polarized  epithelia,  but  they  are  not 
transmembrane  proteins  and  do  not  contribute  physically  to  tight  junction  strands.  
While  occludin  is  found  in  tight  junction  strands  its  role  in  junction  formation  is 
unclear.  ZO-1 and occludin are, however, still regarded as good indicators of tight 
junction integrity in microscopy studies.  Non-microscopy based assays also exist for 
analysing tight junctions, including measurement of transepithelial electrical resistance 
(TER) and permeability to labelled molecules (Matter and Balda, 2003a), and these 
have been used to study the distinct barrier properties of specific epithelia in functional 
studies.  These assays can also be used to quantitatively assess gross defects in tight 
junction formation, and could be used in future to complement the microscopy studies 
presented here. 
 
 
6.2 Identification of effector proteins acting downstream of RhoA and Cdc42 to 
regulate apical junction formation 
 
As discussed in chapter 4 (section 4.6), PRK2 is a known effector protein for RhoA.  In 
vitro the kinase activity of PRK family kinases is enhanced by addition of active RhoA.  
Furthermore, there is evidence that active RhoA localizes at cell-cell contacts during 
junction  formation,  which  could  potentially  recruit  PRK2.    Based  on  the  results   169 
presented in this thesis I propose that RhoA promotes junction formation by regulating 
PRK2.  
 
However it should be noted that GTPase-independent regulatory mechanisms have also 
been  described  for  PRK.    Due  to  its  similarity  to  PKC,  initial  biochemical 
characterization of PRK1 was based on known regulatory mechanisms for PKC.  In 
contrast  to  PKC  family  members,  PRK1  is  not  activated  by  calcium  or 
phosphatidylserine, but is activated by other phospholipids such as phosphatidylinositol, 
and also by unsaturated fatty acids including arachidonic acid and linoleic acid (Mukai 
et  al.,  1994;  Palmer  et  al.,  1995).    PRK2  was  subsequently  found  to  have  similar 
regulatory  mechanisms,  being  activated  in  vitro  by  phospholipids  and  fatty  acids, 
although activation of PRK2 by fatty acids is considerably weaker than activation of 
PRK1  (Yu  et  al.,  1997).    Deletion  analysis  of  PRK1  has  defined  an  autoinhibitory 
region of approximately 60 amino acids within the C2-like domain (Yoshinaga et al., 
1999).  N-terminal truncation of PRK1 before the C2-like domain does not activate 
PRK1, and the truncated protein can still be activated by addition of arachidonic acid.  
However N-terminal truncation of PRK1 just before the kinase domain results in  a 
constitutively active form of PRK1 which lacks the C2-like domain and is no longer 
sensitive to arachidonic acid.  Furthermore, a peptide corresponding to the C-terminal 
portion of the C2-like domain inhibits PRK1 kinase activity, suggesting it acts as an 
autoinhibitory pseudosubstrate.  Based on these experiments, it has been proposed that 
the ability of lipids to activate PRK is based on binding to the C2-like domain and 
relieving autoinhibition (Yoshinaga et al., 1999). 
 
To more directly test the idea that PRK2 acts downstream of RhoA to regulate tight 
junction formation rescue experiments should be performed.  If PRK2 acts downstream 
of RhoA, overexpression of PRK2 might be sufficient to rescue the phenotype caused 
by  depletion  of  RhoA.    However  the  results  of  experiments  overexpressing  Rho 
effector-loop mutants as dominant-negatives suggest that more than one Rho effector 
protein is likely to be acting downstream of RhoA to regulate tight junction formation 
(section 4.3).  Overexpression of PRK2 alone is therefore unlikely to be sufficient to 
rescue the RhoA phenotype.     170 
 
Exogenous expression of mouse PRK2, which is not targeted by some of the human 
siRNA duplexes used in our experiments, rescued the defect in tight junction formation 
caused by knockdown of PRK2 (Figure 4.4).  The signalling pathways upstream and 
downstream of PRK2 can now be assessed by using mutant forms of PRK2 in rescue 
experiments.  Structural studies of the HR1 domains of PRK1 in complex with GTPases 
have highlighted a number of residues that make direct contacts (Maesaki et al., 1999; 
Owen et al., 2003).  These residues can be mutated to interfere with GTPase-binding 
and the mutant proteins can be used in rescue experiments and localization studies to 
determine whether PRK2 function in the regulation of junctions is GTPase-dependent.   
 
As mentioned earlier (section 4.6) there are some reports that PRK proteins can interact 
with Rac1 as well as RhoA (Owen et al., 2003; Vincent and Settleman, 1997).  I have 
not  been  able  to  determine  whether  Rac  is  required  for  tight  junction  formation  in 
16HBE  cells  (discussed  in  section  3.6).    It  therefore  remains  possible  that  PRK2 
regulates  tight  junction  formation  downstream  of  Rac  and  not  RhoA.    There  are 
conflicting reports on the binding specificity of individual HR1 domains of PRK1.  One 
study found that HR1a and HR1b both interact only with RhoA and not with Rac1 
(Flynn et al., 1998), while another found HR1a and HR1b both interact with Rac1 and 
only  HR1a  interacts  with  RhoA  (Owen  et  al.,  2003).    The  binding  specificity  of 
individual HR1 domains of PRK2 has not been determined.  It is possible that different 
HR1  domains  of  PRK2  mediate  interactions  with  different  GTPases.    Mutation  of 
residues involved in GTPase binding might therefore provide a way to test not only 
whether PRK2 regulates tight junction formation in a GTPase-dependent manner, but 
also whether it acts downstream of RhoA or Rac1.  This approach was successfully 
used to show that the Drosophila PRK protein, PKN, acts downstream of Rho and not 
Rac1 during dorsal closure (Betson and Settleman, 2007). 
 
As discussed in earlier (section 5.5), PAK4 is an effector protein for Cdc42.  In vitro the 
kinase activity of PAK4 is not regulated by GTPase-binding, and instead Cdc42 has 
been suggested to regulate PAK activity by controlling its cellular localization.  Based 
on the data presented in this thesis, I propose that Cdc42 promotes junction formation,   171 
at least in part, by regulating PAK4.  To test whether PAK4 function in regulating tight 
junctions is Cdc42-dependent, a similar approach can be taken to that described above 
for PRK2 and RhoA.  Exogenous expression of RNAi-resistant PAK4 rescued the tight 
junction defect caused by depletion of PAK4 (Figure 5.2).  Point mutations can be 
introduced in to the CRIB motif of PAK4 to abolish its interaction with Cdc42, and this 
mutant  protein  can  be  used  to  determine  whether  PAK4  localization  at  cell-cell 
contacts, and PAK4 function in regulating apical junction formation, require Cdc42-
binding.  A similar approach was used to show that the function of Mbt, the Drosophila 
homologue  of  PAK4,  acts  downstream  of  Cdc42  to  regulate  adherens  junction 
formation in photoreceptor cells (Schneeberger and Raabe, 2003). 
 
A second Cdc42-effector protein was identified in the Rho effector screen, Par6B.  Par6 
homologues have well documented roles downstream of Cdc42 in the regulation of cell 
polarity, by controlling the localization and activity of aPKC (discussed in sections 5.5 
and 1.4.4).  While it seems likely that Par6B function in tight junction formation in 
16HBE cells is also dependent on GTPase-binding and regulation of aPKC, this should 
be tested by performing rescue experiments using Par6B proteins with mutations in the 
semi-CRIB motif, that binds to Cdc42 and Rac1, and the PB1 domain, that binds to 
aPKC.  Unfortunately initial attempts to rescue the Par6B phenotype with wild-type 
mouse  Par6B  failed.    A  number  of  possible  reasons  were  discussed  (section  5.5), 
including insufficient expression of the rescue construct and mislocalization, perhaps 
due  to  the  N-terminal  HA  tag.    It  is  highly  unlikely  that  the  phenotype  caused  by 
transfection of Par6B siRNA is non-specific, as 4 distinct siRNA duplexes generated 
this phenotype, and the degree of Par6B protein knockdown correlated well with the 
severity of the phenotype.  Future experiments will resolve this by using untagged or C-
terminally tagged Par6B rescue constructs, and using a different expression vector to 
achieve a higher level of expression. 
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6.3  Mechanisms  through  which  Rho  effector  proteins  regulate  apical  junction 
formation 
 
Epithelial junction formation is a complex multistep process.  For junctions to form, the 
junctional  transmembrane  proteins,  including  E-cadherin  and  claudins,  need  to  be 
recruited to the plasma membrane and stabilized there in a competent state to form 
junctions.  This requires coordination of membrane trafficking pathways, changes in the 
cytoskeleton, and biochemical regulation of junctional proteins.  I have identified 3 Rho 
effector proteins whose activity is required for junctions to form, seen as a failure to 
properly recruit junctional proteins and reorganize the associated actin cytoskeleton at 
cell-cell  contacts.    However  based  on  these  microscopy  studies  it  is  difficult  to 
determine  the  mechanism  through  these  proteins  act.    Instead,  analysis  of  their 
downstream  signalling  pathways  will  be  required  elucidate  the  mechanisms  through 
which they regulate junction formation. 
 
As discussed, Par6B is likely to regulate junction formation through aPKC.  However 
the mechanisms through which PAK4 and PRK2 regulate junction formation remain to 
be determined (Figure 6.1).  Rescue experiments can be used to analyse the signalling 
pathway downstream of PAK4 and PRK2.  Kinase-dead mutants of both have been 
described  (Abo  et  al.,  1998),(Vincent  and  Settleman,  1997),  which  can  be  used  to 
determine  whether  their  function  in  junction  regulation  requires  kinase  activity.    It 
should be noted that kinase-dead proteins, when overexpressed, might potentially act as 
dominant-negatives, which would preclude their use in rescue experiments, but would 
still  enable  assessment  of  whether  kinase  activity  is  important  for  tight  junction 
formation. 
 
As  discussed  earlier  (section  5.5),  some  interesting  PAK4  substrates  have  been 
identified, including LIM kinase, slingshot phosphatase and β-catenin, although it is not 
clear if these represent relevant substrates as far as junction formation is concerned. In 
vitro  PRK  efficiently  phosphorylates  synthetic  peptides  corresponding  to  PKC 
consensus sequences, and a number of protein substrates have also been identified in 
vitro, including several actin associated proteins, but physiologically relevant substrates   173 
for PRK have not been found (Mukai, 2003).  Future work will be required to identify 
interacting  partners,  including  potential  substrates,  for  PAK4  and  PRK2  using 
biochemical  approaches.    A  potentially  interesting  biochemical  interaction  has  been 
found between PAK4 and Par6B, the two Cdc42 effector proteins identified in this 
study, in immunoprecipitation experiments (D.Jin and A.Hall, unpublished data).  This 
interaction has been mapped to the kinase domain of PAK4, raising the possibility that 
Par6B  is  a  PAK4  substrate.    The  physiological  significance  of  this  interaction  is 
currently being investigated. 
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6.4 Final summary 
 
 
Rho GTPases have emerged as key regulators of a number of basic cellular processes, 
including  organization  of  the  actin  and  microtubule  cytoskeletons,  membrane 
trafficking and gene expression.  By controlling these processes, Rho GTPases regulate 
complex cellular behaviours such as migration, division, adhesion and morphogenesis.  
These behaviours need to be tightly controlled during the  normal development and 
homeostasis of an organism, and when misregulated lead to diseases such as cancer.  It 
is therefore essential that cells regulate the activity of Rho GTPases in order to behave 
appropriately.  This regulation is achieved through the action of a large number of Rho 
GEFs  and  GAPs,  which  control  the  activation  status  of  Rho  GTPases,  and  effector 
proteins, which determine the outcome of Rho GTPase signalling. 
 
The aim of this thesis was to identify Rho GEFs, GAPs and effector proteins regulating 
epithelial morphogenesis, in particular apical junction formation, by carrying out RNAi 
screens and using tight junction formation in 16HBE cells as readout.  For reasons 
discussed I failed to identify any Rho GEFs or GAPs in this study, but did identify three 
Rho effector proteins: Par6B, PAK4 and PRK2, two of which had not previously been 
implicated in tight junction formation (PAK4 and PRK2).  Ongoing work is aimed at 
studying  the  mechanisms  through  which  these  proteins  regulate  apical  junction 
formation. 
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